<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><style scope="concept-mention">.block.concept-mention {
  display: block;
}

[hidden].concept-mention {
  display: none !important;
}

.invisible.concept-mention {
  visibility: hidden !important;
}

.relative.concept-mention {
  position: relative;
}

.fit.concept-mention {
  position: absolute;
        top: 0;
        right: 0;
        bottom: 0;
        left: 0;
}

body.fullbleed.concept-mention {
  margin: 0;
        height: 100vh;
}

.scroll.concept-mention {
  -webkit-overflow-scrolling: touch;
        overflow: auto;
}

.fixed-bottom.concept-mention,.fixed-left.concept-mention,.fixed-right.concept-mention,.fixed-top.concept-mention {
  position: fixed;
}

.fixed-top.concept-mention {
  top: 0;
        left: 0;
        right: 0;
}

.fixed-right.concept-mention {
  top: 0;
        right: 0;
        bottom: 0;
}

.fixed-bottom.concept-mention {
  right: 0;
        bottom: 0;
        left: 0;
}

.fixed-left.concept-mention {
  top: 0;
        bottom: 0;
        left: 0;
}

#target.concept-mention:hover {
  background-color: #e8f0fe;
}

#target[noicon].concept-mention {
  padding: 1px;
}

#target.concept-mention:hover[noicon] {
  border: 1px solid #e8f0fe;
        padding: 0;
}

#target.concept-mention {
  display: inline-block;
}

.inline-icon.concept-mention {
  cursor: pointer;
        height: 12px;
        width: 12px;
        padding-left: 4px;
        color: #5e6368;
}

concept-card.concept-mention {
  z-index: 1;
        position: absolute;
}</style><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><style scope="classification-tree">.layout.horizontal.classification-tree,.layout.vertical.classification-tree {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.classification-tree {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.classification-tree {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.classification-tree {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.classification-tree {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.classification-tree {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.classification-tree {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.classification-tree {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.classification-tree {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

classification-tree {
  display: block;
        line-height: 20px;
}

.wrap.classification-tree {
  padding: 6px 12px;
}

.wrap.classification-tree:hover {
  background: #fafafa;
}

.description.classification-tree {
  padding-left: 4px;
}

iron-icon.classification-tree {
  color: #eaeaea;
}

.code[first].classification-tree {
  font-weight: 500;
}

.code[additional].classification-tree {
  font-style: italic;
}</style><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: "…"
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>CA2180830C - Anti-annexin-v monoclonal antibody, process for producing the same, and use thereof 
      - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/CA2180830C/en">
    <meta name="description" content="
      Using human annexin-V or human annexin-V plus dog annexin-V as antigen(s), hybridoma cell lines are prepared which are capable of producing anti-annexin-V monoclonal antibodies having a binding specificity to antigenic determinant site on annexin-V as antigenic protein and belonging to immunoglobulin G class. By the hybridoma cell lines are produced the anti-annexin-V monoclonal antibodies, with which a diagnostic agent is provided for diagnosis of myocardial infarction and angina pectoris.      There is also provided diagnosis of myocardial infarction and angina pectoris using a first and a second monoclonal antibodies produced by the hybridoma cell lines to quantitate human annexin-V in a sample, in which an antigen-antibody reaction on annexin-V in the sample is caused with the first anti-annexin-V monoclonal antibody to form an annexin-V antigen/anti-annexin-V monoclonal antibody complex, the antigenic site of annexin-V of the formed annexin-V antigen/annexin-V monoclonal antibody complex is allowed to be bound with a labeled anti-annexin-V polyclonal or second monoclonal antibody so as to form a labeled form of said annexin-V antigen/anti-annexin-V monoclonal antibody complex bound with the polyclonal or the second monoclonal antibody, and the labeled form of the complex is quantitatively analyzed.  
   
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="Anti-annexin-v monoclonal antibody, process for producing the same, and use thereof 
     ">
    <meta name="DC.date" content="1995-11-10" scheme="dateSubmitted">
    <meta name="DC.description" content="
      Using human annexin-V or human annexin-V plus dog annexin-V as antigen(s), hybridoma cell lines are prepared which are capable of producing anti-annexin-V monoclonal antibodies having a binding specificity to antigenic determinant site on annexin-V as antigenic protein and belonging to immunoglobulin G class. By the hybridoma cell lines are produced the anti-annexin-V monoclonal antibodies, with which a diagnostic agent is provided for diagnosis of myocardial infarction and angina pectoris.      There is also provided diagnosis of myocardial infarction and angina pectoris using a first and a second monoclonal antibodies produced by the hybridoma cell lines to quantitate human annexin-V in a sample, in which an antigen-antibody reaction on annexin-V in the sample is caused with the first anti-annexin-V monoclonal antibody to form an annexin-V antigen/anti-annexin-V monoclonal antibody complex, the antigenic site of annexin-V of the formed annexin-V antigen/annexin-V monoclonal antibody complex is allowed to be bound with a labeled anti-annexin-V polyclonal or second monoclonal antibody so as to form a labeled form of said annexin-V antigen/anti-annexin-V monoclonal antibody complex bound with the polyclonal or the second monoclonal antibody, and the labeled form of the complex is quantitatively analyzed.  
   
   ">
    <meta name="citation_patent_application_number" content="CA:002180830A">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/64/2b/8c/fe9a6d528d2be2/CA2180830C.pdf">
    <meta name="citation_patent_number" content="CA:2180830:C">
    <meta name="DC.date" content="2006-10-31" scheme="issue">
    <meta name="DC.contributor" content="Ryuko Matsuda" scheme="inventor">
    <meta name="DC.contributor" content="Tadahiro Kajita" scheme="inventor">
    <meta name="DC.contributor" content="Yohsuke Ohta" scheme="inventor">
    <meta name="DC.contributor" content="Noboru Kaneko" scheme="inventor">
    <meta name="DC.contributor" content="Individual" scheme="assignee">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            Anti-annexin-v monoclonal antibody, process for producing the same, and use thereof 
     </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><abstract mxw-id="PA75789107" lang="EN" load-source="patent-office" class="style-scope patent-text">
    <div num="1" class="abstract style-scope patent-text"> Using human annexin-V or human annexin-V plus dog annexin-V<br class="style-scope patent-text">as antigen(s), hybridoma cell lines are prepared which are capable of producing anti-annexin-V monoclonal antibodies having a binding specificity to antigenic determinant site on annexin-V<br class="style-scope patent-text">as antigenic protein and belonging to immunoglobulin G class. By the hybridoma cell lines are produced the anti-annexin-V<br class="style-scope patent-text">monoclonal antibodies, with which a diagnostic agent is provided for diagnosis of myocardial infarction and angina pectoris.<br class="style-scope patent-text">     There is also provided diagnosis of myocardial infarction and angina pectoris using a first and a second monoclonal antibodies produced by the hybridoma cell lines to quantitate human annexin-V in a sample, in which an antigen-antibody reaction on annexin-V in the sample is caused with the first anti-annexin-V<br class="style-scope patent-text">monoclonal antibody to form an annexin-V antigen/anti-annexin-V<br class="style-scope patent-text">monoclonal antibody complex, the antigenic site of annexin-V of the formed annexin-V antigen/annexin-V monoclonal antibody complex is allowed to be bound with a labeled anti-annexin-V<br class="style-scope patent-text">polyclonal or second monoclonal antibody so as to form a labeled form of said annexin-V antigen/anti-annexin-V monoclonal antibody complex bound with the polyclonal or the second monoclonal antibody, and the labeled form of the complex is quantitatively analyzed. </div>
  </abstract>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      
        <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/00"><a id="link" href="#" class="style-scope state-modifier">C07K16/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="C07K16/18"><a id="link" href="#" class="style-scope state-modifier">C07K16/18</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      
      <div class="style-scope classification-viewer">
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G"><a id="link" href="#" class="style-scope state-modifier">G</a></state-modifier>
                  <span class="description style-scope classification-tree">PHYSICS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01"><a id="link" href="#" class="style-scope state-modifier">G01</a></state-modifier>
                  <span class="description style-scope classification-tree">MEASURING; TESTING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N"><a id="link" href="#" class="style-scope state-modifier">G01N</a></state-modifier>
                  <span class="description style-scope classification-tree">INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N2333/00"><a id="link" href="#" class="style-scope state-modifier">G01N2333/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Assays involving biological materials from specific organisms or of a specific nature</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N2333/435"><a id="link" href="#" class="style-scope state-modifier">G01N2333/435</a></state-modifier>
                  <span class="description style-scope classification-tree">Assays involving biological materials from specific organisms or of a specific nature from animals; from humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N2333/46"><a id="link" href="#" class="style-scope state-modifier">G01N2333/46</a></state-modifier>
                  <span class="description style-scope classification-tree">Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N2333/47"><a id="link" href="#" class="style-scope state-modifier">G01N2333/47</a></state-modifier>
                  <span class="description style-scope classification-tree">Assays involving proteins of known structure or function as defined in the subgroups</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N2333/4701"><a id="link" href="#" class="style-scope state-modifier">G01N2333/4701</a></state-modifier>
                  <span class="description style-scope classification-tree">Details</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="G01N2333/4718"><a id="link" href="#" class="style-scope state-modifier">G01N2333/4718</a></state-modifier>
                  <span class="description style-scope classification-tree">Lipocortins</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        <template is="dom-repeat" class="style-scope classification-viewer"></template>
        <div class="more style-scope classification-viewer" style="" hidden="">View 1 more classifications</div>
        <div class="more style-scope classification-viewer">Hide more classifications</div>
      </div>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Chemical &amp; Material Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Chemical &amp; Material Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Organic Chemistry"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Organic Chemistry
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline" hidden="">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">CA2180830C</h2>
                  <p class="tagline style-scope patent-result">Canada</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Patent</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/64/2b/8c/fe9a6d528d2be2/CA2180830C.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;annexin&quot;,&quot;monoclonal antibody&quot;,&quot;human&quot;,&quot;hybridoma cell&quot;,&quot;cell line&quot;]" data-before="19941111"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/CA2180830C"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  
                    <dt class="style-scope patent-result">Other languages</dt>
                    <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2180830C/fr"><a id="link" href="#" class="style-scope state-modifier">French</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Ryuko Matsuda"><a id="link" href="#" class="style-scope state-modifier">Ryuko Matsuda</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Tadahiro Kajita"><a id="link" href="#" class="style-scope state-modifier">Tadahiro Kajita</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Yohsuke Ohta"><a id="link" href="#" class="style-scope state-modifier">Yohsuke Ohta</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Noboru Kaneko"><a id="link" href="#" class="style-scope state-modifier">Noboru Kaneko</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  
                  <dt class="style-scope patent-result">
                    <span class="tooltip-hint style-scope patent-result" id="assigneeWarning">Current Assignee</span>
                    <overlay-tooltip positioning-target="#assigneeWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                      The listed assignees may be inaccurate.<br class="style-scope patent-result">
                      Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.
                    
    </div>
  </overlay-tooltip>
                  </dt>
                  <dd class="style-scope patent-result">
                    
    Individual
  
                  </dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">1995</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA2180830C/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline" this="">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA002180830A</div>
                <div class="style-scope application-timeline">Filing date: 1995-11-10</div>
                <div class="style-scope application-timeline">Legal status: Expired - Fee Related</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application CA002180830A events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">1995-11-10</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="Individual"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by Individual</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline"><div date="" class="external-priority style-scope application-timeline">1995-11-10</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO1996015152A1/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Priority claimed from PCT/JP1995/002305</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">1996-05-23</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA2180830A1/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of CA2180830A1</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="granted style-scope application-timeline">2006-10-31</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Application granted</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2006-10-31</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA2180830C/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of CA2180830C</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="legal-status style-scope application-timeline">2015-11-10</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Anticipated expiration</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" current="" critical=""><div date="" class="legal-status style-scope application-timeline">Status</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Expired - Fee Related</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#legalEvents" class="style-scope patent-result">Legal events</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=CA&amp;NR=2180830C&amp;KC=C&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/publication/CA/2180830/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2180830/summary.html">CIPO</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/CA2180830C">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><div mxw-id="PDES62455257" lang="EN" load-source="patent-office" class="description style-scope patent-text">
    <disclosure class="style-scope patent-text">
      <div class="description-paragraph style-scope patent-text"> SPECIFICATIONS<br class="style-scope patent-text">   ANTI-ANNEXIN-V MONOCLONAL ANTIBODIES. AND PREPARATION AND USE<br class="style-scope patent-text">   THEREOF<br class="style-scope patent-text">     Technical Field The present invention relates to anti-annexin-V monoclonal antibodies having binding specificities to antigenic determinant sites on annexin-V, a protein present in blood, plasma and/or 1o serum of humans and mammalian animals, and, more particularly, to such anti-annexin-V monoclonal antibodies suitable for use in the immunological determination of the concentration of human annexin-V in the blood, plasma and/or serum, being present particulary in the human cardiac muscles as a marker of myocardial infarction and angina pectoris.<br class="style-scope patent-text">    The present invention further relates to hybridoma cell lines producing said anti-annexin-V monoclonal antibodies and, more particularly, to such hybridoma cell lines producing the monoclonal antibodies for use in the detection and quantitative 2o analysis of human cardiac-muscle annexin-V as a marker of myocardial infarction and angina pectoris.<br class="style-scope patent-text">    The present invention also relates to a method for the detection of annexin-V in a sample and, more particularly, to a method for the detection or quantitative analysis of human cardiac-muscle annexin-V in the blood and/or serum as a marker of myocardial infarction and angina pectoris. The present invention further relates to human cardiac muscle annexin-V in the plasma and/or serum, monoclonal antibodies for use in the detection and quantitative analysis thereof and hybridoma producing such monoclonal antibodies.<br class="style-scope patent-text">     In addition, the present invention relates to the development and utilization of anti-annexin-V antibodies for the measurement of annexin-V of humans and mammals and the hybridoma cell lines producing such antibodies and, more particularly, to the development and utilization of the anti-human-annexin-V<br class="style-scope patent-text">antibodies for use in quick diagnosis of diseases causing sudden cellular necrosis such as myocardial infarction and angina 1o pectoris causing an ischemic disorder, through the concentration measurement of annexin-V, a protein in the cells or blood.<br class="style-scope patent-text">   Background Art Annexin is a calcium-binding protein being present in tissues and cells of humans and various animals, particularly in their cytoplasmic solubles. This protein is composed of families defined by the amino acid sequences and, at present, annexin I through XII are known. The protein binds to phospholipids and actin depending upon the calcium concentration, and is known to have anti-inflammatory and 2o anticoagulant functions.<br class="style-scope patent-text">    In patients suffering from tissue or cellular necrosis, due to myocardial infarction, for example, various substances contained in the necrosed cardiac-muscle cells leak into blood.<br class="style-scope patent-text">   The current diagnosis of acute myocardial infarction is conducted by detecting such substances in the blood and the substances are generally called myocardial-infarction markers.<br class="style-scope patent-text">   Such myocardial-infarction markers to be measured in biochemical tests for use in the diagnosis of acute myocardial infarction include LD-1, AST, creatin kinase (CK), creatin kinase MB-fraction (CK-MB), myoglobin, lactic dehydrogenase (LDH), myosin light-chain I, and troponin-T (TnT). While the results or the analytical values of these myocardial-infarction markers may be employed independently or in combination in the diagnosis of myocardial-infarction, the prevailing method is to employ them in combination.<br class="style-scope patent-text">   In the case of an ischemic disease such as angina pectoris, arrhythmia is observed arrhythmia within several hours after the onset of the attack, and may lead to arrhythmia death.<br class="style-scope patent-text">   Quick diagnosis and treatment at the early stage are therefore needed in myocardial infarction and angina pectoris.<br class="style-scope patent-text">     However, regarding the above-mentioned various types of myocardial-infarction markers (all are substances leaking from the cardiac muscles into the blood) to be examined in biochemical tests for the diagnosis of acute myocardial-infarction, it has been reported that such myocardial-infarction markers reach their respective peak concentrations in the blood 7 to 78 hours after the attack of myocardial infarction. In addition, the time in which the myocardial infarction markers reach the maximal or peak concentration in the blood may vary considerably from one patient to another. Thus, these markers for the diagnosis of myocardial infarction are considered to be problematic since they make it difficult to establish a quick diagnosis of myocardial infarction and hence they do not contribute to quick selection of therapeutic measures for the patients. </div>
      <div class="description-paragraph style-scope patent-text"> The employment of the results obtained by measuring two or more markers of the aforesaid myocardial-infarction markers for more reliable diagnosis of myocardial infarction is also problematic and far from meeting the need for early-stage therapy of myocardial infarction patients because it takes a long time for the respective myocardial-infarction markers to reach the maximal (peak) concentrations in the blood and such time varies depending upon the patient examined.<br class="style-scope patent-text">     In the case of angina pectoris, marker substances to be 1o examined in biochemical tests for diagnozing the disease have not yet been identified. Thus, biochemical diagnosis of angina pectoris is generally considered to be difficult and a need is felt for the establishment of diagnosis for angina pectoris through biochemical tests.<br class="style-scope patent-text">     The present invention is directed to overcoming the problems in the conventional biochemical tests so as to enable quick diagnosis of myocardial infarction and angina pectoris.<br class="style-scope patent-text">   Disclosure of the Invention It has been found that, among annexin-proteins present in human cardiac muscles, human annexin-V, occurring in the solubles of the cardiac-muscle cells and having a molecular weight of 35,000, i.e. smaller than that of creatin kinase (81,000), generally leaks from the necrosed cardiac muscles of myocardial infarction or angina-pectoris patients in the early stage of the diseases. Thus the present applicant has already disclosed a method for determining the concentration of human annexin-V in human blood, plasma and/or serum and a method for diagnosing myocardial infarction and/or angina pectoris, using dog cardiac-muscle annexin-V polyclonal antibodies which specifically cross-react with such human annexin-V (Japanese Laid-Open Pat.<br class="style-scope patent-text">   Application No.72147/1995).<br class="style-scope patent-text">    Thus, human annexin-V is a novel marker of myocardial infarction whose concentration (in the blood, plasma and serum) reaches the peak within one to several hours after the attack of myocardial infarction.<br class="style-scope patent-text">    The present inventors therefore made extensive studies to provide antibodies capable of specifically recognizing human annexin-V and suitable for use in a method for the assay of human annexin-V in a sensitive, simple and quick manner and found that hybridoma cells, obtained from anti-human-annexin-V-producing lymphocytes and myeloma cells using the conventional cell fusion technique, produce stable anti-human-annexin-V monoclonal antibodies meeting the above-mentioned object for the completion of the present invention.<br class="style-scope patent-text">    The present invention relates to an improvement on the invention of the aforesaid application and is directed to the provision of diagnostic agents and diagnostic methods, by which 2o highly reliable diagnosis of myocardial infarction and/or angina pectoris can be made in a short time after the attack of myocardial infarction or angina pectoris, as well as the provisions of detection substances for detecting and quantitatively analyzing the myocardial-infarction marker or angina pectoris marker and the preparation and use thereof.<br class="style-scope patent-text">    Thus, the present invention is directed to an anti-annexin-V<br class="style-scope patent-text">monoclonal antibody characterized by having a binding specificity to antigenic determinant site on annexin-V as antigenic protein and belonging to immunoglobulin G class, to a hybridoma cell line characterized by being capable of producing an anti-annexin-V<br class="style-scope patent-text">monoclonal antibody having a binding specificity to antigenic determinant site on annexin-V as antigenic protein and belonging to immunoglobulin G class, to a diagnostic agent for myocardial infarction and angina pectoris characterized by comprising an anti-annexin-V monoclonal antibody having a binding specificity to antigenic determinant site on annexin-V as antigenic protein and belonging to immunoglobulin G class, and also to a diagnostic agent for myocardial infarction and angina pectoris characterized by comprising a reagent containing a first anti-annexin-V<br class="style-scope patent-text">monoclonal antibody having a binding specificity to antigenic determinant site on annexin-V as antigenic protein and belonging to immunoglobulin G class and a reagent containing a second anti-annexin-V monoclonal or polyclonal antibody having a binding specificity to antigenic determinant site on annexin-V as antigenic protein and belonging to immunoglobulin G class, with the second antibody being labeled.<br class="style-scope patent-text">     In addition, the present invention is directed to a method for diagnosing myocardial infarction and angina pectoris characterized by comprising an antigen-antibody reaction of annexin-V in a sample with an anti-annexin-V monoclonal antibody to form an annexin-V antigen/anti-annexin-V monoclonal antibody complex and assaying the formed annexin-V antigen/anti-annexin-V<br class="style-scope patent-text">monoclonal antibody complex, to a method for diagnosing myocardial infarction and angina pectoris characterized by comprising causing an antigen-antibody reaction of annexin-V in a sample with an anti-annexin-V monoclonal antibody to form an annexin-V antigen/anti-annexin-V monoclonal antibody complex, allowing the antigenic site of annexin-V of the formed annexin-V<br class="style-scope patent-text">antigen/anti-annexin-V monoclonal antibody complex to bound with a labeled anti-annexin-V polyclonal or monoclonal antibody so as to form a labeled form of said annexin-V antigen/anti-annexin-V<br class="style-scope patent-text">monoclonal antibody complex bound with the polyclonal or monoclonal antibody, and quantitatively analyzing the labeled form of the complex, to a method for analyzing human cardiac 1o muscle or related annexin-V in a sample characterized by comprising causing an antigen-antibody reaction of human annexin-V in the sample with an anti-annexin-V monoclonal antibody to form an annexin-V antigen/anti-annexin-V monoclonal antibody complex and quantitatively analyzing the formed annexin-V<br class="style-scope patent-text">antigen/anti-annexin-V monoclonal antibody complex, and also to a method for analyzing annexin-V in a sample characterized by comprising causing an antigen-antibody reaction of human annexin-V in the sample with a first anti-annexin-V monoclonal antibody having a specificity to antigenic determinant site on annexin-V<br class="style-scope patent-text">antigenic protein to form an annexin-V antigen/anti-annexin-V<br class="style-scope patent-text">monoclonal antibody complex, allowing the antigenic site of human annexin-V of the formed annexin-V antigen/anti-annexin-V<br class="style-scope patent-text">monoclonal antibody complex to be bound with an anti-annexin-V<br class="style-scope patent-text">polyclonal or second monoclonal labeled antibody so as to form a labeled form of said annexin-V antigen/anti-annexin-V monoclonal antibody complex bound with the polyclonal or the second monoclonal antibody, and quantitatively analyzing the labeled form of the complex.<br class="style-scope patent-text">    The present invention is further directed to a method for preparing anti-annexin-V monoclonal antibodies which comprises fusing lymphocytes induced from mice immunized with annexin-V<br class="style-scope patent-text">with myeloma cells to form hybridoma cells, and growing the formed hybridoma cells to produce anti-annexin-V monoclonal antibodies having binding specificities to antigenic determinant sites on annexin-V antigenic protein.<br class="style-scope patent-text">     Human annexin-V to be used as the antigen in the present invention is a protein which may have a molecular weight of 32 to 35 kilodalton and may be one occurring in the human heart.<br class="style-scope patent-text">   The human heart to be used in the present invention is one extracted from a human cadaver and maintaining its activities.<br class="style-scope patent-text">   The antigen protein - human annexin-V protein occurring in human heart - is found in the soluble fractions of the heart and purified by removing the connective tissues and lipids from the cardiac tissue of a human cadaver. The hybridoma cell lines to be used in the present invention for producing anti-human-annexin-V monoclonal antibodies are formed by means of the cell 2o fusion of lymphocytic cells with myeloma cells, in which the lymphocytic cells are spleen (a lymphoid organ) including spleen cells and white pulp of spleen or plasmablast cells prepared from lymph nodes (e.g. lymphoid nodule) and being in the process of the differentiation to plasma cells, from a mammalian animal such as a mouse or the like which was immunized with human annexin-V<br class="style-scope patent-text">as the antigen extracted and purified from human cardiac tissue.<br class="style-scope patent-text">   The myeloma cell strain to be used in the present invention is generally a hypoxanthine-guanine-phosphoribosyltransferase (HGPRT)-deficient one or thymidine-kinase(TK)-deficient one. The HGPRT-deficient strains suitable for use include 8-azaguanine(8-AG)-resistant strain and 6-thioguanine(6-TG)-resistant strain while,the TK-deficient strains suitable for use include bromodeoxyuridine(BUdR)-resistant strain.<br class="style-scope patent-text">   The cell fusion is conducted using a cell fusion accelerator, in which polyethylene glycol (PEG) is primarily used for the cell fusion in the present invention.<br class="style-scope patent-text">    The cell fusion accelerators usable in the present invention 1o include, by substance name or trade name, PEG600, PEG400, PEG1000, PEG3000, PEG6000, GlucamTM E-10, GlucamTM E-20, GlucamTM P-10, polyeth lene y glycol methyl ester (PEG<br class="style-scope patent-text">methyl ester) (molecular weight: 350, 2000 and 5000), PEG 1000, polyglycol P15-200, pluronic F38 polyol Prilled, Decaglycerol, Camul* 101 Butyrate, Tetronic~304 polyol, triglycerol, polyvinylpyrroridone (molecular weight: 1000) and glycerin.<br class="style-scope patent-text">    The anti-human-annexin-V monoclonal antibodies in the present invention can be produced by fusing lymphocytic 2o plasmablast cells extracted from the lymphoid organs of mice or other animals immunized against annexin-V as the antigen with myeloma cells to form hybridomas and growing the hybridomas with, for example, a HAT culture medium, in which the hybridomas for the selective proliferation are, for example, anti-human-annexin-V-monoclonal-antibody-producing hybridoma cell lines HCA-627 and HDA-907 deposited at the National Institute of Bioscience and v Human-Technology, the Agency of Industrial Science and Technology trademark of Japan, an International Depositary Authority for the deposit of microorganism, under the numbers FERM BP-5284 and FERM BP-5286, respectively.<br class="style-scope patent-text">    The selection of the hybridoma cell lines can be made through a HAT-selection, an ouabain-selection or the like.-The anti-human-annexin-V monoclonal antibodies in the present invention can be obtained by culturing the above-mentioned hybridoma clones by a conventional culture process such as the high density culture process, the spinner-flask culture 1o process or the like and purifying the antibodies from the culture supernatant by means of affinity chromatography using a carrier bound with protein-A or a carrier bound with anti-mouse-immunoglobulin.<br class="style-scope patent-text">     In the present invention, the anti-human-annexin-V<br class="style-scope patent-text">15 monoclonal antibodies can be produced by injecting the hybridoma cell lines obtained through the above-mentioned culture into the abdominal cavities of prestene-pretreated immunocompromised mice, salting out, with ammonium sulfate or sodium sulfate, the ascitic fluid induced by the hybridoma cell lines, and purifying the 2o fluid by means of ion-exchange chromatography using DEAF<br class="style-scope patent-text">cellulose to obtain the immunoglobulin (IgG) fractions.<br class="style-scope patent-text">    A hybridoma cell line as termed with respect to the present invention means not only a hybridoma cell just obtained by cell-fusion but also hybridoma cells at any passages 25 subsequent to the primary culture.<br class="style-scope patent-text">    The screening for the resultant hybridoma cell lines can be conducted by detecting the anti-human-annexin-V monoclonal antibodies secreted by the hybridomas in the culture by such methods as immunoassay, radioimmunoassay and ELISA.<br class="style-scope patent-text">    In the present invention, the process of screening for the hybridoma cell lines has been found to be able to obtain various anti-human-annexin-V monoclonal antibodies having different specific reactivities with human-annexin-V antigen.<br class="style-scope patent-text">    By a method similar to that for producing anti-human-annexin-V monoclonal antibodies there can be obtained anti-annexin-V monoclonal antibodies having specific reactivities with the antigenic determinant sites of the annexin-V antigens of l0 dogs and other mammalian animals, by immunizing the mammalian animals with the annexin-V antigens derived from dogs or the like, cell-fusing the lymphocytic cells with myeloma cells to produce the hybridoma cell lines.<br class="style-scope patent-text">     The anti-annexin-V monoclonal antibodies in the present invention are defined to include such anti-annexin-V monoclonal antibodies from mammalian animals as well as anti-human-annexin-V<br class="style-scope patent-text">monoclonal antibodies.<br class="style-scope patent-text">     Thus, cloning is carried out for the hybridoma cell lines which have been screened for the ability to secrete anti human-annexin-V monoclonal antibodies.<br class="style-scope patent-text">    The cloning of the hybridoma cell lines in the present invention can be made by such techniques as limiting dilution, soft agar method, fibrin gel method, cell sorter method and the like.<br class="style-scope patent-text">     The hybridoma cell lines with an ability to produce anti-human-annexin-V monoclonal antibodies thus obtained are subjected to a large-scale fermentation to produce anti-human-annexin-V <br class="style-scope patent-text"> <br class="style-scope patent-text"> monoclonal antibodies.<br class="style-scope patent-text">    The anti-human-annexin-V monoclonal antibodies of the present invention have specific reactivities with the antigenic determinant sites of human annexin-V, a protein antigen. They are antibodies featuring an antigen-antibody reaction with the antigenic protein (human annexin-V) and will thus bind to human annexin-V present in human blood, plasma and/or serum, thereby enabling highly specific and sensitive detection and quantitative analysis of human annexin-V in human blood, plasma and/or serum 1o through such techniques as immunoassay, radioimmunoassay, ELISA<br class="style-scope patent-text">and the like.<br class="style-scope patent-text">    The anti-human-annexin-V monoclonal antibodies of the present invention exhibit specific reactivities with the antigenic determinant sites of human annexin-V, a protein 15, occurring in the human heart, thereby enabling highly specific and sensitive detection and/or quantification of human annexin-V<br class="style-scope patent-text">in the blood, plasma and/or serum, through such techniques as immunoassay, radioimmunoassay, ELISA and the like, as they bind to the antigenic protein, human annexin-V, present in the human 20 blood, plasma and/or serum.<br class="style-scope patent-text">    While human annexin-V concentration in the blood of a normal adult is found, for example, to be 5.6 ng/ml at the highest, it has been found by the application of the present invention that the human annexin-V concentration with a patient suffering 25 myocardial infarction may be, for example, as high as 90 ng/ml even in the stage when the CK value indicated is normal and also that the human annexin-V concentration of a patient suffering angina pectoris may be as high as 29 ng/ml even in the stage when the CK value indicated is normal. The present invention therefore enables a diagnosis of the diseases at earlier stages than possible with the conventional diagnosis based on the CK value.<br class="style-scope patent-text">     According to one aspect of the present invention, there is provided an anti-annexin-V monoclonal antibody produced by a hybridoma cell line which is selected from the group consisting of the hybridoma cell lines deposited as FERM BP-5284 and FERM BP-5286 at the International Depository Authority for the deposit of microorganisms, said anti-annexin-V monoclonal antibody being cross-reactive with annexin-V from the heart cells of one or more mammalian species.<br class="style-scope patent-text">     According to another aspect of the present invention, there is provided a hybridoma cell line selected from the group consisting of the hybridoma cell lines deposited as FERM BP-5284 and FERM BP-5286 at the International Depository Authority for the deposit of microorganisms, said hybridoma cell line having the ability to produce an anti-annexin-V monoclonal antibody which has a binding specificity to an antigenic determinant on annexin-V antigenic protein and which is capable of cross-reacting with annexin-V from the heart of one or more mammalian species.<br class="style-scope patent-text">     According to still another aspect of the present invention, there is provided a diagnostic agent for myocardial infarction and angina pectoris which comprises:<br class="style-scope patent-text">a first reagent containing a first anti-annexin-V<br class="style-scope patent-text">monoclonal antibody being produced by a hybridoma cell line selected from the group consisting of the hybridoma cell lines deposited as FERM BP-5284 and FERM BP-5286 at the International Depository Authority for the deposit of microorganisms;<br class="style-scope patent-text">a second reagent containing a second anti-annexin-V<br class="style-scope patent-text">monoclonal antibody being produced by the other hybridoma cell line selected from said group, or polyclonal antibody, wherein the antibody of the second reagent is labelled;<br class="style-scope patent-text">wherein the antibodies of both reagents are cross-reactive with annexin-V from human heart cells and the annexin-V antigen is annexin-V from heart cells of one or more mammalian species.<br class="style-scope patent-text">     According to yet another aspect of the present invention, there is provided a method for analyzing annexin-V in human cardiac muscle or in a sample which comprises causing an antigen-antibody reaction of human annexin-V in the human cardiac muscle or the sample with an anti-annexin-V monoclonal antibody produced by a hybridoma cell line selected from the group consisting of the hybridoma cell lines deposited as FERM BP-5284 and FERM BP-5286 at the International Depository Authority for the deposit of microorganisms, to form an annexin-V antigen-anti-annexin-V monoclonal antibody complex and quantitatively analyzing the formed annexin V antigen-anti-annexin-V monoclonal antibody complex.<br class="style-scope patent-text">     According to a further aspect of the present invention, there is provided a method for analyzing annexin-V in a sample which comprises the steps of:<br class="style-scope patent-text">causing an antigen-antibody reaction of human annexin-V in the sample with a first anti-annexin-V<br class="style-scope patent-text">monoclonal antibody produced by a hybridoma cell line selected from the group consisting of the hybridoma cell lines deposited as FERM BP-5284 and FERM BP-5286 at the 13a International Depository Authority for the deposit of microorganisms to form an annexin-V antigen-anti-annexin-V monoclonal antibody complex, allowing the antigenic site of human annexin-V of the formed annexin-V antigenic-anti-annexin-V monoclonal antibody complex to be bound with a labelled second anti-annexin-V monoclonal antibody or anti-annexin-V<br class="style-scope patent-text">polyclonal antibody, so as to form a labelled from of said annexin-V antigen-anti-annexin-V monoclonal polyclonal antibody complex bound with labelled anti-annexin-V polyclonal antibody or labelled the second anti-annexin-V monoclonal antibody;<br class="style-scope patent-text">quantitatively analyzing the labelled form of the complex and;<br class="style-scope patent-text">said labelled second anti-annexin monoclonal antibody is produced by labelling second anti-annexin-V<br class="style-scope patent-text">monoclonal antibody being different from the first anti-annexin-V monoclonal antibody and produced by a hybridoma cell line which is selected from the group consisting of the hybridoma cell line deposited as FERM<br class="style-scope patent-text">     BP-5284 and FERM BP-5286 at the International Depository Authority for the deposit of microorganisms.<br class="style-scope patent-text">     Brief Description of the Drawings Fig. 1 illustrates a calibration curve for use in ELISA system for a working example, in which the anti-human-annexin-V monoclonal antibodies of the present invention are employed to determine the concentration of 8M-urea-treated human annexin-V. The ELISA system is made up of a combination of a HRPO-labelled anti-human-annexin-V monoclonal antibody produced by HCA-155H, an anti-human-annexin-V monoclonal antibody-producing hybridoma cell line clone, and having a specific 13b activity with human annexin-V, and another anti-human-annexin-V monoclonal antibody as the solid phase, produced by HCA-290, another anti-human-annexin-V<br class="style-scope patent-text">monoclonal antibody-producing hybridoma cell line clone, and having a specific activity with human annexin-V.<br class="style-scope patent-text">     In the Figure, the ordinate indicates difference absorbance obtained by subtracting an absorbance measurement at the secondary wavelength 690nm from an absorbance measurement at the primary wavelength 492nm and the abscissa indicates the concentration of human annexin-V, in which each ~ mark represents the average difference absorbance and the length of the arrows extending upward or downward from each ~ mark represents the average ~2SD respectively.<br class="style-scope patent-text">     Fig. 2 illustrates a calibration curve for use in ELISA system for another working example, in which the a r ~ ; ~" ,..,-, ., 13c annexin-V monoclonal antibodies of the present invention are employed to determine the concentration of 8M-urea-treated human annexin-V. The ELISA system is made up of a combination of a HRPO-labeled anti-human-annexin-V monoclonal antibody produced by HCA-155H, an anti-human-annexin-V monoclonal antibody-producing hybridoma cell line clone, and having a specific activity with human annexin-V, and another anti-human-annexin-V monoclonal antibody as the solid phase, produced by HCA-57HDR, another anti-human-annexin-V monoclonal antibody-producing hybridoma cell line 1o clone, and having a specific activity with human annexin-V.<br class="style-scope patent-text">    In the Figure, the ordinate indicates difference absorbance obtained by subtracting an absorbance measurement at the secondary wavelength 690nm from an absorbance measurement at the primary wavelength 492nm and the abscissa indicates the concentration of human annexin-V, in which each ~ mark represents the average difference absorbance and the length of the arrows extending upward or downward from each ~ mark represents the average ~2SD respectively.<br class="style-scope patent-text">     Fig. 3 illustrates a calibration curve for use in ELISA<br class="style-scope patent-text">2o system for a further working example different from the examples as shown by Figs. 1 and 2, in which the anti-human-annexin-V<br class="style-scope patent-text">monoclonal antibodies of the present invention are employed to determine the concentration of 8M-urea-treated human annexin-V.<br class="style-scope patent-text">    The ELISA system is made up of a combination of a HRPO-labeled anti-human-annexin-V monoclonal antibody produced by HCA-155H, an anti-human-annexin-V monoclonal antibody-producing hybridoma cell line clone, and having a specific activity with human annexin-V, and another anti-human-annexin-V monoclonal antibody as the solid phase, produced by HCA-293HDR, another anti-human-annexin-V<br class="style-scope patent-text">monoclonal antibody-producing hybridoma cell line clone, and having a specific activity with human annexin-V.<br class="style-scope patent-text">     In the Figure, the ordinate indicates difference absorbance obtained by subtracting an absorbance measurement at the secondary wavelength 690nm from an absorbance measurement at the primary wavelength 492nm and the abscissa indicates the concentration of human annexin-V, in which each 0 mark represents the average difference absorbance and the length the arrows extending upward or downward from each 0 mark represents the average ~2SD respectively.<br class="style-scope patent-text">    Fig. 4 illustrates a calibration curve for use in ELISA<br class="style-scope patent-text">system for a still further working example different from the examples as shown by Figs. 1 through 3, in which the anti-human-15' annexin-V monoclonal antibodies of the present invention are employed to determine the concentration of 8M-urea-treated human annexin-V. The ELISA system is made up of a combination of a HRPO-labeled anti-human-annexin-V monoclonal antibody produced by HCA-155H, an anti-human-annexin-V monoclonal antibody-producing hybridoma cell line clone, and having a specific activity with human annexin-V, and another anti-human-annexin-V monoclonal antibody as the solid phase, produced by HCA-350HDR, another anti-human-annexin-V monoclonal antibody-producing hybridoma cell line clone, and having a specific activity with human annexin-V.<br class="style-scope patent-text">     In the Figure, the ordinate indicates difference absorbance obtained by subtracting an absorbance measurement at the secondary wavelength 690nm from an absorbance measurement at the primary wavelength 492nm and the abscissa indicates the concentration of human annexin-V, in which each ~ mark represents the average difference absorbance and the length of the arrows extending upward or downward from each ~ mark represents the average ~2SD respectively.<br class="style-scope patent-text">   Fig. 5 illustrates a calibration curve for use in ELISA<br class="style-scope patent-text">system for a working example different from the examples as shown by Figs. 1 through 4, in which the anti-human-annexin-V<br class="style-scope patent-text">monoclonal antibodies of the present invention are employed to determine the concentration of 8M-urea-treated human annexin-V.<br class="style-scope patent-text">    The ELISA system is made up of a combination of a HRPO-labeled anti-human-annexin-V monoclonal antibody produced by HCA-660HD, an anti-human-annexin-V monoclonal antibody-producing hybridoma cell line clone, and having a specific activity with human annexin-V, and another anti-human-annexin-V monoclonal antibody as the solid phase, produced by HCA-290HDR, another anti-human-annexin-V monoclonal antibody-producing hybridoma cell line clone, and having a specific activity with human annexin-V.<br class="style-scope patent-text">     In the Figure, the ordinate indicates difference absorbance obtained by subtracting an absorbance measurement at the secondary wavelength 690nm from an absorbance measurement at the primary wavelength 492nm and the abscissa indicates the concentration of human annexin-V, in which each 0 mark represents the average difference absorbance and the length of the arrows extending upward or downward from each 0 mark represents the average ~2SD respectively.<br class="style-scope patent-text">     Fig. 6 illustrates a calibration curve for use in ELISA<br class="style-scope patent-text">system for a further working example different from the examples as shown by Figs. 1 through 5, in which the anti-human-annexin-V<br class="style-scope patent-text">monoclonal antibodies of the present invention are employed to determine the concentration of 8M-urea-treated human annexin-V.<br class="style-scope patent-text">   The ELISA system is made up of a combination of a HRPO-labeled anti-human-annexin-V monoclonal antibody produced by HCA-660HD, an anti-human-annexin-V monoclonal antibody-producing hybridoma cell line clone, and having a specific activity with human annexin-V, and another anti-human-annexin-V monoclonal antibody as the solid phase, produced by HCA-57HDR, another anti-human-l0 annexin-V monoclonal antibody-producing hybridoma cell line clone, and having a specific activity with human annexin-V.<br class="style-scope patent-text">    In the Figure, the ordinate indicates difference absorbance obtained by subtracting an absorbance measurement at the secondary wavelength 690nm from an absorbance measurement at the primary wavelength 492nm and the abscissa indicates the concentration of human annexin-V, in which each ~ mark represents the average difference absorbance and the length of the arrows extending upward or downward from each ~ mark represents the average ~2SD respectively.<br class="style-scope patent-text">     Fig. 7 illustrates a calibration curve for use in ELISA<br class="style-scope patent-text">system for a still further working example different from the examples as shown by Figs. 1 through 6, in which the anti-human-annexin-V monoclonal antibodies of the present invention are employed to determine the concentration of 8M-urea-treated human annexin-V. The ELISA system is made up of a combination of a HRPO-labeled anti-human-annexin-V monoclonal antibody produced by HCA-660HD, an anti-human-annexin-V monoclonal antibody-producing hybridoma cell line clone, and having a specific activity with human annexin-V, and another anti-human-annexin-V monoclonal antibody as the solid phase, produced by HCA-293HDR, another anti-human-annexin-V monoclonal antibody-producing hybridoma cell line clone, and having a specific activity with human anneXin-V.<br class="style-scope patent-text">     In the Figure, the ordinate indicates difference absorbance obtained by subtracting an absorbance measurement at the secondary wavelength 690nm from an absorbance measurement at the primary wavelength 492nm and the abscissa indicates the l0 concentration of human annexin-V, in which each 0 mark represents the average difference absorbance and the length of the arrows extending upward or downward from each 0 mark represents the average ~2SD respectively.<br class="style-scope patent-text">     Fig. 8 illustrates a calibration curve for use in ELISA<br class="style-scope patent-text">15 system for another working example different from the examples as shown by Figs. 1 through 7, in which the anti-human-annexin-V<br class="style-scope patent-text">monoclonal antibodies of the present invention are employed to determine the concentration of 8M-urea-treated human annexin-V.<br class="style-scope patent-text">     The ELISA system is made up of a combination of a HRPO-labeled 2o anti-human-annexin-V monoclonal antibody produced by HCA-660HD, an anti-human-annexin-V monoclonal antibody-producing hybridoma cell line clone, and having a specific activity with human annexin-V, and another anti-human-annexin-V monoclonal antibody as the solid phase, produced by HCA-350HDR, another anti-human-25 annexin-V monoclonal antibody-producing hybridoma cell line clone, and having a specific activity with human annexin-V.<br class="style-scope patent-text">     In the Figure, the ordinate indicates difference absorbance obtained by subtracting an absorbance measurement at the secondary wavelength 690nm from an absorbance measurement at the primary wavelength 492nm and the abscissa indicates the concentration of human annexin-V, in which each 0 mark represents the average difference absorbance with the arrows extending upward or downward from each 0 mark represents the average ~2SD respectively.<br class="style-scope patent-text">     Fig. 9 illustrates a calibration curve for use in ELISA<br class="style-scope patent-text">system for a working example, in which the anti-human-annexin-V<br class="style-scope patent-text">monoclonal antibodies of the present invention are employed to determine the concentration of native human annexin-V. The ELISA<br class="style-scope patent-text">system is made up of a combination of a HRPO-labeled anti-dog-32KP polyclonal antibody, and an anti-human-annexin-V monoclonal antibody as the solid phase, produced by HCA-627, an anti-human-annexin-V monoclonal antibody-producing hybridoma cell line clone, deposited under the number FERM BP-5284 at the International Depositary Authority for the deposit of microorganisms and having a specific activity with native human annexin-V.<br class="style-scope patent-text">    In the Figure, the ordinate indicates difference absorbance obtained by subtracting an absorbance measurement at the secondary wavelength 690nm from an absorbance measurement at the primary wavelength 492nm and the abscissa indicates the concentration of human annexin-V, in which each 0 mark represents the average difference absorbance and the length of the arrows extending upward or downward from each 0 mark represents the average ~2SD respectively.<br class="style-scope patent-text">    Fig.lO is a microscopic photograph, under 200 diameter magnification, of human cardiac muscle tissue subjected to a specific staining by indirect enzyme antibody technique in which anti-human-annexin-V monoclonal antibody HCA-627 was employed as the primary antibody and HRPO-labeled-anti-mouse-immunoglobulin antibody was employed as the secondary antibody. The 'figure demonstrates that human annexin-V was stained in the form o,f uneven aggregates in the cytoplasm within the human heart of a patient with sudden death.<br class="style-scope patent-text">     Fig. 11 is a microscopic photograph, under a 200 diameter magnification, of human cardiac muscle tissue for comparison with the example as shown by Fig. 10. The figure demonstrates that without the use of the anti-human-annexin-V monoclonal antibody, it is impossible to stain human annexin-V and therefore to locate the distribution thereof.<br class="style-scope patent-text">     Fig. 12 illustrates a calibration curve for use in ELISA<br class="style-scope patent-text">system for a working example, in which the anti-human-annexin-V<br class="style-scope patent-text">monoclonal antibodies of the present invention are employed to determine the concentration of native human annexin-V. The ELISA<br class="style-scope patent-text">system is made up of a combination of a HRPO-labeled anti-2o annexin-V monoclonal antibody, produced by HDA-907, an anti-annexin-V monoclonal antibody-producing hybridoma cell line clone, deposited under the number FERM BP-5286 at the International Depositary Authority for the deposit of microorganisms and having a specific activity with native human annexin-V, and another anti-human annexin-V monoclonal antibody as the solid-phase, produced by HCA-627, an anti-human-annexin-V monoclonal antibody-producing hybridoma cell line clone and having a specific activity with native human annexin-V.<br class="style-scope patent-text">   In the Figure, the ordinate indicates absorbance obtained by subtracting an absorbance measurement at the secondary wavelength 690nm from an absorbance measurement at the primary wavelength 492nm and the abscissa indicates the concentration of human annexin-V, in which each ~ mark represents the average difference absorbance measured four times and the length of the arrows extending upward or downward from each 0 mark represents the average ~2SD<br class="style-scope patent-text">1o respectively.<br class="style-scope patent-text">    Fig. 13 shows the results of dilution tests performed on plasma samples by an ELISA system for assay of native human annexin-V concentration using the anti-annexin-V monoclonal antibodies of the present invention. The ELISA system was constructed using a combination of HRPO-labeled antihuman-annexin-V monoclonal antibody produced by anti-annexin-V<br class="style-scope patent-text">monoclonal antibody-producing hybridoma cell line clone HDA-907 (deposited under the number FERM BP-5286 at the International Depositary Authority for deposit of microorganism) and having a specific reactivity with annexin-V and anti-human-annexin-V monoclonal antibody as solid phase produced by anti-annexin-V monoclonal antibody-producing hybridoma cell line clone HCA-627 (deposited under the number FERM BP-5284 at the International Depositary Authority for deposit of microorganism) and having a specific reactivity with native human annexin-V.<br class="style-scope patent-text">   In the Figure, the ordinate shows human annexin-V <br class="style-scope patent-text"> <br class="style-scope patent-text"> concentration measured on the original solution and the series of diluted solution of each sample and the abscissa represents 1/dilution rate for each sample.<br class="style-scope patent-text">   The Best Mode for Carrying out the Invention While the present invention will be further illustrated by the examples given below, the invention is not to be limited by the following examples and description.<br class="style-scope patent-text">     In the following examples the symbol M represents molarity and it indicates, for a solution of mixture, the mol per liter of the solution.<br class="style-scope patent-text">   EXAMPLE 1: Hybridoma Preparation (1) Purification of human annexin-V<br class="style-scope patent-text"> The heart was excised from a human adult cadaver. After clearing the blood, the right ventricle was excised from the heart, followed by the removal of the connective tissue and the lipids therefrom. These operations were carried out in ice or at a 4 °C temperature.<br class="style-scope patent-text">     The heart was added with a buffer solution of the following composition in a ratio of ten times as much of the heart weight:<br class="style-scope patent-text">250mM, sucrose 0.5mM ethylene glycol bis(2-aminoethyl ether) tetraacetate (EGTA), 1mM phenylmethane sulfonyl fluoride (PMSF) and lOmM tris (tris(hydroxymethyl) aminomethane)HC1, pH7.4.<br class="style-scope patent-text">    The heart was then homogenized by a homogenizer and the homogenate was centrifuged at 3000xg for 15 minutes. The separated supernatant is added with 1M CaCl2 solution to give a final concentration of 2mM for mixing, followed by centrifugation at 28,OOOxg for an hour. To the residue was added 2m1 of lOmM <br class="style-scope patent-text"> <br class="style-scope patent-text"> EGTA for suspending the residue. The residue suspension was centrifuged at 28,OOOxg for 1 hour.<br class="style-scope patent-text">   The supernatant was subjected to gel filtration with Sephacryl S-300 (trade name) column available from Pharmacia Co.<br class="style-scope patent-text">for elution with pH 7.4 buffer solution (H) containing O.1M NaCl and 30mM Tris-HCl. The fraction containing protein having a molecular weight of 35 KDa was recovered and passed through an ion-exchange column (Biogelagarose: trade name) with an eluent of mM Tris HC1 solution (pH 7.4) containing NaCl in the to concentration range of 0 to 0.3M for purification by means of NaCl-concentration-gradient elution.<br class="style-scope patent-text">   The human annexin-V thus purified was divided into two portions, one of which was freeze-dried and then dissolved by O.1M sodium phosphate buffer (pH 7.b) containing 8M urea, The other part was freeze-dried and dissolved by O.1M sodium phosphate buffer (pH 7.6). The two parts were both preserved at 4°C. These parts of purified human annexin-V were measured for purity with sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) to quantify the protein concentration.<br class="style-scope patent-text">   Identification was also made of the purified annexin-V<br class="style-scope patent-text">protein: Peptide fractions were prepared by adding lysylendopeptidase and keeping the mixture at 37°C for 15 hours so as to allow the human annexin-V protein to react with lysylendopeptidase. The peptides thus obtained were analyzed for amino acid sequence on a Shimadzu~PPSQ-10 protein sequences to determine the amino acid sequences of the two peptide trademark fractions, based on Edman method (cf. Edman P. "A method for the determination of the amino acid sequence in peptide", Arch.<br class="style-scope patent-text">Biochem, Biophys., 1949, Vo1.22, page 475).<br class="style-scope patent-text">     As the N-terminal amino acid sequences of the two peptides from the purified protein are Glu-Tyr-Gly-Ser-Ser-Leu-Glu for the first and Gly-Thr-Asp-Glu-Glu-Lys-Phe-Ile-Thr-Ile-Phe-Gly-Thr for the second, the protein was identified as annexin-V.<br class="style-scope patent-text">(2) Mice BALB/c inbred-strain female mice 5 to 8 weeks of age were to maintained on a diet of standard pellets feeding water ad libitum in an animal-breeding chamber kept at the temperature of 23+1°C<br class="style-scope patent-text">and the humidity of 70~.<br class="style-scope patent-text">(3) Immunization The human annexin-V 100 micrograms/0.5m1 as prepared in (1) was mixed with an equal amount of Freund's complete adjuvant to be emulsified. The human annexin-V in emulsion was administered as the antigen into the abdominal cavities of four female mice 5 weeks of age in a dose of 15-40 micrograms of the purified annexin-V per mouse. The administration was made every two weeks for two months for the immunization of the mice. The mice were determined for the antibody titer to select mice having a high titer, which were administered, three weeks after, with 50 micrograms of the purified human annexin-V as a booster intravenously through the mice tails for final immunization.<br class="style-scope patent-text">(4) Cell fusion Three days after final immunization, the spleens were excised from BALB/c mice and the spleen cells were suspended in EMEM culture medium to prepare a suspension of spleen cells. The spleen cells were then washed four times with EMEM medium (available from Nissui Co.) and determined fox the number of cells. The result was that 7x108 living spleen cells were obtained.<br class="style-scope patent-text">     Cell fusion was conducted using P3-X63-Ag8 653 culture cells, hereinafter referred to as X63 cells, as parent cell strain, which are 2-amino-6-oxy-8-azapurine (8-azaguanine)-resistant and derived from BALB/c mouse myeloma. X63 cells in the logarithmic growth phase were employed to subculture in RPMI-1640 medium (at a concentration of 20 micrograms/ml and with 8-azaguanine) (available from GIHCO Co.), containing 10~ of immobilized fetal calf serum (hereinafter referred to as FCS) available from Intergen Co. Further cultivation was conducted, from three days prior to the cell fusion, in RPMI-1640 medium containing 10$ of FCS but not containing 8-azaguanine, in which the cells in the logarithmic growth phase were also employed.<br class="style-scope patent-text">  Following washing with RPMI-1640 medium three times, X63 cells were determined for the number of cells, with the result that the number of living X63 cells was 7x10.<br class="style-scope patent-text">     Polyethylene glycol-4000 available from Sigma Co. was dissolved in RPMI-1640 medium to give a concentration of 50~<br class="style-scope patent-text">(w/v) for use in the cell fusion.<br class="style-scope patent-text">    The spleen cells and X63 cells were mixed in a ratio of the spleen cells . X63 cells = 10:1. The mixture was centrifuged at 1500 rpm for five minutes, the supernatant was removed and the cells were well disintegrated to be used in the cell fusion. The cell fusion was carried out, using polyethylene glycol prepared in the aforesaid manner and kept at 37°C, in accordance with the method described in "Kdhller and Milstein . Nature, Vo1.256, pages 495-497 (1975)" and "European Journal of Immunology, Vol.6, pages 511-519 (1976)".<br class="style-scope patent-text">   The cell lines following the cell fusion for the hylaridoma formation were suspended in HAT selection medium containing RPMI-1640 added with FCS of a 10$ concentration, 1x10-4M hypoxanthine, 4x10-7M aminopterine and 1.6x10-5M thymidine, to give a spleen cell concentration of 2.0x106 per ml. Each 50 microliters 1o aliquot of the cell suspension was distributed in 96 wells, and incubated an incubator kept at 37°C temperature and 95~ humidity under a 8% C02 atmosphere. One drop of the HAT medium was added to each well on the first day and the second day from the start of the incubation, followed by the addition of two drops of the 15 same medium on the seventh and ninth day from the start for further incubation. Then incubation was carried out in a HAT-free culture medium. Approx. ten days to two weeks after the start, screening was made for hybridoma cell clones producing anti-human-annexin-V monoclonal antibodies capable of 2o specifically reacting with human annexin-V treated with urea of 8M concentration (8M-urea-treated human annexin-V) and/or with human annexin-V not treated with 8M urea (native human annexin-V). The screening was done by ELISA using a human annexin-V<br class="style-scope patent-text">absorption test and microplates in which human annexin-V as the 25 antigenic protein is adsorbed onto a solid phase.<br class="style-scope patent-text">   All the clones of established hybridoma cell lines producing anti-human-annexin-V monoclonal antibodies as well as anti-dog-32KP polyclonal antibody are sensitized for solid phase. In addition, the anti-human-annexin-V monoclonal antibodies produced from such clones as well as anti-dog-32KP<br class="style-scope patent-text">. polyclonal antibody are labeled with biotin. Thus, a variety of ELISA methods were employed: the solid-phase-coupled clones and anti-dog-32KP polyclonal antibody are used in combination with the biotin-labeled anti-human-annexin-V monoclonal antibodies and also anti-dog-32KP polyclonal antibody, in order to detect clones) producing anti-human-annexin-V monoclonal antibodies which will specifically react with 8M-urea-treated human annexin-V. native human annexin-V and native human annexin-V in the human blood, serum or plasma not treated with 8M urea.<br class="style-scope patent-text">(5) Screening As cell clones appeared ten days after the start of incubation, an absorption test with human annexin-V as the antigen was carried out by ELISA for the supernatants of hybridoma cell lines.<br class="style-scope patent-text">     It was found by the present inventors that the antigenic activity of human annexin-V treated with 8M urea solution is significantly higher than that of native human annexin-V, with anti-32KP polyclonal antibodies described later. Thus, the human annexin-V absorption test was carried out using the two types of antigens: human annexin-V treated with 8M urea (hereinafter referred to as (8M-urea-treated human annexin-V) and human annexin-V with no such urea-treatment (hereinafter referred to as native human annexin-V).<br class="style-scope patent-text">  Thus, a first set is constituted of 50 microliters per well of 8M-urea-treated human annexin-V solution (the 8M-urea-treated human annexin-V concentration being 200ng/ml) and 50 microliters per well of the culture supernatant of hybridoma cell line distributed each U-bottomed well of a microtiterplate, while a second set is constituted of 50 microliters per well of native human annexin-V (the native human annexin-V<br class="style-scope patent-text">concentration being 200ng/ml) and 50 microliters per well of the supernatant of hybridoma cell line distributed in each U-bottomed well of another microtiterplate. Each well was added l0 with 50 microliters of 20~ suspension of Sepharose*4B combined with anti-mouse-immunoglobulin antibody and allowed to stand for 10 minutes following stirring for one hour. With each set, when it was observed that the anti-mouse-immunoglobulin antibody-combined Sepharose*4B completely sedimented on the well bottom, 15 the respective supernatants 25 microliters were employed to measure remaining human annexin-V concentration therein by means of the human annexin-V ELISA method.<br class="style-scope patent-text">   In this measurement, if any anti-human-annexin-V<br class="style-scope patent-text">monoclonal antibodies against human annexin-V was present in the culture supernatant of hybridoma cell line, reactions will occur between human annexin-V and the anti-human-annexin-V monoclonal antibodies, followed by a reaction with anti-mouse-immunoglobulin monoclonal antibody-combined Sepharose* 4B, resulting in the formation of antigen-antibody 25 complexes which are to sediment. This will lead to a decrease in the human annexin-V content remaining in the supernatant and it is therefore possible to identify the presence of any anti-human-annexin-V monoclonal antibodies trademark through the measurement of the human annexin-V<br class="style-scope patent-text">concentration in the supernatant.<br class="style-scope patent-text">    After the screening was completed in the above-mentioned manner for anti-human-annexin-V monoclonal antibodies capable of reacting with human annexin-V as the antigenic protein, a test was conducted to study the difference in epitopes with which the anti-human-annexin-V monoclonal antibodies will react.<br class="style-scope patent-text">    Thus, 8M-urea-treated human annexin-V and native annexin-V<br class="style-scope patent-text">as the antigenic solutions, each having been prepared to have a 1o concentration of 1 microgram/ml, were absorbed onto a microtiterplate in an amount of 50 microliters per well, followed by washing three times with phosphate buffer solution (hereinafter referred to as PBS) containing 0.05$ Tween~20, a Tween~ surfactant, and blocking with PBS containing 1$ BSA to prepare plates with solid phase-coupled human annexin-V antigens.<br class="style-scope patent-text">   A solid phase-coupled human annexin-V antigen in the plates thus obtained was allowed to react, for one hour at room temperature, with a culture supernatant of the hybridoma cell lines producing monoclonal antibodies capable of reacting with 2o human annexin-V screened by the human annexin-V absorption test.<br class="style-scope patent-text">  The resulting antigen-antibody complexes were subjected to three times of washing with the washing solution and allowed to react, for thirty minutes at room temperature, with anti-mouse-immunoglobulin antibodies (from goats) labeled with horseradish peroxidase (hereinafter referred to as HRPO). Following the reaction, the resultant antigen-antibody complexes were subjected to washing four times with the washing solution and allowed to trademark react, at room temperature for five minutes, with OPD substrate solution containing O.1M phosphate-citrate buffer solution, . 2mg/ml o-phenylenediamine and 4mM H202, and then the reaction was terminated with 2N H2S04 and absorbance measurement was performed by the dual wavelength method at' 492nm as the primary wavelength and at 690nm as the secondary wavelength on an ELISA plate reader.<br class="style-scope patent-text">     At the primary wavelength 492nm absorbance is measured with the substrate undergone the reaction due to the bound labeled antibodies, while at the secondary wavelength the absorbance reflects cracks or stains of the microtiterplates. Accordingly, the subtraction of the absorbance at the secondary wavelength from that at the primary wavelength makes it possible to determine the absorbance reflecting the amount of the enzyme on the labeled antibodies which have bound to the solid phase-coupled antigen in proportion to the amount of the antigen.<br class="style-scope patent-text">(6) Studies on reactivities with solid phases sensitized with annexin-V antigens from various organs and animals Studies were made of the anti-human-annexin-V monoclonal 2o antibodies thus obtained for the species-dependent specificities with annexin-V derived from various human organs and animals, using the solid phases sensitized in the above-mentioned manner for human annexin-V.<br class="style-scope patent-text">   With each annexin purified from the various human organs and animals, a solution was prepared to give a concentration of 1 microgram/ml with O.1M phosphate buffer at pH 7.5. 50 microliters of each antigen solution was distributed in a 96-well microtiterplate for the adsorption overnight at 4°C, followed by washing twice with the washing solution and blocking with the blocking solution. The solid phases sensitized with the various annexin-V antigens were allowed to react with the anti-human-annexin-V monoclonal antibodies obtained by the example herein.<br class="style-scope patent-text">     The reaction products were assayed by the ELISA method in the same manner for the screening, for determining the reactivities of the anti-human-annexin-V monoclonal antibodies as obtained by the present invention with the respective annexin-V antigens.<br class="style-scope patent-text">(7) Studies on reaction specificities by Western blotting Homogenized specimens of the human cardiac muscle, the human liver, the human kidney, the human lungs, the beagle's cardiac muscle and the rat's cardiac muscle were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 10 to 20$ polyacrylamide gel to fractionate the protein fractions. The protein fractions are then transferred into nitrocellulose membranes, followed by a blocking with PBS<br class="style-scope patent-text">containing 3~ skim milk and 1$ BSA. Then the protein fractions fixed onto the membranes were allowed to react with the respective monoclonal antibodies to examine reactive protein fractions derived from the various organs and animals.<br class="style-scope patent-text">(8) Establishment of hybridoma cell lines producing monoclonal antibodies Based on the above-mentioned studies, eighty-four strains were screened which are hybridoma cell line clones capable of reacting with 8M-urea-treated human annexin-V, through the absorption test using human cardiac muscle annexin-V. From such strains twenty-one clone strains were strictly selected depending 2 ~ soa3o upon the difference in reactivities with type of annexin-V<br class="style-scope patent-text">derived from the various organs and animals. Thus, the twenty-one strains were classified into the following five groups depending upon the reactivities:<br class="style-scope patent-text">(i) Clones which exhibit a high reactivity in the 8M-urea-treated human cardiac muscle annexin-V absorption test, but do not exhibit reactivities with any of the antigen-sensitized solid phases: five strains (clone HCA-212, clone HCA-290, clone HCA-656, clone HCA-713 and clone HCA-805).<br class="style-scope patent-text">(ii) Clones which exhibit a high reactivity in the 8M-urea-treated human cardiac muscle annexin-V absorption test and also exhibit a high reactivity with the human-annexin-V-sensitized solid phase, but exhibit almost no or a low reactivity with the beagle dog- and rat-derived-annexin-V-sensitized solid phases:<br class="style-scope patent-text">eight strains (clone HCA-69H, clone HCA-155H, clone HCA-231H, clone HCA-671H, clone HCA-770H, clone HCA-784H, clone HCA-803H<br class="style-scope patent-text">and clone HCA-838H).<br class="style-scope patent-text">(iii) Clones which exhibit high reactivities in the 8M-urea treated human cardiac muscle annexin-V absorption test, as well as with all of the solid phases sensitized with annexin-V<br class="style-scope patent-text">antigens derived from the various human organs, the beagle's and the rat's cardiac muscles: four strains (clone HCA-57HDR, clone HCA-293HDR, clone HCA-350HDR and clone HCA-805HDR).<br class="style-scope patent-text">(iv) Clones which exhibit high reactivities in the 8M-urea treated human cardiac muscle annexin-V absorption test and also with the solid phases sensitized with annexin-V antigens from the human cardiac muscle, the human kidney or the human liver, but exhibit only low reactivities with the solid phases sensitized with annexin-V antigens from the beagle's and the rat's cardiac muscles: three strains (clone HCA-507HD, clone HCA-660HD and clone HCA-646HD).<br class="style-scope patent-text">(v) A clone which exhibit high reactivities in the 8M-urea-treated human cardiac muscle annexin-V absorption test as well as in the native human cardiac muscle annexin-V absorption test: one strain (clone HCA-627).<br class="style-scope patent-text">     Thus, there were obtained monoclonal antibodies having different reactivities as classified into the five groups 1o mentioned in the above.<br class="style-scope patent-text">     The reaction specificities of these monoclonal antibodies are shown in Table 1 below. <br class="style-scope patent-text"> <br class="style-scope patent-text"> <span class="patent-image-not-available style-scope patent-text"></span> <span class="patent-image-not-available style-scope patent-text"></span> <span class="patent-image-not-available style-scope patent-text"></span> (9) Cloning The hybridoma cell lines producing monoclonal antibodies as classified into the above-mentioned five groups were subjected to cloning by the limiting dilution to obtain a single clone. In performing the cloning, thymus cells prepared from BALB/c mice and suspended in HAT medium was added as the feeder cell at a rate of 1x106 per well. </div>
      <div class="description-paragraph style-scope patent-text">(10) Identification of mouse immunoglobulin subclass Identification of mouse immunoglobulin subclass was made with the monoclonal antibodies produced by the hybridoma cell lines which have been prepared as having a single clone by means of the above-mentioned cloning. The culture supernatants of the respective hybridoma cell lines were assayed for the mouse immunoglobulin subclass identification using a MONOAb~typing kit (available from Zymed Co.) The result was that seven clones have IgG1 type, eleven clones IgG2a type and three clones IgG2b type, with regard to the H chain. Regarding the L chain, all the clones were found to have k chain (Table 1).<br class="style-scope patent-text">     The respective clones classified into the five groups are shown in Table 1.<br class="style-scope patent-text">  EXAMPLE 2: Production of Monoclonal Antibodies (1) Harvest of ascitic fluid In order to obtain a higher concentration of anti-human-cardiac-muscle-annexin-V monoclonal antibodies, the various hybridoma cells are grown and the resulting respective clones were inoculated, following washing three times with EMEM culture * trademark 2 ~ goa3o solution, into the ascitic cavities of HALB/c mice which have been administered with 2,6,10,14-tetramethyl pentadecane (pristane) in advance into their ascitic cavities. The ascitic fluids were harvested seven to fourteen days after the inoculation of the hybridoma cell lines into the ascitic cavities. The ascitic fluids thus obtained were applied to centrifuge to remove the cellular and residual fractions. The supernatant fractions were pooled for keeping at 4°C.<br class="style-scope patent-text">(2) Purification for the anti-human cardiac-muscle-annexin-V<br class="style-scope patent-text">1o monoclonal antibodies from the ascitic fluids The respective anti-human-cardiac-muscle-annexin-V<br class="style-scope patent-text">monoclonal antibodies were purified by a combination of salting-out and ion-exchange chromatography to recover the purified IgG<br class="style-scope patent-text">fractions.<br class="style-scope patent-text">     Thus, 20m1 of each clone was added with an equal amount of phosphate-buffered saline (PBS), followed by the addition of anhydrous sodium sulfate to give a final concentration of 20%(w/v) with stirring at room temperature. The mixture was stirred for an additional one hour.<br class="style-scope patent-text">20~ Centrifugation was then performed at 12,000 rpm with a high-speed centrifuge (available form Hitachi. Co.) and the resulting residue fraction was dissolved in approx. 10 ml of phosphate-buffered saline. The solution was dialyzed three times against mM sodium phosphate buffer solution (pH 7.0) as the outer solution. On completing the dialysis, from the dialyzed solution the IgG fraction of the anti-human-cardiac-muscle-annexin-V<br class="style-scope patent-text">monoclonal antibody was purified by ion-exchange chromatography using a DEAE (diethylaminoethyl cellulose) column DE-52 (available from Whatman Co.) measuring 1.5 cm in inner diameter and 8 cm in length equilibrated with 20 mM sodium phosphate buffer solution (pH 7.0), from which the purified IIgG fraction was obtained as the pass-through fraction or as the eluent fraction a~ a NaCl concentration in the range of 30 mM<br class="style-scope patent-text">gradationally up to 50 mM formed with 20 mM sodium phosphate buffer solution (pH 7.0) containing 30 mM to 50 mM NaCl. Each of the purified clones was determined for the purity of IgG<br class="style-scope patent-text">fraction, by high performance liquid chromatography using a TSK gel G3000SW column (available from Tosoh. Co.) and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using PhastSystem* available from Pharmacia Co. The purity was found to be 95$ or higher.<br class="style-scope patent-text">     EXAMPLE 3: ELISA Assay System for Human Cardiac Muscle Annexin-V<br class="style-scope patent-text">(1) Preparation of anti-human-cardiac-muscle-annexin-V<br class="style-scope patent-text">monoclonal antibodies for HRPO-labeling The IgG fractions of clones HCA-155 and HCA-660HD were purified in the manner as described in Example 2 to study the application to ELISA system for human cardiac muscle annexin-V<br class="style-scope patent-text">assay.<br class="style-scope patent-text">(2) Preparation of HRPO-labeled anti-human-cardiac-muscle-annexin-V monoclonal antibodies (A) Preparation of anti-human-cardiac-muscle-annexin-V<br class="style-scope patent-text">monoclonal antibodies F(ab')2 For labeling the IgG fractions of the anti-human-cardiac-trademark muscle-annexin-V monoclonal antibodies, each 10 mg of the anti-human-cardiac-muscle-annexin-V monoclonal antibodies was subjected to centrifugal filtration with a centrifugal concentrator (Centricon 10 available from Amicon Co.) to give a final volume of 1 ml. The concentrated antibody was dialyzed against 0.1 M sodium acetate buffer (pH 4.0) containing 0.2 M<br class="style-scope patent-text">   NaCl as the solvent.<br class="style-scope patent-text">     The IgG solution resulting from the dialysis was added with a solution of pepsin (available from Sigma Co.) dissolved in 1 M<br class="style-scope patent-text">1o sodium acetate buffer (pH 4.0) containing 0.2 M NaCl, so that the pepsin is 4~ of the IgG content, followed by reaction at 37°C for 6 to 16 hours. On completing the reaction, the resultant was applied to molecular-sieve chromatography using a Sephadex* G-150 column (available from Pharmacia Co.) for gel filtration, 15 which has been equilibrated with 0.1 M sodium borate buffer (pH<br class="style-scope patent-text">8.0), to obtain the F(ab')2 fragments of the respective anti-human-cardiac-muscle-annexin-V monoclonal antibodies.<br class="style-scope patent-text">(H) Preparation of anti-human-cardiac-muscle-annexin-V<br class="style-scope patent-text">monoclonal Fab'-SH<br class="style-scope patent-text">2o Each of the anti-human-cardiac-muscle-annexin-V monoclonal antibodies F(ab')2 as prepared in the aforesaid (A) was subjected to centrifugation for further concentration by a Centricon*<br class="style-scope patent-text">centrifugal concentrator to prepare the concentrated F(ab')2 fractions of the respective anti-human-cardiac-muscle-annexin-V<br class="style-scope patent-text">25 monoclonal antibodies.<br class="style-scope patent-text">    The concentrated fraction was added with 0.1 ml of 100 mM 2-mercaptoethylamine hydrochloride (available from Kishida trademark 40 Chemicals Co.) solution for reaction at 37°C for 9b minutes. On completing the reaction, the resultant was applied to a Sephadex*<br class="style-scope patent-text">   G-25 column for equilibrium gel filtration (available from Pharmacia Co.) measuring 1.6 cm in diameter and 20 cm in length which has been equilibrated with 0.1 M sodium phosphate buffer (pH 6.0) containing 1 mM EDTA, for fractional purification of the Fab'-SH fraction, followed by centrifugal concentration by a Centricon~l0 centrifugal concentrator, to give a final volume of 1 ml. Thus, the concentrated Fab'-SH fractions of clones HCA-155H and HCA-660HD anti-human-cardiac-muscle-annexin-V monoclonal antibodies were prepared.<br class="style-scope patent-text">(C) Preparation of HRPO maleimide Ten mg (as a protein content) of HRPO (available from Boehlinger Co.) was dissolved in 1 ml of 0.1 M sodium phosphate buffer (pH 6.0). The resulting solution was added with 100 microliters solution of N-hydroxysuccinimide ester (available from Zeeben Chemicals Co.) dissolved in dimethylformamide (DMF) (available from Kishida Chemicals Co.) to give a final concentration of 25 mg/ml, followed 2o by reaction at 30°C for 60 minutes to prepare maleimide ester of HRPO. On completing the reaction, the solution was centrifuged for five minutes at 3000 rpm. The supernatant was applied to a SephadeX G-25 column for equilbrium gel filtration (available from Pharmacia Co.) measuring 1.6 cm in diameter and 20 cm in length, which has been equilibrated with 0.1 M<br class="style-scope patent-text">sodium phosphate buffer (pH 6.0), in order to purify HRPO<br class="style-scope patent-text">maleimide. The purified fraction of HRPO maleimide was then trademark subjected to centrifugal concentration by a Centricon 10 centrifugal concentrator to prepare the concentrated fraction of HRPO maleimide.<br class="style-scope patent-text">(D) Preparation of HRPO-labeled anti-human-cardiac-muscle-annexin-V monoclonal Fab' antibodies ' The concentrated Fab'-SH fraction of each anti-human-cardiac-muscle-annexin-V monoclonal antibody and the concentrated fraction of HRPO maleimide were mixed together at a molar ratio of 1:1, for reaction at 4°C for 15 to 24 hours. On completing the reaction, 2-mercaptoethylamine was added to give a concentration of 2 mM in the reaction solution, followed by reaction at 37°C for 20 minutes in order to block unaltered HRPO<br class="style-scope patent-text">maleimide. The resultant was then subjected to molecular-sieve gelchromatography using a Ultragel~ACA44 column (available from lg Pharmacia Co.) equilibrated with 20 mM sodium phosphate - sodium citrate buffer containing 0.15 M NaCl and 2.5mM EDTA (pH 5.6) and measuring 1.6 cm in diameter and 65 cm in length, for removing unaltered Fab'-SH of the anti-human-cardiac-muscle-annexin-V<br class="style-scope patent-text">monoclonal antibodies and unaltered HRPO maleimide and purifying the HRPO-labeled anti-human-cardiac-muscle-annexin-V monoclonal Fab' antibodies (hereinafter referred to as HRPO-labeled anti-human-cardiac-muscle-annexin-V monoclonal antibodies).<br class="style-scope patent-text">(3) Preparation of anti-dog-32KP polyclonal antibodies IgG<br class="style-scope patent-text">  Anti-dog-32KP-annexin-V polyclonal antiserum was obtained by immunizing rabbits with dog-derived purified 32KP annexin-V<br class="style-scope patent-text">antigen. To three ml of the antiserum was added an equal amount of phosphate-buffered saline (PBS), followed by the addition of anhydrous sodium sulfate to give a final concentration of 20%<br class="style-scope patent-text">* trademark with stirring and an additional stirring for one hour at room temperature. The resultant was then centrifuged at 12,000 rpm for 10 minutes, and the residue obtained was dissolved in approx.<br class="style-scope patent-text">3 ml of saline. The solution was then subjected to dialysis against 20 mM sodium phosphate (pH 7.0) as the solvent. On completing the dialysis, the resulting solution was applied to ion-exchange chromatography using a DEAF cellulose DE-52 column (available from Whatman Co.) equilibrated with 20 mM sodium phosphate buffer (pH 7.0) and measuring 1.5 cm in diameter and 6 cm in length, to purify the IgG fraction of anti-dog-32KP-annexin-V polyclonal antibody. From 3 ml of the anti-dog-32KP=<br class="style-scope patent-text">annexin-V polyclonal antibody-containing antiserum there was obtained 13 mg of the purified IgG fraction.<br class="style-scope patent-text">(4) Preparation of HRPO-labeled anti-dog-32KP-annexin-V<br class="style-scope patent-text">15, polyclonal antibody (A) Preparation of anti-dog-32KP-annexin-V polyclonal antibody F(ab')2 For labeling the purified IgG fraction of the anti-dog-32KP<br class="style-scope patent-text">annexin-V polyclonal antibody, 12 mg of aforesaid antibody was applied to a Centricon 10 centrifugal concentrator (available from Amicon Co.) to give a concentrated volume of 1 ml, followed by dialysis against 0.1 M sodium acetate buffer (pH 4.5) containing 0.2 M NaCl.<br class="style-scope patent-text">     The antibody solution resulting from the dialysis was added with a solution of pepsin (available from Sigma Co.) dissolved in 0.1 M sodium acetate (pH 4.5) containing 0.2 M NaCl to give a concentration of 4% based on the IgG content, followed by reaction at 37°C for 16 hours. On completing the reaction, the resultant was applied to molecular-sieve chromatography using a Sephadex*G-150 column for equilibrium gel filtration (available from Pharmacia Co.) equilibrated with 0.1 M sodium borate buffer (pH 8.0) and measuring 1.6 cm in diameter and 65 cm in length, to fractionate and purify the F(ab')2 fraction of the antibody.<br class="style-scope patent-text">  The resulting fraction was subjected to dialysis against sodium phosphate buffer (pH 6.0) containing 1 mM EDTA as the solvent. On completing dialysis, the dialyzed solution was applied to 1o Centrifugal concentration by a Centricori 10 centrifugal concentrator to give a final volume of 1 ml. The solution resulting from the dialysis was used to prepare the labeled antibody as the anti-dog-32KP-annexin-V F(ab')2 polyclonal antibody. Thus, from 12 mg of the IgG fraction of the anti-15 dog-32KP polyclonal antibody obtained in the above-mentioned manner, there was prepared approx. 7 mg of the F(ab')2 fraction.<br class="style-scope patent-text">(B) Preparation of anti-dog-32KP-annexin-V polyclonal Fab'-SH<br class="style-scope patent-text">  To 7 mg/ml solution of anti-dog-32KP polyclonal antibody F(ab')2 fraction as prepared in above (A) was added 0.1 ml of 100 mM 2-mercaptoethylamine chloride (available from Kishida Chemicals Co.) for reaction at 37°C for 90 minutes. On completing the reaction, the resultant was applied to a Sephadex*<br class="style-scope patent-text">  G-25 column (available fro Pharmacia Co.) for equilibrium gel 25 filtration measuring 1.6 cm in diameter and 20 cm in length equilibrated with 0.1 M sodium phosphate buffer (pH 6.0) containing 1 mM EDTA, to purify the Fab'-SH fraction. The fraction was then subjected to centrifugal~concentration by a * trademark Centricon 10 centrifugal concentrator to a volume of 1 ml. Thus, from 7 mg of the F(ab')2, there was obtained 6.1 mg of anti-dog-32KP annexin-V polyclonal antibodies Fab'-SH.<br class="style-scope patent-text">(C) Preparation of HRPO maleimide Ten mg (as a protein content) of HRPO (available from Boehlinger C0.) was dissolved in 1 ml of 0.1 M sodium phosphate buffer (pH 6.0). The resulting solution was added with 100 microliters solution of N-hydroxysuccinimide ester (available from Zeeben Chemicals Co.) dissolved in to dimethylformamide (DMF) (available from Kishida Chemicals Co.) to give a final concentration of 25 mg/ml, followed by reaction at 30°C for 60 minutes to prepare maleimide ester of HRPO. On completing the reaction, the solution was centrifuged for five minutes at 3000 rpm. The supernatant was applied to a 15 Sephadex G-25 column for equilibrium gel filtration (available from Pharmacia Co.) measuring 1.6 cm in diameter and 20 cm in length, which has been equilibrated with 0.1 M sodium phosphate buffer (pH 6.0), in order to purify HRPO maleimide. The purified fraction of HRPO maleimide was then subjected to 20 (centrifugal) concentration by a Centricon 10 centrifugal concentrator to prepare the concentrated fraction of HRPO<br class="style-scope patent-text">maleimide.<br class="style-scope patent-text">(D) Preparation of HRPO-labeled anti-dog-32KP-annexin-V<br class="style-scope patent-text">polyclonal antibody Fab' 25 The Fab'-SH fraction of anti-dog-32KP-annexin-V polyclonal antibody thus obtained was mixed with the HRPO maleimide fraction at a molar ratio of 1:1, for reaction at 4°C for 15 to 24 hours. Then the resultant was added with 2-mercaptoethylamine hydrochloride to give a concentration of 2 mM in the reaction solution, followed by reaction at 37°C for 20 minutes to block unaltered HRPO maleimide. The resultant was then subjected to gelchromatography using a Ultrogel ACA44 column (available from Pharmacia Co.) equilibrated with 20 mM sodium phosphate-sodium citrate buffer (pH 5.6) containing 0.15 M NaCl and 2.5 mM EDTA<br class="style-scope patent-text">and measuring 1.6 cm in diameter and 65 cm in length, for removing unaltered anti-dog-32KP-annexin-V polyclonal antibody Fab'-SH fraction and unaltered HRPO maleimide and purifying HRPO-labeled anti-dog-32KP-annexin-V polyclonal antibody (hereinafter referred to as HRPO-labelled antibodies).<br class="style-scope patent-text">(E) HRPO activity determination In determining the HRPO enzyme activity of the HRPO-labeled antibodies, 2.98 ml of 0.1 M sodium phosphate buffer (pH 7.0) containing 0.2$ phenol, 0.5 mM hydrogen peroxide and 0.15 mg/ml 4-amino antipyrine were added with 20.microliters of the HRPO-labeled antibodies to give a total volume of 3.0 ml, followed by reaction at 37°C for five minutes, and measurement of absorbance at 500nm by means of the Rate assay. HRPO activity was determined by measuring the difference in absorbance (0 Abs) per one minute.<br class="style-scope patent-text">(5) Preparation of anti-human-cardiac-muscle-annexin-V<br class="style-scope patent-text">monoclonal antibodies solid phase As monoclonal antibodies for use in the solid phase in an ELISA system for the assay of human cardiac muscle annexin-V<br class="style-scope patent-text">clones HCA-290, HCA-627, HCA-57HDR, HCA-293HDR and HCA-350HDR<br class="style-scope patent-text">trademark were selected and the IgG fractions of the respective clones were purified from the ascitic fluids in the same manner described in Example 3.<br class="style-scope patent-text">    The IgG fraction of each of the anti-human annexin-V<br class="style-scope patent-text">monoclonal antibodies was adjusted to have a concentration-of 30 micrograms/ml with 0.1 M sodium phosphate buffer (pH 7.5) containing 0.1$ sodium azide, and distributed in a microtiterplate for ELISA (available from Nunc Co.) at a rate of 100 microliters per well, for sensitization at 4°C overnight.<br class="style-scope patent-text">to Then each well of the microtiterplate was washed three times with phosphate-buffered saline (PBS) containing 0.05 Tween~ 20 surfactant, and then added with 300 microliters of PBS containing 1~ BSA (as the blocking solution), followed by a further blocking operation at 4°C overnight, to prepare_antibody-plates sensitized with anti-human-cardiac-muscle-annexin-V monoclonal antibodies (hereinafter referred to as anti-human-annexin-V monoclonal antibody plates).<br class="style-scope patent-text">(6) Studies on ELISA assay system using anti-human-annexin-V monoclonal antibodies 2o The anti-human-annexin-V monoclonal antibody plates prepared in the above-mentioned manner were added, after the blocking solution discarded, with 10 mM sodium phosphate buffer (pH 7.0) containing 1$ BSA, 0.15 M NaCl and 5 mM EDTA at a rate of 100 microliters per well. Standard antigen solutions were prepared, with 8M-urea-treated human annexin-V antigen (obtained by the treatment with 8M urea), and native annexin-V (obtained by no treatment with 8M urea), to give concentrations of 1.5625 ng/ml, trademark 3.125 ng/ml, 6.25 ng/ml, 12.5 ng/ml, 25 ng/ml, 50 ng/ml and 100 ng/ml. The respective standard antigen solutions were added to the well at a rate of 20 microliters per well, followed by stirring and reaction for one hour at room temperature. On completing the reaction, each well was washed three times with the washing solution. To each of the washed wells were added the HRPO-labeled anti-human-annexin-V monoclonal antibodies Fab' (from clones HCA-155H and HCA-660HD) at a rate of 100 microliters per well, for reaction at room temperature for thirty minutes.<br class="style-scope patent-text">1o Following the reaction, each well was washed six times with washing solution and then added with 100 microliters of OPD<br class="style-scope patent-text">substrate solution containing 2 mg/ml o-phenylenediamine and 4 mM<br class="style-scope patent-text">    H202, for reaction for thirty minutes. The reaction was terminated by adding 2N H2S04 solution at a rate of 100 microliters per well. Absorbance was determined on an ELISA<br class="style-scope patent-text">plate reader by the dual wavelength method at 492nm as the primary and at 690nm as the secondary.<br class="style-scope patent-text">     The absorbance herein intended is obtained by subtracting an absorbance measurement at the secondary wavelength 690nm from that at the primary wavelength 492nm.<br class="style-scope patent-text">     The results of the absorbance measured are given in Table 2 below, with respect to 8M-urea-treated-human annexin-V<br class="style-scope patent-text">standard antigen solutions. <br class="style-scope patent-text"> <br class="style-scope patent-text"> H      O ' ~l   ~      CTL1  u~.-ap~ t~lDm n W    '~     (0U7  ~ tI101N t0d~V'M  <br class="style-scope patent-text"> <br class="style-scope patent-text"> O      S.~N   ~ O O N M tm0 O -(/]  ,~  ~ f N    'rl    &gt;     O O O O O O ~ M  <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'ri  +~                        <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'b   1~                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> O    ~                       <br class="style-scope patent-text"> <br class="style-scope patent-text"> .&gt;a           N                    <br class="style-scope patent-text"> <br class="style-scope patent-text"> x        O~  N d'01N O M Lf1Lf1 f0  M d'ODOOLI1M O N  <br class="style-scope patent-text"> <br class="style-scope patent-text"> l..i  O O O ~ M Iwo o~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> O           <br class="style-scope patent-text"> <br class="style-scope patent-text"> I        ~   O O O O O O ~ N  <br class="style-scope patent-text"> <br class="style-scope patent-text"> H          <br class="style-scope patent-text"> <br class="style-scope patent-text"> c0   U                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> x o    I                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> H    '&gt;7    O     r-I~O d'N O i11M  <br class="style-scope patent-text"> <br class="style-scope patent-text"> U    N      O1    Lf1M OOV~M N 10.-O    rl     (OO   O O O ~ M I~L!100 sav~                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> O    .L~    ~ N   O O O O O O ~-N  <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ 1   1 H                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> I           <br class="style-scope patent-text"> <br class="style-scope patent-text"> .L~  O                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> W     <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~r x      ~ o LT        l..i~r-I  N d'u'1O~01~OO t0 '.1  "      c0-1~  d'O O ~ O O N m -h ~  ~.  TJ~0LlO O O O O O O O  <br class="style-scope patent-text"> <br class="style-scope patent-text"> tv ~   ~ .,~~/]                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~ C   f0~   O O O O O O O O  <br class="style-scope patent-text"> <br class="style-scope patent-text"> U7 O   -N~                    <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~.,O~  U1Ca I    (n C          <br class="style-scope patent-text"> <br class="style-scope patent-text"> -.-I ~  I         O ~-V~u1I~t0LI1N  <br class="style-scope patent-text"> <br class="style-scope patent-text"> V1           00d'OD01Ll1N ~-01 O    H  ~       M O O O r'M I~10OD <br class="style-scope patent-text"> <br class="style-scope patent-text"> W  N     U1  O O O O O O ~ N  <br class="style-scope patent-text"> <br class="style-scope patent-text"> G    O  ~   ~ N   O o0O O O ~OCOcr fd   4-1    O ~   ~ d~~1l0~1'M r-D1 II    O N O O O ~ M l~l000 U7     f..lL.~                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> x    ~  ~   ~ ~   O O O O O O - N  <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'r-1U   .~U7 '    'i~~   ~ 41 N    O  rt7 ~ ~   l0M M N N d0N O  <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~   .Il.~  Z ~   O Wit'0101Ll1M 0001 (0   'r-If-I     ~ O O O ~ M L~Ll101 N +~ O                          <br class="style-scope patent-text"> <br class="style-scope patent-text"> 1.~  ~  U1        O O O O O O r'N  <br class="style-scope patent-text"> <br class="style-scope patent-text"> i-~                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> I       ~               __ cd   r-i O    ~          r1 O  tn I                                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> U  .~  I                      <br class="style-scope patent-text"> <br class="style-scope patent-text"> ao   O  0..                        <br class="style-scope patent-text"> <br class="style-scope patent-text"> G      aoG                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> O  '~    c0G                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> O    ~, ~rl 4-I~ N                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> O ~                    <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~    ~  o     x -~1 a~                                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> ro   o  cn  s~  +~  ~r, +~                                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> Ul          O '~~   N u'1 U7   ~  O   ~ri~ ~   1DN Lf1 ~-, O  01  ~1-J~!    L(1.-N L!1 ~r-IN   ((3f0~                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~ I   1...1O 1 O ~ M l0N L11O O  <br class="style-scope patent-text"> <br class="style-scope patent-text"> N  ~   i~l.a~         ~ N tf1O  <br class="style-scope patent-text"> <br class="style-scope patent-text"> I    C  U   G -+~                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> N    -~Ix   v 1 x .L~    U (0N                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> N    ~  ' ~ N G                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> O  ~   O f..a ,1a  U  c0  U ~                    <br class="style-scope patent-text"> <br class="style-scope patent-text"> H                                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> H           v b~La  01d'M ~O10ODI~  <br class="style-scope patent-text"> <br class="style-scope patent-text"> W    'U     (0U7  O Wit'O O O W M  <br class="style-scope patent-text">~ M   <br class="style-scope patent-text"> <br class="style-scope patent-text"> O      !-iN   O O ~-N ~'01OD .<br class="style-scope patent-text">     O~  <br class="style-scope patent-text"> <br class="style-scope patent-text"> ,p     O +                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> v    '~     &gt;     O O O O O O ~  <br class="style-scope patent-text">   N   <br class="style-scope patent-text"> <br class="style-scope patent-text"> .ri C                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> O                                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> .LZ            v -r-I   n-'T'.      LT  ~Or'OOM LC1M Lf1 M   <br class="style-scope patent-text"> <br class="style-scope patent-text"> LC1      (!J  O d~ODO~t~01tf1 S.-i  O O O - M C~lt1 ~O  <br class="style-scope patent-text"> <br class="style-scope patent-text"> t        ~   O O O O O O ~  <br class="style-scope patent-text">N   <br class="style-scope patent-text"> <br class="style-scope patent-text"> H                                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> c0   U  <br class="style-scope patent-text"> <br class="style-scope patent-text"> o    I                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> H    '~     O     Wit'aOM O d'I~W <br class="style-scope patent-text">     O   <br class="style-scope patent-text"> <br class="style-scope patent-text"> U    v      CT    O M I~00tnO l~ <br class="style-scope patent-text">     N   <br class="style-scope patent-text"> <br class="style-scope patent-text"> O    ~-I    c0(~  O O O ~ N ~ N  <br class="style-scope patent-text">d~  <br class="style-scope patent-text"> <br class="style-scope patent-text"> v      y,~~                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> O    .C1    v N   O O O O O O -N   <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ I                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> r-I   <br class="style-scope patent-text"> <br class="style-scope patent-text"> I                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> .la C    f~       G                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> v    x Z31          5..~.rl  ~-N OOt~O M ~  <br class="style-scope patent-text">     OD  <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'rl      ~   (0.I-~  O O O O ~O01~  <br class="style-scope patent-text">     N   <br class="style-scope patent-text"> <br class="style-scope patent-text"> +'   E  ~   'O(~C~O O O O O O r' v  p   ~ ~,--I(n i~ o~  c0&gt;   O O O O O O O  <br class="style-scope patent-text">     O   <br class="style-scope patent-text"> <br class="style-scope patent-text"> U7 l0  +~N  <br class="style-scope patent-text"> <br class="style-scope patent-text"> I    ~  I                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'r-1   ~  ~         lI1r-u-L~~ tf1N  <br class="style-scope patent-text">     O   <br class="style-scope patent-text"> <br class="style-scope patent-text"> X    U7 ~         O d'O~ODM DOd' ~   <br class="style-scope patent-text"> <br class="style-scope patent-text"> H  N       M O O O ~ d'I~~O  <br class="style-scope patent-text"> <br class="style-scope patent-text"> G    ,~ p1 W  ~1' U7  O O O O O O ~  <br class="style-scope patent-text">     N   <br class="style-scope patent-text"> <br class="style-scope patent-text"> i~                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> G    O  II  'Hv   t~01M O M cTM  <br class="style-scope patent-text">     O   <br class="style-scope patent-text"> <br class="style-scope patent-text"> O E   O M O~O 00O Ov N   <br class="style-scope patent-text"> <br class="style-scope patent-text"> N     ~ N O O O N M L~M  <br class="style-scope patent-text">     I~  <br class="style-scope patent-text"> <br class="style-scope patent-text"> UI U   y...~y,a x    v  ~   v ~   o 0 0 0 0 0 v    O  S..i~ v   l~N 01M ~-01~   <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~   .ilO   Z ~   O d~l~01~ 00M  <br class="style-scope patent-text">     OJ  <br class="style-scope patent-text"> <br class="style-scope patent-text"> O O O ~-M a0t0 I~  <br class="style-scope patent-text"> <br class="style-scope patent-text"> v    .yes~              <br class="style-scope patent-text"> <br class="style-scope patent-text"> h    ~  ~         O O O O O O ~  <br class="style-scope patent-text">     N   <br class="style-scope patent-text"> <br class="style-scope patent-text"> I                    <br class="style-scope patent-text">cd   r1 v v    (0 U~      r1 1a   ~  (t1 O  .C   <br class="style-scope patent-text"> <br class="style-scope patent-text"> I    r-ia, U      I                     <br class="style-scope patent-text"> <br class="style-scope patent-text"> 0o   O                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> t~ ~~  ~ &gt;~                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> O  .-i   N                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> O    ~  O   ~-I~ v tf7 O ~             <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ v  ~        x ..~                <br class="style-scope patent-text"> <br class="style-scope patent-text"> rt~+~ o  rx  s~  +~  ~r, cnv1    fa  O '~G   N LI1 U1,~y~".,x   .riN ~,'  10N to O  L~  -1...1.h    Ll1.-N t!1 .r-Ilf1 !~N   <br class="style-scope patent-text"> <br class="style-scope patent-text"> .1-~I   l..iv I O - M toN Lnp O   <br class="style-scope patent-text"> <br class="style-scope patent-text"> N    f0 ~   .f.~l-Ij~  ~ N lf1 O   <br class="style-scope patent-text"> <br class="style-scope patent-text"> I    G  U   ~ +~                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> N    'rlx   N I X                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> .LZ    U c0N                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> v    ~  ~   ~ v o  c   o s~                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> U  ~c3 U ~                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> H                                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> H                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> a   ~,     ssr~  N O O~N v0O m ao W   'C3    (OU1  ~ 00~ 01N N N<br class="style-scope patent-text">     N <br class="style-scope patent-text"> <br class="style-scope patent-text"> O      S.-IN   O O r'r'd'O~00 ,(~    O .E        <br class="style-scope patent-text"> <br class="style-scope patent-text"> N   ~r-I    ~     O O O O O O ~M <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'D  <br class="style-scope patent-text"> <br class="style-scope patent-text"> O   ~                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> O                <br class="style-scope patent-text"> <br class="style-scope patent-text"> x        LT  l~O O~Q1M N N<br class="style-scope patent-text">     I~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~   ~        f0  O ~Oa100O N O~<br class="style-scope patent-text">     M <br class="style-scope patent-text"> <br class="style-scope patent-text"> tf1      S~-~  O O O ~ d'DOI~<br class="style-scope patent-text">~O <br class="style-scope patent-text"> <br class="style-scope patent-text"> I        ~   O O O O O O ~-M <br class="style-scope patent-text"> <br class="style-scope patent-text"> H                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> c0   U                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> x o   I                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> rl   'O     4J    N 0101l~~-M OD<br class="style-scope patent-text">tt1 U   N      ~     O M L~OO00N tf1 d' O   H      (0Ca  O O O ~ M l~L~<br class="style-scope patent-text">     M <br class="style-scope patent-text"> <br class="style-scope patent-text"> O   .~     ~ N   O O O O O O r-M <br class="style-scope patent-text"> <br class="style-scope patent-text"> cd     ~ I                <br class="style-scope patent-text"> <br class="style-scope patent-text"> ri .Ca   O   <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~r       ~.               <br class="style-scope patent-text"> <br class="style-scope patent-text"> x  ~.  ~ o s.~..~  M o o - ~-o, .. ~   co+~  o - - o +~   a  o   ~ m r~0 0 0 0 0 0 0 . . . . . . <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~o~   0 0 0 0 0 0 0 +~a~               <br class="style-scope patent-text"> <br class="style-scope patent-text"> &gt;   ~  I   V7Ll I   Cn '~I   ~  ~         ~ 000 0 ~ ~ -o x   ~n N         o ~ r-o,.-~ ~<br class="style-scope patent-text">o N   H  O~      M O O ~ r'd'a000 l~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> W  ~     Ul  O O O O O O ~<br class="style-scope patent-text">     M <br class="style-scope patent-text"> <br class="style-scope patent-text"> II    G                <br class="style-scope patent-text"> <br class="style-scope patent-text"> L:   O      ~ ~   ~ l~t~O QlLl1M<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> f0   4-1~   O ~   O ~O010101N OD<br class="style-scope patent-text">d' U     U N O O O ~ M ODL~<br class="style-scope patent-text">     I~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> x   a~ ~o  a~~   0 0 0 0 0 0 ~<br class="style-scope patent-text">r~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> '~-I.n  .a~n b  s.~ a ~o a~   o  o   ~ v   ~r~ro aom,.-.-o +~   .c~m   z ~   o ~oo,aoo,~ oo ~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> r0   '.1.L1     ~ O O O ~ M t~I~<br class="style-scope patent-text">d~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> U   .~.~.~                     <br class="style-scope patent-text"> <br class="style-scope patent-text"> S-1   G  "         O O O O O O ~<br class="style-scope patent-text">     M <br class="style-scope patent-text"> <br class="style-scope patent-text"> i~                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> I      N                      <br class="style-scope patent-text"> <br class="style-scope patent-text"> f0   H  U1 N   N  (t1     H              <br class="style-scope patent-text"> <br class="style-scope patent-text"> h O  L1, I   r-i E   U  'L3 I   G              <br class="style-scope patent-text"> <br class="style-scope patent-text"> a0   O  ~~-I                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> C  ~I  ao&gt;~               <br class="style-scope patent-text"> <br class="style-scope patent-text"> O  O     l0 O   ~  Vl  '~-i~ N              <br class="style-scope patent-text"> <br class="style-scope patent-text"> E                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~...~rx    x '~             <br class="style-scope patent-text"> <br class="style-scope patent-text"> co+~ o  ra  c   +~  u, m~n    x   o 'z3C   N Ln U1'y ~ M   w-IN ~   l0N tf1 O  OW  1-~+~    Lf1- N L(1 N   ~ ~j~            <br class="style-scope patent-text"> <br class="style-scope patent-text"> I   ~..1~ I O ~ M l0N L(1O<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> M   f0 .~  .~L.i~      ~ N 111 O <br class="style-scope patent-text"> <br class="style-scope patent-text"> I   ~  U   s~.+~' N   -~ x   N I X              <br class="style-scope patent-text"> <br class="style-scope patent-text"> U c0U              <br class="style-scope patent-text"> <br class="style-scope patent-text"> v   E  b   &gt;~a~               <br class="style-scope patent-text"> <br class="style-scope patent-text"> o  ~   o s.~               <br class="style-scope patent-text"> <br class="style-scope patent-text"> U  ~0  U ~                <br class="style-scope patent-text"> <br class="style-scope patent-text"> H              <br class="style-scope patent-text"> <br class="style-scope patent-text"> H                                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> W    ?,    ~  Ll  ~O01 Lf1N  ~-Wit'N   <br class="style-scope patent-text">     O    <br class="style-scope patent-text"> <br class="style-scope patent-text"> W    '     10 Vl  O Lf1MM  I~L~01 d' O     L..~N  O O  ~N  ~O~ V'  -V' ~  t U    wl    ~     O O  OO  O~ N   <br class="style-scope patent-text">     M    <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ri   i-~                          <br class="style-scope patent-text"> <br class="style-scope patent-text"> ' O                        <br class="style-scope patent-text"> <br class="style-scope patent-text"> O                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> w-I   x        CT  ~OO~ 01N  ~-N Lf1 O    <br class="style-scope patent-text"> <br class="style-scope patent-text"> i W  .f1      (0  O lf1'-Ol ~PLf1O    <br class="style-scope patent-text"> <br class="style-scope patent-text"> C    u'1      1-i  O O  .-.- ~r10~N   <br class="style-scope patent-text">     N    <br class="style-scope patent-text"> <br class="style-scope patent-text"> I        ~  O O  OO  OO N   <br class="style-scope patent-text">     M    <br class="style-scope patent-text"> <br class="style-scope patent-text"> H                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> c0   U                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> x o    I                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> .-1   'L3   O     l001 MM  NO 00 O    <br class="style-scope patent-text"> <br class="style-scope patent-text"> U    N     d1    O tf1Otf1~M ~   <br class="style-scope patent-text">     N    <br class="style-scope patent-text"> <br class="style-scope patent-text"> O    ~     Q1 ~1  O O  ~'- d'I~01 O    .~    N  N  O O  OO  OO ~   <br class="style-scope patent-text">     M    <br class="style-scope patent-text"> <br class="style-scope patent-text"> f~   ~  I                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> ri I             <br class="style-scope patent-text"> <br class="style-scope patent-text"> O                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> W     <br class="style-scope patent-text"> <br class="style-scope patent-text"> a~   x  .-.o  0 LT      ~  la wI  O O  aoO  m'-M   <br class="style-scope patent-text">     O    <br class="style-scope patent-text"> <br class="style-scope patent-text"> .. ~  Ip .+.~  O O  ON  ~D~ ~1' OO   <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~   ~  O  ''C~~0LlO O  OO  O~ ~   <br class="style-scope patent-text">     O    <br class="style-scope patent-text"> <br class="style-scope patent-text"> O  p~ ~  .,~~                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> -1~~O c(1~  O O  OO  OO O   <br class="style-scope patent-text">     O    <br class="style-scope patent-text"> <br class="style-scope patent-text"> Ul    +~ U                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> I  ~  !~                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> I    Cn wl   ~  ~        ~OO~ i0~C1Ll1N N   <br class="style-scope patent-text">     O    <br class="style-scope patent-text"> <br class="style-scope patent-text"> X    U7 N        O ui ~r' a0l0d' O    <br class="style-scope patent-text"> <br class="style-scope patent-text"> O    H  D1     M O O  ~N  Lt1O O   <br class="style-scope patent-text">     N    <br class="style-scope patent-text"> <br class="style-scope patent-text"> ,.,-]~      <br class="style-scope patent-text"> <br class="style-scope patent-text"> &gt;~   W  ~     U7  O O  OO  Or'N   <br class="style-scope patent-text">     M    <br class="style-scope patent-text"> <br class="style-scope patent-text"> 1.JII    G     <br class="style-scope patent-text"> <br class="style-scope patent-text"> O     ~  N  vDo~ aoao NO o~  <br class="style-scope patent-text">     O    <br class="style-scope patent-text"> <br class="style-scope patent-text"> !0   4-IO  O  ~  O Ll1Nl~ l~V't!1 t0 U     NN O O  r'~  Ll100N   <br class="style-scope patent-text">     M    <br class="style-scope patent-text"> <br class="style-scope patent-text"> .                <br class="style-scope patent-text"> <br class="style-scope patent-text"> x    ~  ~0 N  ~  O O  OO  OO N   <br class="style-scope patent-text">     M    <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ri.f~.p U1 'L3   '&gt;3f-I~  f0 N    O  O  ~  N  ~O01 Md' Ird'M   <br class="style-scope patent-text"> O    <br class="style-scope patent-text"> <br class="style-scope patent-text"> .+~   .W n  z  ~  o ~r,.-oo ~~n~   <br class="style-scope patent-text">ao t0   ~r-1.~     ~ O O  ~~  ~1'01M   <br class="style-scope patent-text">     N    <br class="style-scope patent-text"> <br class="style-scope patent-text"> O    ~  .~                        <br class="style-scope patent-text"> <br class="style-scope patent-text"> 1-i   C  '-'      O O  OO  OO N   <br class="style-scope patent-text">     M    <br class="style-scope patent-text"> <br class="style-scope patent-text"> I       N                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> H                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> N    f0 (0 O  L1.                       <br class="style-scope patent-text"> <br class="style-scope patent-text"> I                                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> U  ''C1I  G                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> ao   O                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~  s~   <br class="style-scope patent-text"> <br class="style-scope patent-text"> O  O     c0C                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> O    ~  V1 ~  ~N                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> E                               <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~  ~  rx    x-~I                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~o+~ o  ra ~   +~                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> x  o  ~~   N  ~, UI~  ~  O  ~r-IN~   l0 Ntt1 l  O  tI1-1-~-1-~    II1~N  Lf1 y  M  ~j ~p ~+.~I  S-.a~I O ~  M10 Nu-1O   <br class="style-scope patent-text">     O    <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~l'   f0 ~C -+-~S-1C          ~N Lf1 O    <br class="style-scope patent-text"> <br class="style-scope patent-text"> 1    ~  U  G  -+~-rl N    -rlx  ~  Ix U  f0N                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> 41   ~  'a7~  NG               <br class="style-scope patent-text"> <br class="style-scope patent-text"> O  ~  O  l.aG                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> U  rt3U  ~         <br class="style-scope patent-text"> <br class="style-scope patent-text"> H   ~.,    N                    <br class="style-scope patent-text"> <br class="style-scope patent-text"> CT~1  aDM O~d~N l~N ~l' W   O    (0C/~  O lI1N 00Lf1l0l-OD <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~.!N   O O ~ N L(1O N --,--I    ~ t N   .1~    &gt;     O O O O O ~-N ~1' .ri   t~      <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'Cl   ~C                          <br class="style-scope patent-text"> <br class="style-scope patent-text"> .,a   a        v x            I~N Lf1L~M M r-M <br class="style-scope patent-text"> <br class="style-scope patent-text"> O        f0  O LC1~ M l~N O 01 lD       L.r  O O ~ N d'a1- L~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> O                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> I        ~   O O O O O O N M <br class="style-scope patent-text"> <br class="style-scope patent-text"> H                               <br class="style-scope patent-text"> <br class="style-scope patent-text"> c0   U                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> x                      _ o   I               <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'L3    ~     ~O~ O O '~'O O N <br class="style-scope patent-text"> <br class="style-scope patent-text"> U   N      a     O u~O o~o~000~O <br class="style-scope patent-text"> <br class="style-scope patent-text"> O   .-I    f0G1  O O ~ ~ M I~O~d' O      I,~~    <br class="style-scope patent-text"> <br class="style-scope patent-text"> O   17     ~ N   O O O O O O ~ M <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ I                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> O                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> W        <br class="style-scope patent-text"> <br class="style-scope patent-text"> W                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> a~   x      zro s~-~1  ~ ~ I~~ o .ri          f0~   O O O N C'I~lI101 +~   ~  ~   T3~0LlO O O O O O O -O  ~   ~ ~,--~~                <br class="style-scope patent-text"> <br class="style-scope patent-text"> .1~G   (0~   O O O O O O O O <br class="style-scope patent-text"> <br class="style-scope patent-text"> UI O   -1-~N                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~, 01  (/]Ca I   V7 l0 -.-I   ~  I         a0M I~~ d~N o0O <br class="style-scope patent-text"> <br class="style-scope patent-text"> X   U7           O inO '-O~d'M '-N   H  ~       M O O ~ N d'O~O DO <br class="style-scope patent-text"> <br class="style-scope patent-text"> &gt;J d~                       <br class="style-scope patent-text"> <br class="style-scope patent-text"> O  ~   '~-~O   I~N l0M I~I~~ O <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~f3   '~-~    O ~   O iI1~ V'N l~N Q~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> II    N N O O ~ N d'01~ II1 )",s", x   N  N   N ~   O O O O O O N M <br class="style-scope patent-text"> <br class="style-scope patent-text"> -rlU   .C7U!                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> N   O  r0  ~ N   l~N - t~L~O N O <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~   .~ ~   Z ~   O LC1N L(101Lf1V'00 c0   -~-1l..r    ~ O O ~ N d'01~ p~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> O                     <br class="style-scope patent-text"> <br class="style-scope patent-text"> l..r   ~  U1        O O O O O O N M <br class="style-scope patent-text"> <br class="style-scope patent-text"> i~              <br class="style-scope patent-text"> <br class="style-scope patent-text"> I      ~                        <br class="style-scope patent-text"> <br class="style-scope patent-text"> H        <br class="style-scope patent-text"> <br class="style-scope patent-text"> O   fd         r1 I   r~ (U                       <br class="style-scope patent-text"> <br class="style-scope patent-text"> U  .~  I                    <br class="style-scope patent-text"> <br class="style-scope patent-text"> 0o   O  f~                       <br class="style-scope patent-text"> <br class="style-scope patent-text"> O  'CJ   c0 O   ~  -rl ~ ~ N                <br class="style-scope patent-text"> <br class="style-scope patent-text"> E                              <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~a~ ~  o     x .                <br class="style-scope patent-text"> <br class="style-scope patent-text"> a~+~ o  ~n  ~   +~               <br class="style-scope patent-text"> <br class="style-scope patent-text"> U1U1        O 'D~ N u1 U7~  ~  O   -.-iN   W O N In O  01  -i~.IJ    LC1~ N tf1 -r-IN   f0f0~                <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~ I   SaN I O ~ M ~oN m O O <br class="style-scope patent-text"> <br class="style-scope patent-text"> Lfl   (0 ~,  ~ L-1&gt;~..        ~ N Lf1O <br class="style-scope patent-text"> <br class="style-scope patent-text"> I   C  U   G +~-r1 N   -r1x   N i X                <br class="style-scope patent-text"> <br class="style-scope patent-text"> U c0N                <br class="style-scope patent-text"> <br class="style-scope patent-text"> v   ~  'a  ~ ~ G                <br class="style-scope patent-text"> <br class="style-scope patent-text"> -'t   O  ~   O S-ia~               <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~7   U  c0  U ~                <br class="style-scope patent-text"> <br class="style-scope patent-text"> H   ~.,    N                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> t-7  '~     CrLl  01lf1l~M 00V'Lf1 W   O      f0C/1  O tD~ l0a0N O<br class="style-scope patent-text">o0 ,!a    L~N   O O ~ M Lf10101 l&lt;) ~ .f.               <br class="style-scope patent-text"> <br class="style-scope patent-text"> N   i~     &gt;     O O O O O O r-M <br class="style-scope patent-text"> <br class="style-scope patent-text"> -ri  G                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'b O                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> .17  Ca x       b~  oo~r~ c~~rI~~<br class="style-scope patent-text">o +~  o        cu  o u,~ c~w ao~<br class="style-scope patent-text">o, m o        s.~ o o ~ N ~ ooao ~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> ,o       ~, I        ~   0 0 0 0 0 0 -M <br class="style-scope patent-text"> <br class="style-scope patent-text"> t0  U                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> x o   I                    <br class="style-scope patent-text"> <br class="style-scope patent-text"> r-I  '~     N     I~M tor-O O 00 U   4J     CT  O d'O a~aom N<br class="style-scope patent-text">o~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> O   r-I    ~0(~  O O ~ ~ M 00I~<br class="style-scope patent-text">     N <br class="style-scope patent-text"> <br class="style-scope patent-text"> O   .~    N N   O O O O O O ~<br class="style-scope patent-text">     M <br class="style-scope patent-text"> <br class="style-scope patent-text"> cd     ~ I                <br class="style-scope patent-text"> <br class="style-scope patent-text"> r-i I                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> O                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> f~             <br class="style-scope patent-text"> <br class="style-scope patent-text"> a~  x      ~no i7~         S-.1-rl  ~ tf1M M N 01V' Ll1 -,1  .. ~   f0.~  O O O 'd'LC1~ V' C   'C1(0CaO O O O O O O<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> G   ~  O   ~ -,--I(~             <br class="style-scope patent-text"> <br class="style-scope patent-text"> -h O~  c0&gt;   O O O O O O O<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> U1 ~O  +.~N                <br class="style-scope patent-text"> <br class="style-scope patent-text"> I   C~ I                      <br class="style-scope patent-text"> <br class="style-scope patent-text"> -ri  ~  ~         a0a0M o~~ O d~<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> X   U7 ~         O d'~ O ~DI~I~<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> N   H  N       M O O ~ M d'00L~<br class="style-scope patent-text">l~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> s~  W  d'    UI  O O O O O O r-M <br class="style-scope patent-text"> <br class="style-scope patent-text"> i~               <br class="style-scope patent-text"> <br class="style-scope patent-text"> G   O  II  '~-a~   ODv0M OOV'Wit'M<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> (0  'r-i    O ~   O Lflr'N d'00~<br class="style-scope patent-text">     M <br class="style-scope patent-text"> <br class="style-scope patent-text"> v N O O ~ N L(1ODaD<br class="style-scope patent-text">d~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> U   ~ y",i x   a~ ~   v ~   0 0 0 0 0 0 ~<br class="style-scope patent-text">     M <br class="style-scope patent-text"> <br class="style-scope patent-text"> ,o ~   ~ ~     _ O   O  S.-I~ v   t~0~00d'00L~N<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> ,cao   z ~   o m o o~~ o ~o ~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> c0  -.-Iu7      r-O O ~ N V~ovo0 d~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> l.-i  ~  ~         O O O O O O ~<br class="style-scope patent-text">     M <br class="style-scope patent-text"> <br class="style-scope patent-text"> I                            <br class="style-scope patent-text">~0  ~  N                      <br class="style-scope patent-text"> <br class="style-scope patent-text"> N   r0 U7      .--i 1-i  G  N       E              <br class="style-scope patent-text"> <br class="style-scope patent-text"> O                     <br class="style-scope patent-text"> <br class="style-scope patent-text"> I   ri Q, U      I   C           <br class="style-scope patent-text"> <br class="style-scope patent-text"> a~  O  's3 -ri 0~                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> O  rl    (~               <br class="style-scope patent-text"> <br class="style-scope patent-text"> O   ~  O   '~-a~                <br class="style-scope patent-text"> <br class="style-scope patent-text"> (!) O ~     <br class="style-scope patent-text"> <br class="style-scope patent-text"> x -~, ~a+~o  rx  ~   +~             <br class="style-scope patent-text"> <br class="style-scope patent-text"> U1UI   ~1  O '&gt;7~   N Ll1 tn~ ~  x   -~~ ~   .DN ~n cno  I~  .+~.+~    u,~ N ~r, -,..I,r  ~ ~ &gt;              <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~1-~I   S.-iN I O ~ M l0N lf1O<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> l0  f0 ~   ~ S-I~         ~ N 1f1 O <br class="style-scope patent-text"> <br class="style-scope patent-text"> I   G  U   ~ +~W              <br class="style-scope patent-text"> <br class="style-scope patent-text"> N  ~~Ix   a~I x .!~    U ~t1N              <br class="style-scope patent-text"> <br class="style-scope patent-text"> v   ~  ~   ~ v s~         <br class="style-scope patent-text"> <br class="style-scope patent-text"> .-I  o  ~   o sa .ia  U  c0  U ~                <br class="style-scope patent-text"> <br class="style-scope patent-text"> Ei H   '.,    N               <br class="style-scope patent-text"> <br class="style-scope patent-text"> f-1   'D     ~ L   O N I~OOOO.-W   O      t0fly  r-a~tmn N ~ ~<br class="style-scope patent-text">     M <br class="style-scope patent-text"> <br class="style-scope patent-text"> S.-iN   O O r'N tf1~ l~<br class="style-scope patent-text">     M <br class="style-scope patent-text"> <br class="style-scope patent-text"> .,--I    ~ .H   <br class="style-scope patent-text"> <br class="style-scope patent-text"> v   ~1-~    ~     O O O O O ~ N<br class="style-scope patent-text">     V' W  <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'C1 O                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> Ca x        tT  t~o,o,~ o,~ 00 +~   O        rt1  O L~N M 01p d~<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> G   ~D       S-I  O O ~-N ~'O N<br class="style-scope patent-text">r-I        &gt;   O O O O O r'N<br class="style-scope patent-text">d~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> H                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> rtf   U            <br class="style-scope patent-text"> <br class="style-scope patent-text"> x o   I                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> -I   zs     v     v~~ ~ o o ao~r, o. <br class="style-scope patent-text"> <br class="style-scope patent-text"> U   U      Cn    O iDao.-l~t0M<br class="style-scope patent-text">~O <br class="style-scope patent-text"> <br class="style-scope patent-text"> O   ~      41f-a  O O O N ~ oo~<br class="style-scope patent-text">o0 O   .~     N N   O O O O O O ~-M <br class="style-scope patent-text"> <br class="style-scope patent-text"> H                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> I        <br class="style-scope patent-text"> <br class="style-scope patent-text"> O                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> !~   W                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> a~  x  ~.  ~ o t~      ~   S..i~r-1  N l0d~N d~ODt0 tf1 .. ~   (p.~J  O O N ~ ~ 1DLf1 -N   E  O   'a3c0(~O O O O O O N <br class="style-scope patent-text"> <br class="style-scope patent-text"> /j +~ ~   ~0~   O O O O O O O<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> U1     -+-~N                <br class="style-scope patent-text"> <br class="style-scope patent-text"> I                <br class="style-scope patent-text"> <br class="style-scope patent-text"> 1   Cn 1=                     <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'ri ~  f~        011Dd'I~O l0I~<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> X   Vl N         O 00~ ~'01Lf11D<br class="style-scope patent-text">M <br class="style-scope patent-text"> <br class="style-scope patent-text"> N   H  01      M O O ~ N V~O ~<br class="style-scope patent-text">     N <br class="style-scope patent-text"> <br class="style-scope patent-text"> W  ~     U1  O O O O O ~ N<br class="style-scope patent-text">     V' 1...~II    G                <br class="style-scope patent-text"> <br class="style-scope patent-text"> O      '~-~N   ( ~ I~M N I~Lf1 O <br class="style-scope patent-text"> <br class="style-scope patent-text"> (0   '~-~N   O ~   O I~~-N 01N M<br class="style-scope patent-text">l0 U     N N O O r'N V'01~(1 O <br class="style-scope patent-text"> <br class="style-scope patent-text"> x   N  ~0  N ~   O O O O O O N<br class="style-scope patent-text">d~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'ri.p  .G~U1 ':~   'C3!.a ~ t0 O  O   ~ ~   l0l~l~M 1DO N<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> i~   ..CZU7 z ~   O I~tf1M ~ M V' c0   -rl.4      ~ O O r-N tI1O O<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> &gt;..1   ~  v        O O O O O - N<br class="style-scope patent-text">d' I      v co   ~  m N   c0 cu s~   ~  .~      E      <br class="style-scope patent-text"> <br class="style-scope patent-text"> o  a.                     <br class="style-scope patent-text"> <br class="style-scope patent-text"> I   H                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> a0   O  w-1 -i  W ~  <br class="style-scope patent-text"> <br class="style-scope patent-text"> O  O     coC              <br class="style-scope patent-text"> <br class="style-scope patent-text"> O   E  Ul O ~                <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~,v  ~  rx    x .~             <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~o+~ o  r~  ~   +~    <br class="style-scope patent-text"> <br class="style-scope patent-text"> x   o ra~   N m UI~  (~ M   w-IN ~   ~ON Lf1 O  O~  ~i-~i-~    tf1~ N Lf1 w1 N   f0f0~              <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~ I   Sav I O ~-M ~ON ~.nO<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> l~   (0 ~   -IJ1-1C         ~ N Lf1 O <br class="style-scope patent-text"> <br class="style-scope patent-text"> I   ~  U              <br class="style-scope patent-text"> <br class="style-scope patent-text"> N   w-1x   41I                <br class="style-scope patent-text"> <br class="style-scope patent-text"> U c0N              <br class="style-scope patent-text"> <br class="style-scope patent-text"> a~   E  'o  ~ N s~             <br class="style-scope patent-text"> <br class="style-scope patent-text"> O  C   O S..if~             <br class="style-scope patent-text"> <br class="style-scope patent-text"> .11   U  cp  U ~                <br class="style-scope patent-text"> <br class="style-scope patent-text"> c0 Ei H   ~y     tv 'L1 b1O   O M d~N ~DN l0 t11 W   O      f0V7  ~ OlO 00Ll1~ lD<br class="style-scope patent-text">l0 .L~    LrN   O O N M Lf1N ~<br class="style-scope patent-text">     I~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> (/I   ~r~    U +                <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~     ~     O O O O O r'N<br class="style-scope patent-text">c"~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> W                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> O         <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~1   La       N                <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~rl   x        b~  aom o ~ t~o O        (O  O lDM 01M d'M<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> l0       ~.1  O O r'N Lf1O O<br class="style-scope patent-text">     Lf1 I        ~   O O O O O ~ N<br class="style-scope patent-text">     M <br class="style-scope patent-text"> <br class="style-scope patent-text"> H                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> c0   U                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> x                      _ z3     a~    ~ o~aoo ~ ao~<br class="style-scope patent-text">     Ir, U   N      b~    O M io~ ~ ~oO<br class="style-scope patent-text">m O   .-i    c0L1  O O O N u~oo~<br class="style-scope patent-text">     N <br class="style-scope patent-text"> <br class="style-scope patent-text"> O      /,..~[/~         <br class="style-scope patent-text"> <br class="style-scope patent-text"> O   .l~    ~ N   O O O O O O ~-M <br class="style-scope patent-text"> <br class="style-scope patent-text"> f0     &gt; 1 .L~   O                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> G           <br class="style-scope patent-text"> <br class="style-scope patent-text"> v   x  --  ~ o CT      ~   S.-iwl  a-~ ~ c~~O tDtn N <br class="style-scope patent-text"> <br class="style-scope patent-text"> .. ~   (p.~  O ~ M ~i'~-OO~O<br class="style-scope patent-text">     M <br class="style-scope patent-text"> <br class="style-scope patent-text"> O   'C7(0(~O O O O O O O <br class="style-scope patent-text"> <br class="style-scope patent-text"> O  p1  ~ -,--~(/~             <br class="style-scope patent-text"> <br class="style-scope patent-text"> -1~-&gt;iD  ~0~   O O O O O O O<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> N                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> I   U7Ca I                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> m~l   ~  ~         01N COO a0ODa0 O <br class="style-scope patent-text"> <br class="style-scope patent-text"> X   U7 N      O u~o~d~~ M o~<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> O   H  01      M O O O M Lf1~ 01 d' W  ~     U1  O O O O O ~ -M <br class="style-scope patent-text"> <br class="style-scope patent-text"> II    C                <br class="style-scope patent-text"> <br class="style-scope patent-text"> O      '~-aN   OOL~d'M O I~~<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> H-~~   O ~   O ~OlDQ1M O ~<br class="style-scope patent-text">     Lf1 U   N N O O ~ N Lf1O ~<br class="style-scope patent-text">d' x   N  c0  v ~   O O O O O ~ N<br class="style-scope patent-text">     M <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ri.La .&gt;aUl O  O   ~ N   L~O~l0d~N l0O<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~   .~ U7  z ~   O l~d~LI1M l~O<br class="style-scope patent-text">     L!1 (0   wl .LZ     ~ O O ~ N if1O~O<br class="style-scope patent-text">~O <br class="style-scope patent-text"> <br class="style-scope patent-text"> fa   G  v         O O O O O O N<br class="style-scope patent-text">     M <br class="style-scope patent-text"> <br class="style-scope patent-text"> I      v (I7   .-i(J~             <br class="style-scope patent-text"> <br class="style-scope patent-text"> H              <br class="style-scope patent-text"> <br class="style-scope patent-text"> S.-~   G  .~      E              <br class="style-scope patent-text"> <br class="style-scope patent-text"> O  Cl.                    <br class="style-scope patent-text"> <br class="style-scope patent-text"> I   H                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> U  '&gt;7 I   C              <br class="style-scope patent-text"> <br class="style-scope patent-text"> a0   O  -~-I                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> s~                        <br class="style-scope patent-text"> <br class="style-scope patent-text"> O  O     t0 O   ~  V7  '~-i~ N              <br class="style-scope patent-text"> <br class="style-scope patent-text"> E                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> &gt;.,~  "..,cx    x -r-I             <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~o+~ o  r~  s~  +~  u, x   o w ~   N Lr, m~, ~  o   -.-iN   W o N m, ~U1 O  Lf1 i-~+~    Lf1.-N If1 M   c0f0~              <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~ I   &gt;.~N I O ~ M lDN u'1O<br class="style-scope patent-text">     O <br class="style-scope patent-text"> <br class="style-scope patent-text"> ao   tp ~   +~S-~G         ~-N u'1 O <br class="style-scope patent-text"> <br class="style-scope patent-text"> I   ~  U  ~ -N-.-I             <br class="style-scope patent-text"> <br class="style-scope patent-text"> N   ..~x   a~I x U f0 O   ~  '   G v -~1   O  G   O !.-i t7   U  c0  U ~                <br class="style-scope patent-text"> <br class="style-scope patent-text"> Figures 1 thorough 8 illustrate calibration curves for human annexin-V, in which the results of measurement as given in Tables 2-1 through 2-8 are plotted in diagrams with the absiccia being the concentration of human annexin-V antigen and the ordinate being the difference in the absorbance measured between at 492nm and at 690nm.<br class="style-scope patent-text">     The calibration curves are excellent ones as the absorbance increases with increasing concentration of human annexin-V<br class="style-scope patent-text">substantially linearly as high as a concentration of 100 ng/ml.<br class="style-scope patent-text">1o The use of these calibration curves enables reliable assay of human annexin-V concentration in samples to be examined (plasma and serum). It is also possible to determine the concentration of human annexin-V with good reproducibility even as low as a concentration of 1 ng/ml, as can be seen Figure 1.<br class="style-scope patent-text">     The calibration curves as shown by Figures 1 through 8 are of reliable use for the determination of the concentration of human annexin-V.<br class="style-scope patent-text">     With the native human annexin-V without 8M-urea-treatment as the standard antigen, the absorbance detected was approx. 5$ to 10% of that with 8M-urea-treated human annexin-V, demonstrating that the system has a low reactivity to the native human annexin-V antigen.<br class="style-scope patent-text">     EXAMPLE 4: Assay of Human Annexin-V Using Anti-human-annexin-V Monoclonal Antibody HCA-627 and HRPO-labeled-anti-dog-32KP-annexin-V Polyclonal Antibody Assay of human annexin-V concentration was conducted by ELISA using anti-human-annexin-V monoclonal antibody HCA-627, which has been found to exhibit a high reactivity with native annexin-V without 8M-urea treatment, in combination with anti-dog-32KP-annexin-V polyclonal antibody.<br class="style-scope patent-text">     Thus, 100 microliters of anti-human-annexin-V monoclonal antibody HCA-627, secreted from hybridoma cell line HCA-627 strain capable of producing an anti-human-annexin-V monoclonal antibody, was distributed in wells at a rate of 100 microliters to per well, to prepare solid-phase well coupled with anti-human-annexin-V monoclonal antibody in the manner for preparing the solid-phase as described in Example 4 (5).<br class="style-scope patent-text">     To the solid phase wells was added lOmM sodium phosphate buffer (pH 7.0) containing 1~ BSA, 0.15M NaCl and 5mM EDTA at a 15 rate 100 microliters per well.<br class="style-scope patent-text">     Following the distribution of the reaction buffer, each well was added with a standard solution. As the standard solution in this Example were used standard solutions of 8M-urea treated human annexin-V antigen and standard solutions of native human 2o annexin-V antigen. Thus, one set of the solid phase wells were added with the standard solution of 8M-urea-treated human annexin-V whereas the other set of the solid phase wells were added with the standard solutions of native annexin-V antigen.<br class="style-scope patent-text">    Following the distribution of the standard solutions, an antigen-25 antibody reaction was allowed to take place in each well with stirring for one hour. After the antigen-antibody reaction, each well was washed four times with the washing solution and then added with 100 microliters of the HRPO-labeled-anti-dog-annexin-V polyclonal Fab' antibody (100mU per ml of the reaction buffer) followed by an antigen-antibody reaction for thirty minutes with stirring. Then, each well was washed eight times with the washing solution and added with 100 microliters of OPD substrate solution for the color production reaction at room temperature for thirty minutes.<br class="style-scope patent-text">     With the lapse of the time for the color production, each well was added with the reaction-terminating solution ( 2N H2S04 solution) to terminate the reaction, followed by absorbance 1o measurements at the primary wavelength 492nm and secondary wavelength 690nm on an ELISA plate reader to assay the samples and the standard solutions for the concentration of human annexin-V.<br class="style-scope patent-text">    The absorbance was obtained by subtracting an absorbance 15 measured at the secondary wavelength 690nm from that at the primary wavelength 492nm. Thus, a calibration curve was prepared by plotting the absorbance data against the human annexin-V<br class="style-scope patent-text">concentration with reference to the antigen protein standard solution. Based on such calibration curve, a sample can be 20 calibrated for the concentration of the antigenic protein, human annexin-V.<br class="style-scope patent-text">     In the Table 3 below, there are given absorbance data on the standard antigen of native annexin-V obtained by ELISA using anti-human annexin-V monoclonal antibody HCA-627 and the HRPO-25 labeled-anti-dog-32KP polyclonal antibody. <br class="style-scope patent-text"> <br class="style-scope patent-text"> 1       :sCa  O Q~u~u1~ d~t' (0V]  N M l~N N V~N I~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> -ri     S-.1N   O O O ~ N d'00Ln X       ~ t N       ~     O O O O O O O '-C       ~2 I         N                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> C         ~   O~a0N ~ I~I~l~O <br class="style-scope patent-text"> <br class="style-scope patent-text"> (d        (O  ~ M l0N ~ N N CO <br class="style-scope patent-text"> <br class="style-scope patent-text"> E         L-I  O O O ~ N d'COd' O                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> O O O O O O O  <br class="style-scope patent-text"> <br class="style-scope patent-text"> Cn -ri H  -+.) a W  ~   ~   N     I~1D01l~N O V~01 O   LT    ~ M L(1.-.-.-N QO <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~, '(~ 01  (0Gl  O O O ~'N d'00M <br class="style-scope patent-text"> <br class="style-scope patent-text"> f0      v N   O O O O O O O ~-I   ~ I                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> N                               <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'O                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> -rlO   G                        <br class="style-scope patent-text"> <br class="style-scope patent-text"> i-~.~  N                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> wi  01 +.~ d'  b O                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> (~" ~Q,'1..1-r1  .-r-r-N N QD~ Lf1 &gt;  .~      t0+~  O O O O O O O Wit' I      II  't7f0~1O O O O O O O O <br class="style-scope patent-text"> <br class="style-scope patent-text"> -I      ~ -,.-I~                <br class="style-scope patent-text"> <br class="style-scope patent-text"> -rlN   N  f0~   O O O O O O O O <br class="style-scope patent-text"> <br class="style-scope patent-text"> X  G   U   +~v N  O   ~ U1C.a U                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> N            <br class="style-scope patent-text"> <br class="style-scope patent-text"> .-i O                        <br class="style-scope patent-text"> <br class="style-scope patent-text"> Pr  .~        O1OpM N aDM 10N <br class="style-scope patent-text"> <br class="style-scope patent-text"> -rl    ~     Ul  ~ M l0N ~ M N --1-~ar  "     -1-~N O O O ~ N d'ODII1 x         ~   . . . . . . .  <br class="style-scope patent-text"> <br class="style-scope patent-text"> z  N   ~   w v   o 0 0 0 0 0 0 -'I-iI   f0    U           <br class="style-scope patent-text"> <br class="style-scope patent-text"> O  b~  .~  1JS...I                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> O   pr  N ~         <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'b      .~U7  ~ &lt;'~ 01Ll1r-Lf1Cb f0 1   'CJ ~ (0  ~ M l0~ ~-N N Wit' UI -rl -rl ~ N ~ O O O - N V'OOd' -,~ r,  z ~                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> O   N                        <br class="style-scope patent-text"> <br class="style-scope patent-text"> E                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> N  N   I                        <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~ .n  .~          <br class="style-scope patent-text"> <br class="style-scope patent-text"> tn c0  U                        <br class="style-scope patent-text"> <br class="style-scope patent-text"> x a.  ~   o I    <br class="style-scope patent-text"> <br class="style-scope patent-text"> o  rx  o x   .ra +~     -~I o X                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~                       <br class="style-scope patent-text"> <br class="style-scope patent-text"> o   &gt;~  +~~                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> -rI    ~   (d~     N lf1 l-I~     tDN tf1 O   .-I -1-~  (~..  LC1~ N II1 O  -,--I(0  C N N                <br class="style-scope patent-text"> <br class="style-scope patent-text"> U  ~   !~ N ~   O ~ M l~N Ll1O O <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~I1 O   U -.-i-~-1        - N 1f1O <br class="style-scope patent-text"> <br class="style-scope patent-text"> G   ~   ~ +~+~               <br class="style-scope patent-text"> <br class="style-scope patent-text"> M  -rl U   O t0C                <br class="style-scope patent-text"> <br class="style-scope patent-text"> .ci o   U z v U                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> c0 Figure 9 illustrates a calibration curve prepared from the results of the assay as given in Table 3. Thus, the reliable calibration curve was obtained for the concentration of the native human annexin-V antigen in the ELISA system using the anti-human-annexin-V monoclonal antibody HCA-627 and the HRPO-labeled anti-dog-32KP polyclonal antibody.<br class="style-scope patent-text">     EXAMPLE 5: Detection and Quantitative Analysis of Human Annexin-V in Samples from Patients with Myocardial Infarction, by ELISA Using Anti-human-annexin-V Monoclonal Antibody HCA-627 and HRPO-labeled-anti-dog-32KP Polyclonal Fab'.<br class="style-scope patent-text">     The combination of anti-human-annexin-V monoclonal antibody HCA-627 and HRPO-labeled-anti-dog-32KP polyclonal Fab' prepared in the above-mentioned manner, which has been found to have an excellent sensitivity in assaying the native human annexin-V, was examined for its applicability to the assay of human annexin-V<br class="style-scope patent-text">concentration in the clinical samples from patients with myocardial infarction.<br class="style-scope patent-text">     Thus, the solid phase composed of anti-human-annexin-V<br class="style-scope patent-text">monoclonal antibody was added, after disharging the solution, with 10 mM sodium phosphate (pH 7.0) containing 1~ HSA, 0.15M<br class="style-scope patent-text">    NaCl and 5mM EDTA at a rate of 100 microliters per well. Antigen standard solutions of native human annexin-V (1.5625ng/ml, 3.125ng/ml, 6.25ng/ml, 12.5ng/ml, 25ng/ml, 50ng/ml and 100ng/ml) and human plasma samples are added each at a rate of 20 microliters per well, followed by stirring and an antigen-antibody reaction for one hour at room temperature. With the lapse of the time for the antigen-antibody reaction, each well was washed three times with the washing solution. Then, to the wells was added HRPO-labeled-anti-dog-32KP polyclonal Fab' antibody having been prepared to have an appropriate concentration (100mU per ml of the reaction buffer) at a rate of 100 microliters per well, followed by an antigen-antibody reaction for thirty minutes at room temperature. With the lapse of the time for the antigen-antibody reaction, each well was washed eight times with the washing solution.<br class="style-scope patent-text">1o Following the washing, each well was added with 100 microliters of OPD substrate solution containing O.lm phosphate-citrate buffer, 2mg/ml o-phenylenediamine and 4mM H202, for color production reaction for thirty minutes at room temperature.<br class="style-scope patent-text">     With the lapse of the time for the color production reaction, each well was added with 2N H2S04 as reaction terminating solution to terminate the color production reaction.<br class="style-scope patent-text">     The color produced in each well was assayed at the primary wavelength 492nm and at the secondary wavelength 690nm. The assay was conducted by measuring absorbance on an ELISA plate reader at the primary wavelength 492nm and at the secondary wavelength 690nm. The absorbance for a sample to be examined or for a standard solution was obtained by subtracting an absorbance measurement at the secondary wavelength 492nm from that at the primary wavelength 690nm, to determine the concentration of human cardiac-muscle annexin-V in the sample or the standard solution.<br class="style-scope patent-text">     The measurements for the human plasma samples were obtained by reading the human annexin-V concentration in the respective samples with reference to the calibration curve which has been prepared based on the absorbance measurements of the standard solutions of varying human annexin-V concentration.<br class="style-scope patent-text">  EXAMPLE 6: Application of the Enzyme-Antibody Method of the Invention to the Assay of Blood Samples (1) Diagnosis of myocardial infarction A 75-year-old man with a pain in the chest at 6:00 a.m. was hospitalized at 8:30 a.m. of the same day on suspicion of acute ~ myocardial infarction because of abnormality on the electrocardiogram and the pain in the chest. At 9:00 a.m. of the day (i.e. three hours from the the attack) while CK (creatine phosphate enzyme) value indicated 108U/L in the normal range, . annexin-V was found to be an increased value of 90.4ng/ml. With the lapse of three days from attack, annexin-V decreased down to l3.lng/ml. The abnormality on the electrocardiogram in this case indicated the finding of acute myocardial infarction and the assay of human annexin-V concentration in the plasma sample was found to be of use in a quick diagnosis of myocardial infarction.<br class="style-scope patent-text">2o It was later established that 70$ of patients are diagnostic of myocardial infarction, in cases where the annexin-v concentrations in the plasma of the patients were determined to be 50ng/ml or more as the annexin-V concentration in the blood of the patient with myocardial infarction is relatively high.<br class="style-scope patent-text">(2) Diagnosis of angina pectoris An 58-year-old man, who complained of two times of pains in the chest attacked at 2:30 p.m. and 6:30 p.m. and continued over to 15 minutes, was hospitalized at 7:30 of the same day on suspicion of angina pectoris because of abnormality in the electrocardiogram and the relatively short pain in the chest.<br class="style-scope patent-text">    While the CK value was a normal value of 83U/L, the annexin-V<br class="style-scope patent-text">concentration was an increased value of 29.9ng/ml. The annexin-V<br class="style-scope patent-text">value decreased down to 29.9ng/ml at 12:00 and l5.lng/ml at 15:00 of the same day, demonstrating the restoration to normal. The case was assessed to be suspicions of angina pectoris because of the clinical symptom and the abnormality on the 1o electrocardiodiagram was then diagnostic of angina pectoris, in which it was found that the concentration of human annexin-V in the plasma also increases in a case of angina pectoris.<br class="style-scope patent-text">     The concentration of human annexin-V in the blood of a patient with angina pectoris is much higher than the normal value, although it is relatively low as compared with in the case of myocardial infarction. It was later established that 70~ of the patients were diagnostic of angina pectoris, in cases where the human annexin-V concentrations in the plasma of the patients were determined to be 20 to 50ng/ml.<br class="style-scope patent-text">(3) Annexin-V concentration in the blood from normal adults Annexin-V concentration in the blood from normal male adults 24 to 76 years of age were determined to be 0.9 to 11.3ng/ml, whereas those from normal female adults 24 to 76 years of age were 0.8 to 10.6ng/ml, with the average being 6.2ng/ml, the maximum 11.3ng/ml and the minimum 0.8ng/ml. However, there were observed no age-dependent variations. <br class="style-scope patent-text"> <br class="style-scope patent-text"> EXAMPLE 7: Application of the Enzyme Antibody Method to Cardiac Muscle Tissue Specific Staining (1) The anti-human-annexin-V monoclonal antibodies obtained in Example 3 was applicable not only to an ELISA method but to staining specifically localized or distributed areas of human annexin-V in the cardiac muscle tissue by means of an indirect enzyme antibody method.<br class="style-scope patent-text">     Furthermore, the use of the HRPO-labeled anti-human-annexin-V antibodies prepared in Example 4 makes it possible to l0 make a short-time specific staining of the cardiac muscle tissue by means of a direct enzyme antibody method.<br class="style-scope patent-text">     The following is given by taking the indirect enzyme antibody method as an example: paraffin-treated or frozen slices of the cardiac muscle tissue were fixed on a slide glass and allowed, following the paraffin-removal or blocking, to react with the anti-human annexin-V monoclonal antibodies having been prepared to have an appropriate concentration (IgG concentration:<br class="style-scope patent-text">500 to 1000 micrograms/ml) as the primary antibody at room temperature over an hour in a humid box. The resultant was then washed with phosplate-buffered saline (PBS) three times for five minutes each, followed by a reaction with HRPO-labeled anti-mouse-immunoglobulin antibodies as the secondary antibody for thirty minutes in a humid box. The resultant was washed three times for five minutes each, followed by addition of substrate solution of 4-aminoantipyrine type or diaminobenzidine for reaction over thirty minutes. On completing reaction, the slide-glass was washed with PHS and then sealed with a sealant such as glycerol through a covering glass, for a microscopic observation of the stained areas.<br class="style-scope patent-text">    The results are given in Figures 10 and 11, in which the distribution of localized human annexin-V in the cardiac muscle tissue was stained with brown color and developed in -black, demonstrating that the invention is applicable to a tissue-staining for-cardiac muscle by means of an enzyme antibody method as well as to an ELISA.<br class="style-scope patent-text">     EXAMPLE 8: Hybridoma Preparation (1) Mice Inbred-strain BALB/c female mice 5 to 8 weeks of age were maintained on a diet of the standard pellets, feeding water ad libitum in an animal-breeding chamber (23+1°C, humidity 70$).<br class="style-scope patent-text">(2) Inmmunization Dog-annexin-V extracted and purified from dog cardiac muscles (cf. Japanese Laid-open patent application No.72147/<br class="style-scope patent-text">1995) and the human annexin-V purified from human cardiac muscles as described in Example 1 were each dissolved in O.1M sodium phosphate buffer (pH 7.6) and dialyzed against the same buffer.<br class="style-scope patent-text">  Following the dialysis, the respective annexin-V antigens was prepared so as to give solutions of a concentration of lmg/ml, which were distributed into EppPndorf tubesat a rate of 50 microliters per tube, followed by freeze-drying at -400°C to keep the purified native dog- and human-cardiac muscle-derived annexin-V antigens for immunization.<br class="style-scope patent-text">   Dog annexin-V 0.2m1 (200 micrograms) as prepared in the above-mentioned manner was added with 0.3m1 of physiological saline to give a volume of 0.5mI. The antigen solution thus prepared was mixed with 0.5m1 of Freund's complete adjuvant, followed by thorough emulsification. The dog annexin-V in emulsion as the antigen was administered into the abdominal cavities of four female mice of 5 week-of age in a dose of the purified dog annexin-V 40 micrograms per mouse for the intial immunization.<br class="style-scope patent-text">    Dog annexin-V antigen 0.2m1 (200 micrograms) as prepared in the aforesaid manner was taken in a test tube, to which was added l0 0.3m1 of physiological saline to give a volume of 0.5m1. The solution thus prepared was added with 0.5m1 of RIBI Adjuvant System (RAS) MPL+TDM Emulsion* R-700 (available from RIBI. Immuno Chem. Research Inc., Hamilton, MT., USA), in which lml of plysiological saline was added per vial for making the solution.<br class="style-scope patent-text">     The resultant mixture was vigorously stirred in a vortex mixer for approx. three minutes for emulsification. With this dog annexin-V antigen in emulsion the mice were immunized as booster immunizations two weeks, four weeks and six weeks after the intial immunization in a dose of 50 maicrograms per mouse. A<br class="style-scope patent-text">2o further booster immunization was carried out twenty-three weeks after the initial immunization in a dose of the dog annexin-V<br class="style-scope patent-text">antigen 30 micrograms per mouse, with the antigen having been prepared in the same manner as mentioned above using RIBI<br class="style-scope patent-text">  Adjuvant System (RAS) MPL+TDM Emulsion, R-700. Following the booster immunization the blood was collected from the respective mice at intervals to prepare sera, which were assayed by the aforesaid absorption test for antibody titers against native dog trademark cardiac muscle- and human-annexin-V to examine the production of specific antibodies. Based on the result of the assay for the antibody titer, mice were selected having a high titer. The selected mice were administered, twenty-six weeks after the initial immunization, with the native annexin-V (having been prepared by dissolving in lml of physiological saline to give a concentration of 50 micrograms/ml) intravenously through the mice tails as a booster. At this point the mouse sera were again assayed for the antibody titer to select mice having a higher titer. The selected mice were administered, one week after the preceding booster immunization, with lml of the native human annexin-V (having been prepared with physiological saline to give a concentration of 100 micrograms/ml) slowly and intravenously through the tails of the mice for final immunization.<br class="style-scope patent-text">(3) Preparation of spleen cells Three days after the final immunization, the spleen were excised from the BALB/c mice in the same manner as described in Example 1. The excised spleen cells were suspended in EMEM<br class="style-scope patent-text">culture medium (available from Nissui Co.) to prepare a 2o suspension of spleen cells. The spleen cells were washed four times with EMEM culture medium and determined for the number of cells. The resultant spleen cells are 4.7x108.<br class="style-scope patent-text">(4) Preparation of parent strain Cell fusion was conducted using P3-X63-Ag8.653 culture cells (hereinafter referred to as X63 cells) as parent cell strain, which are 2-amino-6-oxy-8-azapurine (8-Azaguanine) -resistant and derived from BALB/c mouse myeloma.<br class="style-scope patent-text">    X63 cells in the logarithmic growth phase were employed to subculture in RPMI-1640 medium (in a concentration of 20 micrograms/ml and with 8-azaguanine) (available from GIBCO Co.) containing 10% of immobilized fatal calf serum (hereinafter referred to as FCS). Further cultivation was carried out, from three days in advance to the cell fusion, in RPMI-1640 culture medium containing 10% FCS but not containing 8-azaguanine to maintain the growth ability in the logarithmic phase. The X 63 cells were washed three times with RPMI-1640 medium and determined for the number of cells. The number of living X63 cells was 1.5x108.<br class="style-scope patent-text">(5) Cell fusion Polyethylene glycol-400 available from Sigma Co. was dissolved in RPMI-1640 culture medium to give a concentration of 50% (W/V), followed by heating at 37°C for use.<br class="style-scope patent-text">     The spleen cells and X63 cells were mixed together in a ratio of the spleen cells: the X63 cells=10:1. The mixture was centrifuged at 1500 rpm for five minutes, the supernatant was removed and the pelletized cells were thoroughly disintegrated for use in cell fusion. The cell fusion was conducted, using polyethylene glycol prepared in the aforesaid manner and kept at 37°C, in accordance with the method described in "Kohler and Milstein: Nature, Vo1.256, pages 495-497 (1975)" and "European Journal of Immunology, Vol.6, pages 511-519 (1976)".<br class="style-scope patent-text">     The cell line following the cell fusion were suspended in HAT selection medium containing RPMI-1640 added with FCS of a 10%<br class="style-scope patent-text">concentration, 1x10-4 hypoxanthine, 4x10-7 aminopterin and 1.6x10-5M thymidine, to give a spleen-cell concentration of 2.0x106 per ml. The cell suspension was distributed in a 96-well microtitreplate at a rate of 50 microliters per well, and incubated in an incubator kept at a 37°C temperature and a 95$<br class="style-scope patent-text">humidity under a 8% COZ atomsphere. One drop of the HAT medium was added to each well on the first day and the second day from the start of the incubation, followed by the addition of two drops of the same medium seven and nine days after start, for further incubation. Then, incubation was carried out in a HAT-free culture medium. Approx. ten days to two weeks after the 1o start of incubation, screening was made, as the first screening, for clones producing anti-annexin-V monoclonal antibodies having a common reactivity to native human annexin-V and native dog annexin-V, in which the screening was done by, an annexin-V absorption test using the native human 15 annexin-V and dog annexin-V antigens.<br class="style-scope patent-text">   The selected clones were then subjected to the second screening by means of a capture method for monoclonal antibodies, through which were selected hybridoma cell line clones producing monoclonal antibodies suitable for use in a O sandwich ELISA system for a sensitive assay of annexin-V in combination with monoclonal antibodies HCA-627. The monoclonal antibodies HCA-627 are produced by hybridoma cell line HCA-627 strain which has been deposited under the number BP-5284 at the National Institute of Bioscience and 25 Human-Technology, the Agency of Industrial Aeience and Technology of Japan.<br class="style-scope patent-text">(6) Screening (i) First Screening As cell clones appeared ten days after the start of incubation, the absorption test with native dog- and human-annexin-V as the antigens was carried out by ELISA for the supernatants of the hybridoma cell line cultures.<br class="style-scope patent-text">     It was found by the present inventors that an ELISA system employing a combination the monoclonal antibodies HCA-627 bound to the cells as the solid phase and the HRPO-labeled anti-dog-32KP polyclonal antibodies can be applied to the assay of native human annexin-V and dog annexin-V antigens. The system was thus 1o utilized to screen monoclonal antibodies which will efficiently react with the native annexin-V.<br class="style-scope patent-text">   Thus, the first set was constituted of the supernatant of hybridoma cell line clone culture obtained by the subject cell fusion and the native human annexin-V antigen solution (100ng/ml) with each being distributed in U-bottomed wells of a microtitreplate at a rate of 50 microliters per well, while the second set was constituted of the supernatant of the same hybridoma cell line clone culture and the native dog annexin-V antigen solution (100ng/ml) with 2o each being distributed in a plurality of U-bottomed wells of another microtitreplate at a rate of 50 microliters per well.<br class="style-scope patent-text">  Each set was added with 50 microliters of 20$ suspension of Sepharose~4B combined with anti-mouse-immunoglobulin antibody and allowed to stand for 10 minutes following stirring for the one hour. With each set, when it was observed that the anti-mouse immunoglobulin antibody-combined sepharose~ 4B completely sedimented on the well-bottoms, the respective supernatants 50 trademark microtilers were assayed for human annexin-V or dog annexin-V<br class="style-scope patent-text">content remaining therein by means of the aforesaid annexin-V<br class="style-scope patent-text">  ELISA method.<br class="style-scope patent-text">(ii) Selection of monoclonal antibodies by. the first screening In this assay, if any anti-cardiac-muscle-anriexin-V<br class="style-scope patent-text">monoclonal antibodies against native dog- and human-annexin-V<br class="style-scope patent-text">remain in the culture supernatant of a hybridoma cell line, a reaction will occur between the native dog- or human-annexin-V<br class="style-scope patent-text">and the anti-human-annexin-V monoclonal antibodies, followed by a reaction with anti-mouse-immunoglobulin monoclonal antibody-combined Sepharose~ 4B, resulting in the formation of antigen-antibody complexes which are to sediment. This will lead to a decrease in the annexin-V content remaining in the supernatant and it is therefore possible to identify the occurrence of any anti-annexin-V monoclonal antibodies.<br class="style-scope patent-text">(iii) Second screening If there were successfully selected anti-annexin-V<br class="style-scope patent-text">. monoclonal antibodies having a reactivity with native human- and dog-annexin-V antigens, screening was then made, through the 0 following capture ELISA, for hybridoma cell line clones producing any monoclonal antibodies suitable for establishing a sandwich ELISA system for sensitive assay of annexin-V, in combination with the monoclonal antibodies HCA-627 produced by hybridoma cell line HCA-627 strain which has been deposited as an International Deposit under the number FERM BP-5284.<br class="style-scope patent-text">(iv) Capture ELISA method A solution was prepared of the IgG fraction of polyclonal antibody having a specificity to the Fc portion of goat-derived trademark anti-mouse immunoglobulin (available from Nordic Co.), with O.1M<br class="style-scope patent-text">sodium phosphate solution (pH 7.5) containing 0.1% sodium azide to give a concentration of 50 microliters/ml. The solution was distributed in a 96-well titerplate (available from Nunk Co,) at a rate of 50 microliters per well for adsorption at 4°C<br class="style-scope patent-text">overnight.<br class="style-scope patent-text">   The resultant was then washed three times with washing phosphate buffer (hereinafter referred to washing solution) containing 0.05% Tween-20, followed by blocking with PHS<br class="style-scope patent-text">1o containing 1% BSA to prepare anti-mouse-immunoglobulin G-Fc polyclonal antibody-bound wells as the solid phase.<br class="style-scope patent-text">(v) Based on the results of the absorption test with native human- and dog-annexin-V, the culture supernatants of hybridoma cell lines producing monoclonal antibodies with a high reactivity 15 with the native human- and dog annexin-V was added into the wells bound with the anti-mouse-immunoglobulin G-Fc polyclonal antibody as the solid phase at a rate 50 microliters per well, following the removal of the blocking solution from each well.<br class="style-scope patent-text">  Upon the completion of reaction for one hour at room temperature, 2o each well was washed three times with the washing solution. With a phosphate buffer of pH 7.0 containing 1% HSA and. 5mM EDTA<br class="style-scope patent-text">(hereinafter reaction buffer solution), a solution of native human annexin-V was prepared to give a concentration of 100ng/ml.<br class="style-scope patent-text">  To each well was added 50 microliters of the solution of native 25 human annexin-V, for a further reaction over one hour, followed by washing three times with the washing solution. HRPO-labeled HCA-627-Fab' antibody were conditioned with the reaction buffer trademark solution to have an appropriate concentration, and then added to the respective wells for reaction over thirty minutes. The dilution of the HRPO-labeled antibodies was done in such manner that the mouse immunoglobulin was lOmicrograms/ml, in order to block the adsorption of the HRPO-labeled antibodies onto the well bound with the anti-mouse -immunoglobulin G-Fc polyclonal antibodies as the solid phate. On completing the reaction, each well was washed three times with the washing solution, followed by reaction with OPD substrate solution (containing O.1M<br class="style-scope patent-text">1o phosphate-citrate buffer added with 2mg/ml o-phenylenediamine and 4mM H202) for five minutes at room temperature. The reaction was terminated with 2N H2S04, to determine absorbance at the primary wavelength 492nm and at the secondary wavelength 690nm on an ELISA plate reader. Measurements at the primary wavelength 492nm i5 are attributed to the substrate chromogen produced by the bound labeled-antibody, whereas the measurements at the secondary wavelength reflect flaws or stains on the microtiterplate.<br class="style-scope patent-text">     Hy subtracting an absorbance measurement at the secondary wavelength from an absorbance measurement at the primary 2o wavelength, it is possible to determine the true absorbance in response to the amount of chromogen changed due to the enzyme on the labeled-antibodies which have been bound to antigen in proportion to the amount of the antigen bound to the solid-phase.<br class="style-scope patent-text">     This second screening enables obtainment of an annexin-V<br class="style-scope patent-text">25 monoclonal antibody having reactivities with the native human and dog-annexin-V antigens and being capable of recognizing an antigen determinant site different from another site on the indentical annexin-V molecule to be recognized by anti-annexin-V <br class="style-scope patent-text"> <br class="style-scope patent-text"> monoclonal antibody HCA-627, thereby providing an optimal combination with the anti-annexin-V monoclonal antibody HCA-627 for a sandwich ELISA system. Thus, a hybridoma cell line can be obtained which produces the monoclonal antibody to provide the optimal combination with the anti-human-annexin-V monoclonal antibody HCA-627 for the sandwich ELISA system.<br class="style-scope patent-text">(7) Studies on reactivities with the solid-phases, sensitized with annexin-V antigens derived from various animals Studies were made on animal-dependent reactivities of the various anti-annexin-V monoclonal antibodies identified by the aforesaid screening, by allowing them to react with microtiterplate solid phases composed of annexin-V antigens extracted and purified from various animals.<br class="style-scope patent-text">(8) Preparation of microtiterplates with solid phase-coupled native annexin-V antigens Native annexin-V antigens extracted and purified from the human heart, the dog heart, the rat heart and the bovine lung were each adjusted with O.1M phosphate buffer at pH 7.5 to give an antigen solution of 1 microgram/ml. Each antigen solution was distributed in a 96-well microtiterplate (available from Nunk Co.) at a rate of 50 microliters per well, followed by adsorption at 4°C overnight, washing three times with the washing solution and then blocking at 4°C overnight with the blocking solution.<br class="style-scope patent-text">    Thus, the solid phase wells sensitized with various annexin-V<br class="style-scope patent-text">antigens were prepared for use.<br class="style-scope patent-text">     Studies were made of the anti-annexin-V monoclonal antibodies produced by the hybridoma cell lines obtained by the above described screening, with respect to their reactivities with the various annexin-V antigens bound to the plates as solid phase. Thus, reaction was performed, at room temperature for one hour, of the respective culture supernatants of hybridoma cell line clones producing the various anti-annexin-V monoclonal antibodies (the original solutions) or their purified IgG<br class="style-scope patent-text">fractions (prepared to give a final concentration of 1 microgram/ml) with the respective solid phase wells sensitized with the native annexin-V antigens derived from the various l0 animals, followed by washing three times with the washing solution. A further reaction was carried out with HRPO-labeled anti-mouse-immunoglobulin antibodies (derived from goats) at room temperature for thirty minutes, followed by washing four times with washing solution and reaction with OPD substrate solution (containing 0.1M phosphate-citrate 4mM H202) at room temperature for thirty minutes. Then the reaction was terminated with 2N H2S04 solution for absorbance assay at the primary wavelength 492nm and the secondary wavelength 690nm on an ELISA plate reader. Measurements at the primary 2o wavelength 492nm are attributed to the substrate chromogen produced by the bound labeled-antibody, whereas the measurements at the secondary wavelength reflects the detection of flaws or stains on the microtiterplate.<br class="style-scope patent-text">     By subtracting an absorbance measurement at the secondary wavelength from an absorbance measurement at the primary wavelength, it is possible to determine the true absorbance in response to the amount of chromogen changed due to the enzyme on the labeled-antibodies which have been bound to antigen in proportion to the amount of the antigen bound to the solid-phase.<br class="style-scope patent-text">(9) Cloning Based on the absorption test using the native human- and dog-annexin-V and through the above described capture ELISA<br class="style-scope patent-text">system, the selection was made of hybridoma cell line clones which produce anti-annexin-V monoclonal antibodies to provide a prospective sensitive sandwich ELISA system for assaying native annexin-V in combination with the anti-annexin-V monoclonal antibody produced by hybridoma cell line HCA-627 strain (deposited under the number FERM PB-5284 at the National Institute of Bioscience and Human-Technology,the Agency of Industrial Science and Technology, Japan). The hybridoma cell line clones were subjected to a cloning operation by means of limiting dilution to obtain a single clone. In performing the cloning, thymus cells prepared from BALB/c mice and suspended in HAT medium was added as feeder cells at 1x106 per well.<br class="style-scope patent-text">(10) Identification of mouse immunoglobulin subclass Identification of mouse immunoglobulin subclass was made with respect to the monoclonal antibodies produced by the 2o hybridoma cell lines which have been prepared as having a single clone by means of the above-mentioned cloning. The culture supernatants of the respective hybridoma cell lines were assayed for the mouse immunoglobulin subclass identification using MONOAb typing kit (available from Zymed Co.). </div>
      <div class="description-paragraph style-scope patent-text">(11) Establishment of hybridoma cell lines producing anti-annexin-V monoclonal antibodies As a result of the first screening for the subject cell fusion, 200 strains were obtained which were positive in the absorption test using the native human- and dog-annexin-V<br class="style-scope patent-text">antigen. In addition, the second screening through the above described capture ELISA were selected 8 clones, which can establish the sandwich ELISA system in combination with anti-annexin-V monoclonal antibody produced by hybridoma cell line HCA-627 strain deposited as an International Deposit under the number FERM BP-5284. Cloning through the limiting solution was conducted with regard to said eight elones to establish the 1o respective hybridoma cell clones. Table 4 below gives reaction specificities of the anti-annexin-V monoclonal antibodies obtained by the subject cell fusion, No.2.<br class="style-scope patent-text">     In table 4 there are given, for comparison, the reactivities of clones HCA-627, HCA-155H, HCA-507HD and HCA-293HDR obtained in 15~ the previous cell fusion of Example 1.<br class="style-scope patent-text">    Different from the clones established in Example 1 (HCA-115H, HCA-507HD and HCA-293HRD), all the anti-annexin-V<br class="style-scope patent-text">monoclonal antibodies produced by hybridoma cell line clones established in the subject Example demonstrate to have a high 20 reactivity with the native human- and dog-annexin-V (cf. the absorption tests in Table 4).<br class="style-scope patent-text">    It is also shown from the screening by the capture ELISA<br class="style-scope patent-text">system that the clones are able to provide an efficient and sensitive sandwich ELISA system in combination with the anti-25 annexin-V monoclonal antibody produced by hybridoma cell line clone HCA-627 strain (deposited as an International Deposit under the number FERM BP-5284) (cf. the Capture Method in Table 4).<br class="style-scope patent-text">   In addition, from the studies of the reaction system in which annexin-V antigens from humans and the various animals are bound as solid phase it was found that the hybridoma cell line clones established in the subject Example have a reactivity as monoclonal antibody totally different from some of the clones established in Example 1, HCA-115H, HCA-507HD and HCA-293HDR, as they do not exhibit any reactivity with the antigens of bound annexin-V as the solid phase derived from such animals (cf. Table 4), although they exhibit a strong reactivity with native annexin-V in the absorption test, i.e. with the antigens in 1p liquid phase.<br class="style-scope patent-text">    As can be seen from the above, the eight strains as screened by the capture ELISA system, anti-annexin-V monoclonal antibody-producing clones, are all capable of providing a sandwich ELISA<br class="style-scope patent-text">system in combination with the monoclonal antibody clone HCA-627 15 (Table 4) and recognizing an epitope totally different from one to be recognized by the clone HCA-627.<br class="style-scope patent-text">    As given in Table 4, the immunoglobulin subtypes of the anti-annexin-V monoclonal antibodies produced by the eight strains of hybridoma cell line clones established in the subject 2o Example are all IgG type, with respect to the H chain. Regarding the L chain all the clones have k-chain (cf. Table4). <br class="style-scope patent-text"> <br class="style-scope patent-text"> H (O          &gt;   ~ N       O O O O tr1M O O <br class="style-scope patent-text">,~ ~                  <br class="style-scope patent-text">~                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> N O    I     M       M t~N M ~-V'00I~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> CT W          ~     O       00N N V'l0t0O ~-O I           G                            <br class="style-scope patent-text">     O .Q                        <br class="style-scope patent-text">.~                                          <br class="style-scope patent-text"> <br class="style-scope patent-text"> G ~ 'D        -r-I~   I I I                <br class="style-scope patent-text">-~-I          O   <br class="style-scope patent-text">c0 -.-1 -~ N          X   O O       N ~OM d~NN 01l~<br class="style-scope patent-text">     I ~r-f        -.-1 +~ -i ~                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> &gt;~ S-.r       O   O                        <br class="style-scope patent-text">-r-I          +~                           <br class="style-scope patent-text">r1 l0 I t~              <br class="style-scope patent-text"> <br class="style-scope patent-text"> U ~ ~i-~      C                            <br class="style-scope patent-text">     O C    (0 O ~   <br class="style-scope patent-text"> <br class="style-scope patent-text"> N +~                                       <br class="style-scope patent-text"> <br class="style-scope patent-text">-ri p., h a ~         co ~ rx          .+~                          <br class="style-scope patent-text">     I~          <br class="style-scope patent-text"> <br class="style-scope patent-text"> U ro          I                            <br class="style-scope patent-text">     U ~           ~                            <br class="style-scope patent-text">x N                                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> CIl U         ~   ~ ~       ~ M O ~ Lf1d'N M <br class="style-scope patent-text"> <br class="style-scope patent-text">     O tD                                        <br class="style-scope patent-text"> <br class="style-scope patent-text"> I U .J~      c0    ~       ~ .-~ ~ pr-.~ -rl        E     O I I I O O O O OO O O <br class="style-scope patent-text">     C7 +~         ~              <br class="style-scope patent-text">~                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> c0 c0         ~   G                        <br class="style-scope patent-text">u1 CT         O                            <br class="style-scope patent-text">     C -rl U       <br class="style-scope patent-text"> <br class="style-scope patent-text"> E ~ ~         x   o 0       o 0 0 0 00 0 o H .~          U                          <br class="style-scope patent-text">3 x 't7 O <br class="style-scope patent-text"> <br class="style-scope patent-text"> O                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> -r-I                         <br class="style-scope patent-text">~-.                          <br class="style-scope patent-text"> <br class="style-scope patent-text"> (~          r-I~.J                          <br class="style-scope patent-text">oy                      +~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> E a"                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~ a~         sa u1 O    ~     O     ~ N m N o00~o~~ t~aoo~~ <br class="style-scope patent-text">-~           N                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ C~    ~     U7    CO      l~01L~01I~l00101r-i +-~     O     +~                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> E-~ G   O   ~ .L7                         t0 --I   c0 .1-~  ~                     <br class="style-scope patent-text">~'r tn  ~ ~     +~                     0 c0 U   O -~-I  U                                 <br class="style-scope patent-text">&gt;       y,~                                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> -~  --1 i~  ~     ~                            U<br class="style-scope patent-text">     I       +~                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'LJ +~ t0   N     O                            p ~       G                                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> O   C1 z    ~   H       <br class="style-scope patent-text">-~-I    ev C   S-a X   U   ~ .1-~                         O<br class="style-scope patent-text">01o w   O .&gt;~   .s~   G1 v       ~     '-' +~  U1 -E-~ c0    S.-i C       O           <br class="style-scope patent-text"> <br class="style-scope patent-text"> G   ~7 -rl  ~     O     ao~ t~~ t~O o~o~ooaoO O ..<br class="style-scope patent-text">~       U   N                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ 3 ~       o m     o~      a,o a~a~o~ovo o +~                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> .~                           <br class="style-scope patent-text">co C                                               <br class="style-scope patent-text"> <br class="style-scope patent-text"> O                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> O                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> U                 .-i O   ~ G         H .~-~                         <br class="style-scope patent-text">o\o c   rt~ v       E                              <br class="style-scope patent-text"> <br class="style-scope patent-text"> o   +~ E    ~     s~                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> u1 ~    i~    O     - ~ M t~O aou~N aov~ooao -rt     O     ~           <br class="style-scope patent-text"> <br class="style-scope patent-text"> v x +~  o     cn    00      000,~ ao~~ o~a~<br class="style-scope patent-text">-~I   +~             <br class="style-scope patent-text"> <br class="style-scope patent-text"> &gt;   H ~     -rl ~ ,~                           <br class="style-scope patent-text">+~    c0 1   N .~    +~    .~                           <br class="style-scope patent-text">c0    (Y, G ~     U                                  <br class="style-scope patent-text">S-i -~  O -~    ~      <br class="style-scope patent-text">&gt;       ~                                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> X   -rl +.~ N                         <br class="style-scope patent-text">     I                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> 41 +~ c0   fx    O                            <br class="style-scope patent-text">~       U         <br class="style-scope patent-text"> <br class="style-scope patent-text"> C   C1 z    U   H -.-i -rl           ..                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> X       ..Ca~ +~                           <br class="style-scope patent-text">~     o~                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> c0  O .&gt;~   c0    C1 v       O     "                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> I   u1 +~   ~     f.a ~       U                                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> -~  .~ -rt        O     ao~ I~N ooO ooaotwo ovo~<br class="style-scope patent-text">t~            ~                <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~  ~ 3 ~       o tn    o~      a~o ~ o~a,a~o~o~<br class="style-scope patent-text">-+~                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> o tn v +~  .la o  x .x.xx .x.x.x.xx.~c.x.x U   rl -r~ :s N                                        <br class="style-scope patent-text"> <br class="style-scope patent-text"> O C~                       <br class="style-scope patent-text"> <br class="style-scope patent-text"> -r'~N ~ ~                 fdt0R1 U   U1 ~                .-N N N                <br class="style-scope patent-text">-N            <br class="style-scope patent-text"> <br class="style-scope patent-text"> N   ~ ~ O               U'C7U'U'U'U'U'U'U'C7U'U' C1  O ~ tn _ C/~ ~ H H               H H H H H H H H HH H H  <br class="style-scope patent-text"> <br class="style-scope patent-text"> O                                               <br class="style-scope patent-text"> <br class="style-scope patent-text"> -I  I                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~  CP O                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> U   ~ I o z ro  o ~ ro                    rx N   .r-i                    toC.a tp i &gt; N                                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> rx  tn ~                  x x x -~, I G                                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~ ~                t~Lf1t~M N tDt~~ O00M O <br class="style-scope patent-text">     O                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> .C ~           N tnO o~O t~O O ~Oa0ofO <br class="style-scope patent-text">-rl ~                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> d'  N I ~               l0- tf1N N 1001~  ~-~ N <br class="style-scope patent-text">     X U                                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> -r-I      I I I I 1 I I 1 1I I I <br class="style-scope patent-text">     N                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> U   r-I                                        <br class="style-scope patent-text">.t.) 'D ~                                        <br class="style-scope patent-text"> <br class="style-scope patent-text"> v O &gt;~    U U U U f~f~L CaLCaCaLl G ~                                        <br class="style-scope patent-text">t0 .c~ U z ~               x x x x x x x x xx x x t0 to ~                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~o H                                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> o                       ~   ~ z ~ z ~ z z o   ~ o .-o ~ o v-x             ,~  o m v m o m ~n m         s..~            cn  r,a r,~ rl ~                               <br class="style-scope patent-text"> <br class="style-scope patent-text"> .~  .~~ .s~~ ,~              <br class="style-scope patent-text">~                               <br class="style-scope patent-text"> <br class="style-scope patent-text"> o         ~             rl  co co  ~o U             .&gt;~ (-,~ E1~ H ~-I                <br class="style-scope patent-text">~                               <br class="style-scope patent-text"> <br class="style-scope patent-text"> !.a        P4            c0 co                      -+-~N N ~ N O p U~                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> &gt;                       ~n  N U v U v U    <br class="style-scope patent-text">     U                               <br class="style-scope patent-text"> <br class="style-scope patent-text"> N  E                                                       <br class="style-scope patent-text"> <br class="style-scope patent-text"> -rlO                                               O <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'D s~                              <br class="style-scope patent-text"> <br class="style-scope patent-text"> O  'r-i          f~                 <br class="style-scope patent-text">     O                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> C a)      \ O   ~                                    +-~<br class="style-scope patent-text">     CT                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> .,..~~   ~   &gt;   ,1    y .,.i .,..~                <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~ G .~(0  I   ~ +~  ~   E                                <br class="style-scope patent-text">.~     +~                                          <br class="style-scope patent-text"> <br class="style-scope patent-text"> t~ N +~-~  ~   O c0 +-~     ~  <br class="style-scope patent-text"> <br class="style-scope patent-text"> -rlC1  .~-I  tr1   ~   O                                .--i w-i     N                                    <br class="style-scope patent-text">~                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> -~3 I   X E -rl       avM   o   o   O  o o m n N ~ ~ro cp -+~  O   N O ~ +~  ~   ~ ~   ~   ~   ao O r-o o o O     <br class="style-scope patent-text">rl c0 ~ ~.,cn  ~ S.a~ -.1 O   ~ O   LIl  M   ~O O O O O O O O O O<br class="style-scope patent-text">'C7     ~             <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ ~1-~f0  &gt;~4-1~ Ul N       \                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> O    -.-i.~  ~   ,-a ~   I O   M   M   M  O O O O O O O O U<br class="style-scope patent-text">     N       G                <br class="style-scope patent-text">tT                                          <br class="style-scope patent-text"> <br class="style-scope patent-text"> --~&gt; ~ f~.   ~ ~ ~   O                                    O<br class="style-scope patent-text">~-i U  I .r-iI   ~ v N U7  ..-1 -N      r-O  ~ -+.~'L7 &gt; CT~     -a-~  C                                O<br class="style-scope patent-text">-rl .("'..rlU .rl -r-I.ri.rl   U   N      <br class="style-scope patent-text">     U7      .--I                                       <br class="style-scope patent-text">,L", o  x ~o~   +-~+~~ ~   ~o,na.         <br class="style-scope patent-text">~       +~                                          <br class="style-scope patent-text"> <br class="style-scope patent-text"> v v o   cn~ o a~  a~co~                                ..<br class="style-scope patent-text">v       .~I              <br class="style-scope patent-text"> <br class="style-scope patent-text"> C fxcn  z ~ m 3   cx~                                  <br class="style-scope patent-text">cn     3 &gt;  c &gt;~            <br class="style-scope patent-text"> <br class="style-scope patent-text"> &gt; .~-~I   \                                     <br class="style-scope patent-text"> <br class="style-scope patent-text"> X  +~.~c0  I rt1r-~I  b~                                   <br class="style-scope patent-text">.G      3 ~ -I-i.~  C fx.-~                                        <br class="style-scope patent-text">+~      C                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> 3 ~rliz, -~I  m ~   ~   o -rl     N     <br class="style-scope patent-text"> <br class="style-scope patent-text"> 3 I   ~C~ 3 O       o~                               <br class="style-scope patent-text">3       v~                                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~0 '&gt;7  ~   N O \ .ri w   iDN   vD  ao  u~ O O O r-~ M M O <br class="style-scope patent-text">.r1 t  N ~,U7  G J.-I~ +.~ O   ~ O   O   O   M  O O O O O 00O O <br class="style-scope patent-text">'C7     +~              <br class="style-scope patent-text"> <br class="style-scope patent-text"> -rlN +~c0  ~ '~-~~ ~0        O   O   O   I~ O O O O O O O O <br class="style-scope patent-text"> N       ~                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> +-&gt;. . .C  ~   O N   G I                                <br class="style-scope patent-text">~-I~-IN       ~             <br class="style-scope patent-text"> <br class="style-scope patent-text"> C  +'&gt; f~.   ~ ~n    O     O   O   O   O  O O O O O O O O <br class="style-scope patent-text">-rl     -rI                                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> -riw-iI   N N +~    .ri ~       ~    <br class="style-scope patent-text"> <br class="style-scope patent-text"> U7+~'   ~ ~ +~    +~                                   <br class="style-scope patent-text">.rl     wl ~   <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'a-~~ U -rl .rl-rlSa    U   N                                <br class="style-scope patent-text"> <br class="style-scope patent-text">\        <br class="style-scope patent-text"> <br class="style-scope patent-text"> O  O rt1~   +~+-~c0    t0.~                                 <br class="style-scope patent-text">~    ~                                          <br class="style-scope patent-text">     CT                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> C/lN O   r0&gt;~U U   U t0d' p       ~.                                          <br class="style-scope patent-text"> <br class="style-scope patent-text"> rxv~  z ~ x v~  rx~ ~                            <br class="style-scope patent-text">~n      ~                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> -~ a~          ~                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~ +~          a~    ~-, -~, U  ~   +&gt;  &gt; ~ .rl   \            <br class="style-scope patent-text"> <br class="style-scope patent-text"> -rl  .~~0  I O ~ +~  :s .~                                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> '~-~  i~~   C Ca~ &gt;~                          <br class="style-scope patent-text">+~                                                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> .rip -~-Is;1 .~  N C   c-  O                                <br class="style-scope patent-text">-~-1    ~                                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> U  cn3 I   x E a o       o, a~ ~s v   a~o \ .~, N   .n ,--~                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> a  .~~ cn  ~ s~~ +~  o   ~ ~   ~   ~   ao 0 0 ~no o M ~ o zs      ~                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> cn   +~~o  ~ ~ ~ co        0   0   0   00 0 0 0 0 0 0 0 0 a~      \   <br class="style-scope patent-text"> <br class="style-scope patent-text"> I .rl.~  ~   O N   ~   I O   O   O   ~O O O O O O O O O <br class="style-scope patent-text">     N       a~                                          <br class="style-scope patent-text"> <br class="style-scope patent-text"> &gt;~ a~~ C1.   W n .r-IO                        <br class="style-scope patent-text">.,..I    ~                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> O  -r-I-rlI   N N .1-~  -rl  ~ O   O   O      O O O O O O O O <br class="style-scope patent-text">+~      ~                                        <br class="style-scope patent-text"> <br class="style-scope patent-text"> .rir-I.E.~''~J~ LT+~    +~                       <br class="style-scope patent-text">-ri     .ri .1~O U .rl .~-1.rlS-i   U   N                                <br class="style-scope patent-text"> <br class="style-scope patent-text">.~                                          <br class="style-scope patent-text"> <br class="style-scope patent-text"> U  C!)c0r-I +~+~t0    ct1.~o~                               <br class="style-scope patent-text">~       ~                                        <br class="style-scope patent-text">+~     <br class="style-scope patent-text"> <br class="style-scope patent-text"> c0   v O   c0G N N   v c0~                                <br class="style-scope patent-text">p       -rl v  .~tx~n  z ~ x tn  W ~                  <br class="style-scope patent-text">vo      3 cx +~                                                    <br class="style-scope patent-text"> <br class="style-scope patent-text"> 3           ~ N   rl a~      \     <br class="style-scope patent-text"> <br class="style-scope patent-text"> zs m   +~  &gt;   ~ w   \                                    <br class="style-scope patent-text">..-I                              <br class="style-scope patent-text"> <br class="style-scope patent-text"> N  N .~t0  I   ~ +~  CT               <br class="style-scope patent-text">.C      +~                                          <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ +.~.-a ~   o ~o +~      ~                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~  +~..-ff.~.-rl  u~    -   O  <br class="style-scope patent-text">-~-I    N                                          <br class="style-scope patent-text">~                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> I a I   x ~ .~I       o, +~ ~   a~  a~o +~                                  <br class="style-scope patent-text">+~                                          <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ cn  ~ &gt;.~s~    o   .                                <br class="style-scope patent-text">ro      ..~                           <br class="style-scope patent-text">~                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> o  +~+~co  ~ w ~o a~      cn \                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> U  U .r1.~  ~   N ~   ~   I O   l0  N   O  I~00N v0O 00t~Q1 N       d1 ~o&gt; a     ~ x a~  o     N   OO  N   lf1 0 0 ~ o ~ 0 0 0 -~I     ~                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> a~-~I   a~a~~n    -~,  E o   o,      o, 0 0 0 0 0 0 0 0 .h      ~               <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~r (x.+-~T3  ~ ~ ~     +~  ~ .                              <br class="style-scope patent-text">.~I                                                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> U -rl .r.1..-i(0    U N O       N      O O O O O O O O <br class="style-scope patent-text">     U7      ~           <br class="style-scope patent-text">.C                                          <br class="style-scope patent-text"> <br class="style-scope patent-text"> a1   ~0~   +~.NE ~-i rt7.~                                 <br class="style-scope patent-text">     C       +~               <br class="style-scope patent-text"> <br class="style-scope patent-text"> N O   c0~ ~ N   v c0v~                               <br class="style-scope patent-text">v    -rl ,.ca  rxtn  z ~ x 3   rx~ .                             <br class="style-scope patent-text">cn      3 H                                                          <br class="style-scope patent-text"> <br class="style-scope patent-text"> EXAMPLE 9: Production of Monoclonal Antibodies (1) Harvesting of ascitic fluids In order to obtain anti-annexin-V monoclonal antibodies of a higher concentration the various hybridoma cell lines are grown and the resulting respective clones were innoculated, following washing three times with EMEM culture solution, into the ascitic cavities of BALH/c mice which have been administered with 2, 6, 10, 14-tetramethyl pentadecane (pristane) in advance into their ascitic cavities. The ascitic fluids were harvested seven to fourteen days after the innoculation of the hybridoma cell lines into the ascitic casities. The ascitic fluids thus obtained were applied to a centrifuge to remove the cellular and residual fractions. The supernatant fractions were pooled for keeping at 4°C with the addition of sodium azide as antiseptic.<br class="style-scope patent-text">(2) Purification of monoclonal antibodies from ascitic fluids The IgG fractions of the monoclonal antibodies were obtained by applying the ascitic fluids obtained from the hybridoma cell lines to affinitychromatograpy using ConSep~LC100 device and a protein-A column (available from Perceptive Co.). The purified 2o IgG fractions of the respective clones were determined for purity by HPLC using a TSK*gel G3000SW column (available from Tosoh Co.) and SDS-PAGE using PhastSystem~ (available from Pharmacia Co.).<br class="style-scope patent-text">  The result was that all the monoclonal antibodies from the hybridoma cell lines have a purity of 98$ or more.<br class="style-scope patent-text">trademark EXAMPLE 10 . Studies on ELISA System for Assay of Human Annexin-V<br class="style-scope patent-text">(1) Preparation of HRPO-labeled anti-annexin-V monoclonal antibodies Studies were made on the applicability of the monoclonal antibodies as estatleshed in the above to an ELISA system for assay of native human annexin-V.<br class="style-scope patent-text"> Thus, as representatives there were selected anti-annexin-V<br class="style-scope patent-text">monoclonal antibodies HDA-676, HDA-907, HDA-1606 and HDA-1937, which had been produced by the anti-annexin-V monoclonal antibody-producing hybridoma cell line clones. The selected monoclonal antibodies were applied to affinity purification using a ConSepLC 100 device and a protein-A column (available from Perceptive Co.) to purify the IgG fractions.<br class="style-scope patent-text">(2) Preparation of Horseradish peroxidase (HRPO) labeled Monoclonal antibodies (A) Preparation of anti-human-annexin-V monoclonal antibodies F(ab')2 For labeling the IgG fractions of the anti-annexin-X<br class="style-scope patent-text">monoclonal antibodies, the purified IgG fractions of the respective anti-annexin-V monoclonal antibodies HDA-676, HDA-907 (deposited as an International under the number FERM BP-5286 at the National Institute of Bioscience and Human-Technology, the Agency of Industrial Science and Technology of Japan), HDA-1606 and HDA-1937 were each concentrated by a Centricon 10 centifugal concentrator (available from Amicon Co.) to give a concentration of lml from lOmg. The resultant was then dialyzed against O.1M<br class="style-scope patent-text">~ trademark sodium acetate buffer (pH 3.7) containing 0.2M NaCl as solvent.<br class="style-scope patent-text">    Each dialyzed IgG solution was added with pepsin in an amount of 40 of IgG for reaction at 37°C over 2 to 4 hours. On completing the reaction, the resultant was applied to molecular-sieve chromatography using a Sephadex G-150 column (available from Pharmacia Co.) equilibrated with O.1M borate buffer (pH 8.0) to obtain the F(ab')2 fragment. With every clone, lOmg of the IgG<br class="style-scope patent-text">fraction provided approx. 5mg of F(ab')2 fraction with a high yield. There was almost no difference in yield among the clones.<br class="style-scope patent-text">to (B) Preparation of anti-annexin-V monoclonal antibodies Fab'-SH<br class="style-scope patent-text">    Each of the anti-annexin-V monoclonal antibodies F(ab')2 from HDA-676, HDA-907, HDA-1606 and HDA-1937, as prepared in the above method (A), was subjected centrifugal concentration by a Centricon 10 centrifugal concentrator to give lml of each anti-annexin-V monoclonal antibody F(ab')2 fraction.<br class="style-scope patent-text">     To each concentrated fraction lml was added with O.lml of 100mM 2-mercaptoethylamine hydrochloride solution (available from Kishida Chemicals Co.) for reaction at 370°C for 90 minutes. On completing the reaction, the resultant was purified using a 2o Sephadex G-25 column for equilibrium gel filtration measuring l.6cm in diameter and 20cm in length (available from Pharmacia Co.) and equilibrated with O.1M sodium phosphate buffer (pH 6.0) containing 1mM EDTA, to fractionate the Fab'-SH fraction.<br class="style-scope patent-text">    Following the fractionation, the resultant purified fraction was pooled for centifugal concentration with a Centricon 10 centifugal concentrator to give a volume of lml. Thus, the concentrated anti-annexin-V monoclonal antibodies Fab'-SH<br class="style-scope patent-text">fractions were obtained from the respective clones . HDA-676, HDA-907, HDA-1606 and HDA-1937.<br class="style-scope patent-text">(C) Preparation of HRPO maleimide 20mg (as protein content) of HRPO (available from Boehringer Co.) was dissolved in lml of O.1M sodium phosphate buffer (pH 6.0). The resulting solution was added with I00 microliters of solution of N-hydroxysuccinimi ester (available from Zeeben Chemicals Co.) dissolved in dimethyl formanide (DMF ) ( available from Kishida Chemicals Co.) to give a final concentration of 25mg/1, followed by reaction at 30°C for 60 minutes to prepare maleimide ester of HRPO. On completing the reaction, the solution was centrifuged for five minutes at 3000 rpm. The supernatant was applied to a Sephadex G-25 column for equilibrated gel filtration (available from Pharmacia Co.) measuring l.6cm in diameter and 20cm in length, which has been equilibrated with O.1M<br class="style-scope patent-text">sodium phosphate buffer (pH 6.0), in order to purify HRPO<br class="style-scope patent-text">maleimide. The purified fraction of HRPO maleimide was then subjected to centrifugal concentration by a Centricon 10 centrifugal concentrator to prepare the concentrated fraction of HRPO maleimide.<br class="style-scope patent-text">(D) Preparation of HRPO-labeled anti-annexin-V monoclonal antibodies Fab' The concentrated Fab'-SH fraction of the anti-annexin-V<br class="style-scope patent-text">monoclonal antibody was mixed with the concentrated fraction of HRPO maleimide at a molar ratio of 1 . 1, for reaction at 4°C for 15 to 24 hours. On completing the reaction, 2-mercaptoethylamine was added to give a final concentration of 2mM in the reaction solution, followed by reaction at 37°C for 20 minutes in order to block unaltered HRPO maleimide. The resultant was then subjected to molecular-sieve gelchromatography using a Ultragel ACA44 column (available from Pharmacia Co.) equilibrated with 20mM<br class="style-scope patent-text">sodium phosphate-sodium citrate buffer (pH 5.6) containing 0.15M<br class="style-scope patent-text">   NaCl and 2.5M EDTA and measuring l.6cm in diameter and 65cm in length, for removing unaltered Fab'-SH of the auti-annexin-V monoclonal autibodies and unaltered HRPO maleimide and purifying the respective, HRPO-labeled anti-annexin-V<br class="style-scope patent-text">1o monoclonal antibodies Fab' (hereinafter referred to as HRPO-labeled anti-annexin-V monoclonal antibodies).<br class="style-scope patent-text">(E) Activity determination of HRPO-labeled antibodies In determining HRPO enzyme activity of the HRPO-labeled antibodies, 2.98m1 of O.1M sodium phosphate buffer (pH 7.0) containing 0.2% phenol, 0.5mM hydrogen peroxide and 0.15mg/ml 4-amino antipyrine was added with 20microliters of the HRPO-labeled antibody to give a total volume of 3.Oml, followed by reaction at 37°C for five minutes, and measurement of absorbance at 500nm by means of the Rate assay. HRPO activity was determined by measuring the difference in absorbance (0 Abs) for one minute.<br class="style-scope patent-text">(6) Preparation of anti-annexin-V monoclonal antibody solid phase coupled wells.<br class="style-scope patent-text">     In order to obtain monoclonal antibody for use as solid phase in an ELISA system for assay of human annexin-V, monoclonal antibody HDA-627, produced by hybridoma cell line HCA-627 strain which has been deposited under the number FERM BP-5284 at the International Depositary Authority for the deposit of microorganism, was applied to affinity purification using ConSepLC-100 device and a protein A column (available from Perceptive Co.) to purify the IgG fraction from the ascitic fluid.<br class="style-scope patent-text">    The IgG fraction of anti-annexin-V monoclonal antibody HCA-627 was adjusted to have a concentration of 30micrograms/ml with O.1M sodium phosphate buffer (pH 7.5) containing 0.1% sodium azide, and distributed in a microtitreplate for ELISA (available from Nunk Co.) at a rate of 100 microliters per well, for sensitization at 4°C overnight. Then each well of the microtitreplate was washed three times with phosphate-buffered saline (PBS) containing 0.050 Tween 20 surfactant, and then added with 300 microliters of PHS containing 1% BSA (as the blocking solution), followed by a further blocking operation at 4°C<br class="style-scope patent-text">overnight, to prepare antibody-plates sensitired with anti-human-annexin-V monoclonal autibodies (hereinafter referred to as auti-human-annexin-V monoclonal antibody plates).<br class="style-scope patent-text">(7) Studies on ELISA assay system using anti-annexin-V<br class="style-scope patent-text">monoclonal antibodies The anti-annexin-V monoclonal antibody plates as prepared above were added, following discarding the blocking solution, with phosphate buffer of pH 7,0 (reaction buffer) containing 1~<br class="style-scope patent-text">   HSA and 5mM EDTA at a rate of 100 microliters per well. Standard antigen solutions were prepared so as to give native annexin-V<br class="style-scope patent-text">standard antigen concentrations of 1.563ng/ml, 3.125ng/ml 6.25ng/ml, 12.5ng/ml, 25ng/ml, 50ng/ml and 100ng/ml. The respective standard antigen solutions were added to the wells at a rate of 20 microliters per well, followed by stirring and reaction at room temperature for one hour. On completing the reaction, each well was washed three times with the washing solution. Then, to the wells were added the HRPO-labeled anti-s annexin-V monoclonal antibodies Fab' (clones . HDA-676, HDA-907, HDA-1606 and HDA-1937 ) at a rate of 100 microliters per well, . for reaction at room temperature for thirty minutes. Following the reaction, each well was washed six times with the washing solution and then added with 100 microliters of OPD substrate 1o solution containing O.1M phosphate-citrate buffer added with 2mg/ml o-phenylenediamine and 4mM H202, for reaction for thirty minutes. The reaction was terminated by adding 2N H2S04 solution at a rate of 100 microliters per well. Absorbance was determined' on an ELISA plate reader at the primary wavelength 492nm and at 15 the secondary wavelength 690nm.<br class="style-scope patent-text">     The absorbance herein intended is obtained by subtracting an absorbance measurement at the secondary wanelength 690nm from that at the primary wanelength 492nm.<br class="style-scope patent-text">     The results of absorbance measurements with respect to the 20 representative native annexin-V standard antigen solutions were given in Table 5. <br class="style-scope patent-text"> <br class="style-scope patent-text"> Z I $oa3o I                <br class="style-scope patent-text"> <br class="style-scope patent-text"> X               '~1.-I  00~ O ~ ODl0L(1M <br class="style-scope patent-text"> <br class="style-scope patent-text"> &gt; 00N d1M tf1crM l0 &gt;~              t0s~U               <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~L.i  00N O ~-~~ - M <br class="style-scope patent-text"> <br class="style-scope patent-text"> S~                                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~0 c0         T!O                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> x    .~         1-1~r-I  l0L~tI1N 00~f1Lf1d' C1         f0+~  O ~ - d~01i000~O <br class="style-scope patent-text"> <br class="style-scope patent-text"> U    I  'L3f0CaO O O O O~ N ~P <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'L~        G wiU7O O O O OO O '-'r-I   -r~        f0 +~   ~          ~ ~   O O O O OO O O <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~0   O          V7Ca z    cn h O    N          U                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> CT    h 01lDO M0100d0 I          (0    O h ~DN NN h N <br class="style-scope patent-text"> <br class="style-scope patent-text"> Q1N  ~          S.-i    O O ~ M l0~ O O <br class="style-scope patent-text"> <br class="style-scope patent-text"> cn+~ U          N                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> x          &gt;     o 0 0 0 0~ c~~r h h ~ r-~ .00 U1H  ~                O h 10N MN O h N ~l 'O   UI  d'O O r'M ~O~-~ OD <br class="style-scope patent-text"> <br class="style-scope patent-text"> .1W  O          +~                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> T7   .~       G     O O O O O~ N M <br class="style-scope patent-text"> <br class="style-scope patent-text"> O tn wI         N                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> ,~N  +~         E                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'r-I-rl~          N     h h h ~ tf1M l0O <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~'b ~          S.-i    O h l~~ .-~ 0100 ~ O             ~   M O O ~ M l0~ O  <br class="style-scope patent-text"> <br class="style-scope patent-text"> .L~h          U1 wi O          r0    O O O O Or-N V <br class="style-scope patent-text"> <br class="style-scope patent-text"> n--I+~ 01       O                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> l0~  I                              <br class="style-scope patent-text"> <br class="style-scope patent-text"> h O toO NN    <br class="style-scope patent-text"> <br class="style-scope patent-text"> O    Ca         '~-a    O 0010N MLf1t0V' x  ~       O   N O O ~-M tD~ O ~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> U (t3 l-I    O O O O O~-N M <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ O  N O       N                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> O ~I ~  ov      ,LZ                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> U  ~  l0        y   D O V'~ V'1Dh O <br class="style-scope patent-text"> <br class="style-scope patent-text"> O  .L1        ~     O 00l~N ~-N ~NN <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'E"~C  c0 I       z   ~ O O ~ M l~~ O  <br class="style-scope patent-text"> <br class="style-scope patent-text"> O O   <br class="style-scope patent-text"> <br class="style-scope patent-text"> I  ~             O O O O O~ N ~Y <br class="style-scope patent-text"> <br class="style-scope patent-text"> C    O      <br class="style-scope patent-text"> <br class="style-scope patent-text"> O 'TiI1rN                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> -r1.~ (Y,01 +~   x &gt;~a~                              <br class="style-scope patent-text"> <br class="style-scope patent-text"> o  n   c .&gt;a.~        o ~                     <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ +~                                <br class="style-scope patent-text"> <br class="style-scope patent-text"> O C  O  U   .1-~~         II1 U ~  w--I~   co~ &gt;       N           <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~ ~o  ~ x I       ~ N u, (0 .Il +~  (~~ r-i  LC1~ N ~I1 !-~ ~ N -ri~           <br class="style-scope patent-text"> <br class="style-scope patent-text"> O   U ~ X O~  O ~ M iDNm O O <br class="style-scope patent-text"> <br class="style-scope patent-text"> .S1u!  U wl~ -~-i          ~N u~O <br class="style-scope patent-text"> <br class="style-scope patent-text"> U    ~  .~  &gt;~+~~ +~G              .-O  ~   O c0G ~      <br class="style-scope patent-text"> <br class="style-scope patent-text"> .L1   U  '-' U z Fig. 12 illustrates a calibration curve for human annexin-V<br class="style-scope patent-text">obtained by plotting the measurements on the human annexin-V<br class="style-scope patent-text">antigen solutions with standard antigen solution absorbance as ordinate and human annexin-V antigen concentration as abscissa.<br class="style-scope patent-text">     The calibration curve as shown in Fig. 12 is excellent one, as it demonstrates that the absorbance rises with increasing concentration of human annexin-V, substantially linearly from a low concentration up to as high as 100ng/ml.<br class="style-scope patent-text">     The calibration curve also indicates that the subject 1o example enjoys a wider dynamic range and hence provides a more sensitive system, as compared with the calibration curve for native human annexin-V antigen in which there was employed the combination of the monoclonal antibody as solid phase produced by hybridoma cell line clone HCA-627 strain deposited under the number FERM BP-5284 as an International Deposit with HRPO-labeled anti-32KP polyclonal Fab' antibody.<br class="style-scope patent-text">    It should be noted, however, that the combination of the anti-annexin-V monoclonal antibody HCA-627 as solid phase coupled to wells and the HRPO-labeled anti-dog-32KP annexin-V polyclonal Fab' antibody is not problematic at all in sensitivity for assay of human annexin-V.<br class="style-scope patent-text">   The use of the calibration curve as obtained in the subject example (Fig. 12) enabled us to assay annexin-V concentration in the blood, plasma and serum in a highly reproducible and reliable manner from a low concentration to a high concentration, in which there was employed a combination of the monoclonal antibody produced by hybridoma cell line HCA-627 strain deposited as an International Deposit under the number FERM BP-5284 with the HRPO-labeled monoclonal antibody produced by hybridoma cell line HDA-907 strain also deposited as an International Deposit under the number FERM BP-5286.<br class="style-scope patent-text">    The calibration curve of Fig. 12 was obtained by employing an extremely low concentration of HRPO-labeled anti-annexin-V<br class="style-scope patent-text">monoclonal antibody HDA-907-Fab' which may have a HRPO activity of 3 to 4mU/ml. It is thus possible to provide a more sensitive system.<br class="style-scope patent-text">    As can be seen from Table 5 and Fig. l2 on the calibration curve obtained with the standard antigen, the CV values are within 3.6% for four times of measurements of the standard antigen concentration in the range of from a human annexin-V<br class="style-scope patent-text">concentration as low as lng/ml up to as high as 100ng/ml, demonstrating the system enables a highly reproducible assay of annexin-V concentration. From the foregoing, the subject ELISA<br class="style-scope patent-text">system using the aforesaid monoclonal antibodies for assay of annexin-V will be fully satisfactory in use as an ELISA system to determine native annexin-V concentration in the human blood.<br class="style-scope patent-text">     As shown in Figs. 1 through 8, in a case where native human annexin-V antigen without 8M-urea-treatment was used as standard antigen in an ELISA system using the combination of the monoclonal antibodies, the absorbance was very small, for example, as in Example 1, only about 5o to about 10$ of 8M-urea treated antigen. Hy contrast, the ELISA system using the monoclonal antibodies as obtained in the subject example has made a remarkable improvement in reactivity with native human annexin-V antigen. <br class="style-scope patent-text"> <br class="style-scope patent-text"> It was found that the HRPO-labeled Fab' antibodies of the anti-annexin-V monoclonal antibody clones (HDA-676, HDA-907, HDA-1606 and HDA-1937) having a reactivity with human- and dog-annexin-V and selected by the screening operation in the subject example all exhibit a high reactivity with human annexin-V and therefore provide a good combination with HCA-627 as shown in Example 1 in obtaining an excellent calibration curve for human annexin-V antigen concentration.<br class="style-scope patent-text">(8) Possibility of Detection and Quantitative Analysis of Human Annexin-V in Samples by Sandwich ELISA in which Anti-Human-Annexin-V Monoclonal Antibody (HCA-627) and Anti-Native-Human- and Dog-Annexin-V Monoclonal Antibody Clone (HDA-907) are used From among possible combinations of the monoclonal antibodies as prepared above for use in sensitive assay of native human annexin-V, as a representative was selected the combination of anti-annexin-V monoclonal antibody HCA-627 as solid phase coupled to wells and HRPO-labeled anti-annexin-V monoclonal antibody HDA-907-Fab to study its application to assay of clinical samples by ELISA.<br class="style-scope patent-text">     Thus, into the anti-human-annexin-V monoclonal antibody HCA<br class="style-scope patent-text">. 627-coupled plates was added, after discarding the blocking solution, reaction buffer solution (sodium phosphate buffer at pH<br class="style-scope patent-text">7.0 containing 1% BSA and 5mM EDTA)at a rate of 100 microliters per well. An antigen standard solution of native human cardiac mustle-derived annexin-V (Ong/ml, 1.5625ng/ml, 3.125ng/ml, 6.25ng/ml, 12.5ng/ml, 25ng/ml, 50ng/ml or 100ng/ml) and a human plasma sample are added each at a rate of 20 microtiters per well, followed by stirring and reaction for one hour at room temperature. Each well was washed four times with the washing solution. Then there was added the HRPO-labeled anti-annexin-V monoclonal antibody HDA-907-Fab' having been prepared to have a concentration of 4mU/ml as HRPO enzyme activity, at a rate of 100 microliters per well for reaction for thirty minutes at room temperature, followed by washing four times with the washing solution. After the washing the wells were added with OPD substrate solution (containing O.1M<br class="style-scope patent-text">phosphate-citrate buffer added with 2mg/ml o-phenylenediamine and 4mM H202) at a rate of 100 microliters per well, followed by absorbance measurements at the primary wanelength 492nm and at the secondary wanelength 690nm on an ELISA plate reader.<br class="style-scope patent-text">     The human plasma samples were determined for native human annexin-V concentration by reading the calibration curve which was prepared by plotting the absorbance against varying concentration of human cardiac muscle-derived annexin-V as standard antigen. The data for the calibration curve are given in Table 5 and Fig. l2. As mentioned previously, the absorbance increased with increasing concentration of the human annexin-V<br class="style-scope patent-text">standard antigen.<br class="style-scope patent-text">(9) Sample dilution tests.<br class="style-scope patent-text">     Dilution tests were performed on a plasma sample prepared by adding purified annexin-V antigen to normal plasma(Sample 1), a plasma sample with a low value of annexin-V concentration (Sample 2) and a plasma sample with a high value of annexin-V <br class="style-scope patent-text"> <br class="style-scope patent-text"> concentration (Sample 3). Each sample was subjected to a series of successive doubling dilution. Each series of samples, including the original sample solution, were assayed for annexin-V concentration by the ELISA system for annexin-V assay using the combination of the monoclonal antibody clone HCA-627 as solid phase coupled to well and the HRPO-labeled monoclonal antibody clone HDA-907 -Fab'.<br class="style-scope patent-text">     The results are given in Table 6, Tables 6-1 through 6-3 and Fig. l3. <br class="style-scope patent-text"> <br class="style-scope patent-text"> M            <br class="style-scope patent-text"> <br class="style-scope patent-text"> N   UJM ~ I~dOM V~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> r-1~ l~00O~1001 O                <br class="style-scope patent-text"> <br class="style-scope patent-text"> 5..~~ ~ N l!1r-N N <br class="style-scope patent-text"> <br class="style-scope patent-text"> f0      - N d' (d O                <br class="style-scope patent-text"> <br class="style-scope patent-text"> N                      <br class="style-scope patent-text"> <br class="style-scope patent-text"> I I            <br class="style-scope patent-text">     G                      <br class="style-scope patent-text"> <br class="style-scope patent-text"> N   N            <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~    -~  N  O v0OvN tf1 r-1  N Lf1Lf1Lf101 N     C                <br class="style-scope patent-text"> <br class="style-scope patent-text"> E~    ~  E=  O O ~ M 1D <br class="style-scope patent-text"> <br class="style-scope patent-text"> N         (0 I                <br class="style-scope patent-text"> <br class="style-scope patent-text"> N     t~               <br class="style-scope patent-text"> <br class="style-scope patent-text"> (p    -ri v     X                <br class="style-scope patent-text"> <br class="style-scope patent-text"> O                <br class="style-scope patent-text"> <br class="style-scope patent-text"> '-'   G                <br class="style-scope patent-text"> <br class="style-scope patent-text"> G                <br class="style-scope patent-text"> <br class="style-scope patent-text"> -I  N ~ LwO N u~O <br class="style-scope patent-text"> <br class="style-scope patent-text"> E   .-i01M OON OOO~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~    ~   ~ O N Wit'O~IWI1 U1    ~   (0        r-M<br class="style-scope patent-text">~                <br class="style-scope patent-text"> <br class="style-scope patent-text"> v     x   cn H      <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~        v +~           <br class="style-scope patent-text"> <br class="style-scope patent-text"> a~u, N         O N tf1 r-I       -r1~ N lf1 L1    i~M l~N 111 N L(1 V7        -rlO O O O O  <br class="style-scope patent-text"> <br class="style-scope patent-text"> C   f~       <br class="style-scope patent-text"> <br class="style-scope patent-text"> O                <br class="style-scope patent-text"> <br class="style-scope patent-text"> O     wl iJ               <br class="style-scope patent-text"> <br class="style-scope patent-text"> N                      <br class="style-scope patent-text"> <br class="style-scope patent-text"> ri  O            <br class="style-scope patent-text"> <br class="style-scope patent-text"> --I   -r-I+~           <br class="style-scope patent-text"> <br class="style-scope patent-text"> Ca  t0 N     N                <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~r    r"'I~.           <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~riN 10 l0    f0  -~M r-aDd'N  <br class="style-scope patent-text"> <br class="style-scope patent-text"> v~  ~ x x x x x x a~                     <br class="style-scope patent-text"> <br class="style-scope patent-text"> a H                      <br class="style-scope patent-text"> <br class="style-scope patent-text"> U        <br class="style-scope patent-text"> <br class="style-scope patent-text"> c0                   G                              <br class="style-scope patent-text"> <br class="style-scope patent-text"> O                    <br class="style-scope patent-text"> <br class="style-scope patent-text"> S.a                  U                              <br class="style-scope patent-text"> <br class="style-scope patent-text"> O                                                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> !~ G                              <br class="style-scope patent-text"> <br class="style-scope patent-text"> I~l~1DN L11O ~               N     O ~D~ N tf1 O      r-iO~M OJN 0040b1              ~1    N Lf1L!1Lf101 rl f0~             -r~             f0 E              <br class="style-scope patent-text"> <br class="style-scope patent-text"> S..i  O N d'01L~Lf1~               ~.I    O O ~ M l0 O           - M ~              N              <br class="style-scope patent-text"> <br class="style-scope patent-text"> I    &gt; G             t0              ~       <br class="style-scope patent-text">     C              <br class="style-scope patent-text"> <br class="style-scope patent-text"> !~  <br class="style-scope patent-text"> <br class="style-scope patent-text"> x                    I                              <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~    cn x               m cd   +~              N               +~      <br class="style-scope patent-text"> <br class="style-scope patent-text"> &gt;~                                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~    a~              ~              a~             <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~    a~   <br class="style-scope patent-text"> <br class="style-scope patent-text"> N   a1~ON O O O                 O     ~-- M M l~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> l...i  O~M OD~ N l0~               5..~    N vD10Lf101 .C   ~ N             (0              ~ N          <br class="style-scope patent-text"> <br class="style-scope patent-text"> U7  O N d'01l~d'~               U7    O O r'M l0 tT   ~O     r-M ~               l0 '[~                  4-1 'O   ~               O                              <br class="style-scope patent-text"> <br class="style-scope patent-text"> c0   O                            O              <br class="style-scope patent-text"> <br class="style-scope patent-text"> Ll1l~O~M O O N     O~O Wit'~ Wit' S-I~ 01M ODM Ll1O ~               &gt;,..I~   '-II1Ll1Lf101 .C7  N               ri              O              <br class="style-scope patent-text"> <br class="style-scope patent-text"> O N d'01a0I~fC3             ~     O O r-M lO <br class="style-scope patent-text"> <br class="style-scope patent-text"> '~   E           ~ M    <br class="style-scope patent-text"> <br class="style-scope patent-text"> N    ~                                              <br class="style-scope patent-text"> <br class="style-scope patent-text"> z .~              z sa a    ~               ~o o   ~               o   u, ~    ~rl  N L!1        N ~1            ~ri  N II1 ~.-I                              S-I             <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~  ~ N m       ~            +~  ~-N ui O                               O              <br class="style-scope patent-text"> <br class="style-scope patent-text"> (.2, ~   M t0N Lf1    N -r-i          ~   M l~N Lf1 ~       +~             <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~    ~-i  O O ~-N iI1  ~ ~             ~--i  O O r-N v.n U                               U              <br class="style-scope patent-text"> <br class="style-scope patent-text"> a    -~I              a ~o            -~I            <br class="style-scope patent-text">~o   co                              ~o &gt;;   r~  0 0 0 0 0 - s; .~           r~  0 0 0 0 0 u~   ~.            r~             <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~o                   ro c0 E           <br class="style-scope patent-text"> <br class="style-scope patent-text"> o    ~               o ~ ~           c ~a o               co I            o mz +~   +~              +~ .~           +~             <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ ~ x n    ~I              r~ --      ~-, ---I'N t0                        C~  N ~O      <br class="style-scope patent-text">-IJ             <br class="style-scope patent-text"> <br class="style-scope patent-text"> l0M r-ODd'N .-N           (0  M ~-OOd~N  <br class="style-scope patent-text"> <br class="style-scope patent-text"> i    a~rxx x x x x x I               a~  x x x x x x rx ~o a v    ~               a~              E              <br class="style-scope patent-text"> <br class="style-scope patent-text"> .n   v~     .R              ~n ~o H                    H                              <br class="style-scope patent-text"> <br class="style-scope patent-text"> O     b1r-IM ~ I~00M<br class="style-scope patent-text">d' f0~ ~ L~0001~O<br class="style-scope patent-text">     O~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> O   r-N L(1r-N<br class="style-scope patent-text">     N <br class="style-scope patent-text"> <br class="style-scope patent-text"> G     ~ ~       ~ N<br class="style-scope patent-text">~' W                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> X     +~           <br class="style-scope patent-text"> <br class="style-scope patent-text"> N                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> v a~           <br class="style-scope patent-text"> <br class="style-scope patent-text"> L.i  tDQOL~~ 01 N <br class="style-scope patent-text"> <br class="style-scope patent-text"> I~01O I~<br class="style-scope patent-text">l~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> N          <br class="style-scope patent-text"> <br class="style-scope patent-text"> f0  ~ N Lf1N N<br class="style-scope patent-text">     M <br class="style-scope patent-text"> <br class="style-scope patent-text"> N         r'N<br class="style-scope patent-text">d' 4~    4~           <br class="style-scope patent-text"> <br class="style-scope patent-text"> O     O    <br class="style-scope patent-text"> <br class="style-scope patent-text"> N     !.a  O M I~d'vD<br class="style-scope patent-text">tD <br class="style-scope patent-text"> <br class="style-scope patent-text"> N ~ ~ tDI~~1d' ,j~           <br class="style-scope patent-text"> <br class="style-scope patent-text"> f0  ~   - N L!1c-N<br class="style-scope patent-text">     N <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ N<br class="style-scope patent-text">     V' z . N               <br class="style-scope patent-text">r-I               <br class="style-scope patent-text"> <br class="style-scope patent-text"> z x   o Md1    ~r-11..~N tI1 O r'N Lf1 N~ri~   ~ ~ M l0N tf1 ~ O   ~ U O O ~ N m f2rt1-,~ -,1c0 .~.+~ ~1G4O O O O O <br class="style-scope patent-text"> <br class="style-scope patent-text"> (0  c0 ~~ is O~ ~   O            <br class="style-scope patent-text"> <br class="style-scope patent-text"> r0U   w U1~   +~           <br class="style-scope patent-text"> <br class="style-scope patent-text"> O                <br class="style-scope patent-text"> <br class="style-scope patent-text"> c0~ U                <br class="style-scope patent-text"> <br class="style-scope patent-text"> O                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> Cav .;-~N ~O     <br class="style-scope patent-text"> <br class="style-scope patent-text"> M      O f0M ~ COd'N<br class="style-scope patent-text">r-~ rxx x x x x x .o      n, v co H                   <br class="style-scope patent-text"> <br class="style-scope patent-text"> With Sample 1, a sample prepared by adding annexin-V to normal plasma, the annexin-V concentration in blood varies with the dilution rate, forming a straight dilution line directing toward the origin. With both Sample 2 and Sample 3 (a sample having a high annexin-V concentration), the annexin-V measurement varies in a close relationship with the dilution rate, also forming a substantially straight dilution line directing toward the origin.<br class="style-scope patent-text">     Thus, as it was found that the annexin-V measurement is closely related with the dilution rate, forming a straight dilution line directing toward the origin for all samples with or without annexin-V addition, the subject system can provide an assay system for quantitating the annexin-V concentration in samples without interference by possible components in the plasma.<br class="style-scope patent-text">    In addition, for the purpose of confirming the reliability of the subject system for assay of clinical samples, recovery tests were conducted by adding human annexin-V as purified annexin-V antigen to plasma and serum samples.<br class="style-scope patent-text">(10) Human annexin-V recovery tests in ELISA system for assay of human annexin-V<br class="style-scope patent-text">    With respect to the ELISA system as studied above in which there are used anti-annexin-V monoclonal antibody HCA-627 as solid phase coupled to wells and HRPO-labeled anti-annexin-V<br class="style-scope patent-text">monoclonal antibody HDA-907-Fab', recovery tests for human annexin-V were conducted to examine whether purified annexin-V<br class="style-scope patent-text">antigens as added to plasma or serum are recovered without any influence on the measurements of annexin-V by components present in the plasma or serum.<br class="style-scope patent-text">(11) Procedure for recovery test Purified human annexin-V antigen solutions were prepared to have a concentration of 40.8ng/ml, 14.6ng/ml and 4.7ng/ml. To each of three human plasma samples and two human serum samples was added one of the purified human annexin-V antigens having the three different(high, middle and low) concentrations in a proportion of 9 volumes of sample to 1 volume of antigen to observe annexin-V concentration in each sample. The human annexin-V antigen solution was replaced by buffer solution which was also added to each sample in the same proportion as in the case of human annexin-V antigen, so as to observe human annexin-V<br class="style-scope patent-text">concentration in each sample per se. Human annexin-V antigen concentration as added was determined through assay of a sample-like solution prepared by adding human annexin-V antigen to reaction buffer solution instead of the plasma or serum sample in the same proportion as in such sample.<br class="style-scope patent-text">   The concentration of human annexin-V recovered was obtained by subtracting measured human annexin-V concentration of a sample 2o per se from measured human annexin-V concentration as added, as given by the following equation(1):<br class="style-scope patent-text">    The concentration of annexin-V antigen recovered (ng/ml) - Measured human annexin-V concentration of a sample added with the antigen of the respective concentration (ng/ml) - Measured human annexin-V concentration of the per se (ng/ml) ..... (1) The recovery rate at the concentration of annexin-V <br class="style-scope patent-text"> <br class="style-scope patent-text"> recovered was obtained by the following equation (2):<br class="style-scope patent-text">     Recovery Rate (%)_ (Concentration of human annexin-V<br class="style-scope patent-text">recovered when added with the antigen of the respective concentration/Human annexin-V concentration as added)x100 ..... (2) The results of the recovery tests are summarized in Table 7. <br class="style-scope patent-text"> <br class="style-scope patent-text"> S-I       Lf1d''-l0N Q1Lf1l0I~O t0L(1tf1dO01 o~~                      <br class="style-scope patent-text"> <br class="style-scope patent-text"> .r X~ L(110I~0~II101l0N lf1~ ~ O Lf1COI~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> c0NO         O o~o~O O O O O o~O o~o~O o~o~<br class="style-scope patent-text">     N                                      <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~U         .-+~                                     <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~N        <br class="style-scope patent-text">(0 x ~rx rx M tt1~ ~-I~V'00L(1~'d'l~N M 01 &gt;  ~          X71r1N M 01~ M 00N N M M 01Lf1Lf101Lf1 I  .~  ~     ~p~                              <br class="style-scope patent-text"> <br class="style-scope patent-text"> .CN      l.-I  ~ O lI1I~l~1Dl01DO l0d~00l0Lf1 .rl~ +~CT      U   ~ N V~V W QO  ~ d'  ~ M   ~ d' f1 X  O -~-I.rl      &gt; ~                              <br class="style-scope patent-text"> <br class="style-scope patent-text"> a~ .~I3 +~                            <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~                                          <br class="style-scope patent-text"> <br class="style-scope patent-text"> cob ~a~  I                                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> t~a~ ~   a~      <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~'L7&gt;..-I1.-iN   O o1M r-~ p .-N d'a0t~a0~ O 01 G  C 'L7I~   ~   M Lf11O0101d''d~L11M N 01O LI1O O <br class="style-scope patent-text"> <br class="style-scope patent-text"> (d ~ ,~~U   ~ ~     <br class="style-scope patent-text">~                                      <br class="style-scope patent-text"> <br class="style-scope patent-text"> U   .riO   ~0~   ~ O Ina0a0a0t0l0~-l0d'ODvol0N<br class="style-scope patent-text">     O                                      <br class="style-scope patent-text"> <br class="style-scope patent-text"> xa   a~a~  ~ N v'~r~r,ao  ~ ~   - M     <br class="style-scope patent-text">-~I                                    <br class="style-scope patent-text"> <br class="style-scope patent-text"> x  o v vcn  ~ E                               <br class="style-scope patent-text">+-~                                    <br class="style-scope patent-text"> <br class="style-scope patent-text"> U .~GN                                     <br class="style-scope patent-text">c0 'b   3 CIx  I                                 <br class="style-scope patent-text">     S~                <br class="style-scope patent-text"> <br class="style-scope patent-text"> l0O 00O N 00d'ODd'01I~l0II100N <br class="style-scope patent-text"> <br class="style-scope patent-text"> S-I~ N  ~   S.-~~ ~ ~ ~ ~ M dDN ~ 01M M 0101lf10101 C                                      <br class="style-scope patent-text"> <br class="style-scope patent-text"> U1 -r-Ia ~t1+~  UI+~  ~ o l0u,II1u,tptf10,.od'o W u,o U             o O  .i-~~ ~~   ~O~   r-N d'd'tI100  ~ M   ~ M   - V' N  G f0~4-1 N N                               <br class="style-scope patent-text">     O               <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ cnxO   ~                                 <br class="style-scope patent-text">     U                         <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~                                <br class="style-scope patent-text"> <br class="style-scope patent-text"> &gt;   ~ow -, I   S.aN          <br class="style-scope patent-text">.-I                                    <br class="style-scope patent-text"> <br class="style-scope patent-text"> c ~ +~s~                 <br class="style-scope patent-text"> <br class="style-scope patent-text"> .rlU G~         tDODV'~ I~~i'~ aDI~tf100M t0N V~<br class="style-scope patent-text">\                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ N~         ~ O ~O~ M dDO O~O I~M 01O~d~01 ~                                <br class="style-scope patent-text"> <br class="style-scope patent-text"> UO                                     <br class="style-scope patent-text">~                                      <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ -hCU         d'd'O W W d'tI1d'O~d'M 1DV~Wit'~<br class="style-scope patent-text">v               I11 ON           ~ M   - d'  r-M   r-M   - M <br class="style-scope patent-text"> <br class="style-scope patent-text"> x  .~~ Urx +~                                       <br class="style-scope patent-text"> <br class="style-scope patent-text"> 'U   I f.-i'L3 a~   c +~a~        o o ~ o o r-o o r-o o ~-o o ~-~.                                     <br class="style-scope patent-text"> <br class="style-scope patent-text"> &gt;_,  .~G~         ~ ~ ao~ ~ ao~ ~oao~ ~oao~ ~ 00 .-i ~ x o.o ~                                      <br class="style-scope patent-text"> <br class="style-scope patent-text"> U7 c0N U~\        d'd'O d'd'O d'd'O d'~t'O d'~t'O <br class="style-scope patent-text"> <br class="style-scope patent-text"> f0 ~ ~ C~T          ~ d'  ~ d~ ~ d~  r-d~  - d' C                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~  x ~ U~o--N     I                                           <br class="style-scope patent-text"> <br class="style-scope patent-text"> +~    ~ ~ s.~                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~n    ..~o v     x .~Ia H     v +~                                <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~ sa s~ a~ .~+~a\                                      <br class="style-scope patent-text"> <br class="style-scope patent-text"> a~ s~   ~ ~tT          ~  o     ~     o, IOC           N     O     N     Lf1    Lf1 O  U1 c0U U7'-' U  c0 E ~ to    N                    <br class="style-scope patent-text"> <br class="style-scope patent-text"> N  ~  ~ O ~N                 d' rx ~  x U ..~m I                              <br class="style-scope patent-text"> <br class="style-scope patent-text"> N           ~     t11 rl L1 ~ -r-I             I     I   N  <br class="style-scope patent-text"> <br class="style-scope patent-text"> E  ~ +~.            z     z           o     0 cn ~o u ~oo     .~    ~     x     M     M  <br class="style-scope patent-text"> <br class="style-scope patent-text"> a~ ~n H U z            x     x     H     o, o. <br class="style-scope patent-text"> <br class="style-scope patent-text"> o v              co    co    co a     a     ~     a a~a.             ~     ~     ~     ~     a a ~              ~     ~o    ~o    a   c~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> .C~   H Ul             f1.    f3~    (1.    UJ    U7 H                                        <br class="style-scope patent-text"> <br class="style-scope patent-text"> The result of the recovery test was excellent in the plasma samples with from a low value (1.27ng/ml) up to a high value (42.Omg/ml) of annexin-V concentration in sample per se, as the antigen recovery rate was between 96% and 1090 in the concentration range of human annexin-V antigen added (from 4.7ng/ml to 40.8ng/ml).<br class="style-scope patent-text">    The recovery rate was also excellent with respect to the serum samples, as it was between 91% and 106% in the concentration range of human annexin-V antigen added, i.e. from a low concentration (4.7ng/ml) up to a high concentration (40.8ng/ml).<br class="style-scope patent-text">   As can be seen from the foregoing, the subject ELISA system for assay of annexin-V has a good prospect of application to the assay of clinical samples because it has enabled reliable 15~ quantitative analysis without being influenced by components of the plasma and serum.<br class="style-scope patent-text">    EXAMPLE 11: Application of the Present Invention to Analysis of Blood Sample by Enzyme Antibody Method (1) Pretreatment of collected blood Intvavenuously collected whole blood was placed without delay into a 1.8m1 collecting tube containing 0.2m1 of 3.8%<br class="style-scope patent-text">sodium citrate, followed by mild stirring and centrifugation at 2500 rpm for 10 minute to isolate plasma. The isolated plasma was immediately or, following after frozen for keeping until use for keeping, supplied for use in the assay of annexin-V<br class="style-scope patent-text">concentration.<br class="style-scope patent-text">   In the case when EDTA salt is used in place of sodium citrate, 3 to 5 mM EDTA 2 potassium or EDTA 2 sodium may be placed in the blood collecting tube to isolate plasma following centrifugation.<br class="style-scope patent-text">(2) Diagnosis of myocardial infarction Analysis of blood collected three hours after the onset from a 72-year-old lady and having no symptom of hemolysis indicated CK (creatine phosphate enzyme) value of 50U/L, a normal value, and annexin-V concentration in plasma of 16.4ng/ml, an increased value. The case was later affirmatively diagnostic of myocardial infection because of elevation of CK value up to 1108U/L and a typical abnormality on the electrocardiogram. Annexin-V<br class="style-scope patent-text">concentration in plasma returned to a normal value three days after the onset of the disease.<br class="style-scope patent-text">    This case indicates that the assay of annexin-V<br class="style-scope patent-text">concentration in plasma in the first sampling of blood with no hemolysis is of use in diagnosis of myocardial infarction.<br class="style-scope patent-text">    Annexin-V concentration in plasma of a patient with myocardial infection is relatively high in an early stage of the disease (within 6 hours after the onset of attack). From the analysis of blood samples without homolysis from patients complaining of pains in the chest, it was later established that 70% of the cases, where annexin-V concentration in blood was determined to show lOng/ml or more, is diagnostic of myocardial infarction.<br class="style-scope patent-text">(3) Diagnosis of angina pectoris Blood with no hemolysis from a 55-year-old man who complained of a pain in the chest three hours after a first pain, was collected three and a half hours after the onset and analyzed for annexin-V concentration in plasma, with the result that the concentration was 5.8ng/ml. Analysis was also conducted on blood samples from the same patient thereafter for CK values in the blood with the result that the values were 140U/L or less, all a normal value. Coronary angiography taken later showed a high degree of stenosis on the right coronary artery. Thus, based on this fact with reference to the clinical symtoms, the case was affirmatively diagnozed as angina pectoris.<br class="style-scope patent-text">     This case demonstrates that the analysis of blood with no l0 hemolysis to determine annexin-V concentration in plasma is of use in the diagnosis of angina pectoris. While annexin-V<br class="style-scope patent-text">concentration in plasma of a patient with annexin-V angina pectoris is relatively low as compared with a case of myocardial infarction, approx. 700 of cases, where CK value of a patient 15 complaining of pains in the chest was not diagnostic of angina pectoris but the annexin-V concentration in plasma showed 5ng/ml or more, were diagnozed as angina pectoris.<br class="style-scope patent-text">(4) Annexin-V concentration in normal adults Annexin-V concentration in plasma from blood with no 2o hemolysis of normal males 22 to 75 years of age is in the range of 0.6 to l.9ng/ml, whereas that of normal females 24 to78 years of age is in the range of 0.5 to l.7ng/ml, with the average being l.Ong/ml, the maximum l.9ng/ml and the minimum 0.5ng/ml. There was observed neither sex-dependent nor age-dependent variations.<br class="style-scope patent-text">25 Hemolysis will bring a higher value of annexin-V<br class="style-scope patent-text">concentration measurement in plasma because annexin-V leaks into the plasma from the decomposed leukocytes, platelets and erythrocytes. In treating blood sample following the collection, care should therefore be taken not to cause hemolysis to occur, for example, through use of a fine collecting needle or avoidance of vigorous shaking of blood samples. Slight hemolysis will give no substantial influence on the assay of annexin-V concentration in blood, enabling such assay. Thus, the assay of annexin-V concentration in plasma is of use in the diagnosis of myocardial and angina pectoris.<br class="style-scope patent-text">(5) Comparison with example 7 In Example 7 the numerical values of analysis, including the normal values, are somewhat higher than those in Example 9. This is because the analysis in Example 7 includes measurement of annexin-V concentration due to hemolysis which have occurred during the treatment of the blood samples.<br class="style-scope patent-text">     Example 7 therefore suggests that, as long as blood samples are treated in the same manner, assay of annexin-V concentration in plasma is of use in the diagnosis of myocardial infarction and angina pectoris even if hemolysis occurs.<br class="style-scope patent-text">(6) As can be seen from the description of the invention, anti human-annexin-V monoclonal antibody HCA-627 and anti-human annexin-V monoclonal antibody HDA-907 obtained by the present invention are monoclonal antibodies which are capable of specifically recognizing an annexin-V antigenic molecule through different antigenic determinants on an identical annexin-V<br class="style-scope patent-text">molecule.<br class="style-scope patent-text">     The sandwich ELISA system using the two monoclonal antibodies enables the assay of annexin-V antigen in a highly sensitive manner, providing excellent quantitative analysis as can be seen from the satisfactory results of the dilution tests and the recovery tests.<br class="style-scope patent-text">    In addition, the two monoclonal antibodies are capable of cross-reacting with both human-annexin-V antigen and dog annexin-V antigen. The two cross-reacting monoclonal antibodies are considered to recognize antigenic determinants common to the different types of annexin-V antigen molecules. Thus, in preparing standard antigen for assay annexin-V, such monoclonal antibodies make it possible to provide less expensive dog-derived annexin-V without causing the ethical issue with respect to extraction and purification of human-derived annexin-V.<br class="style-scope patent-text">   Industrial Applicability The present invention is directed to the production of novel anti-human-annexin-V monoclonal antibodies by culturing hybridoma cell lines HCA-627 strain (deposited on November 6, 1995 as an International Deposit under the number FERM BP-5284 at the National Institute of Bioscience and Human-Technology, the Agency of Industrial Science and Technology of Japan, at Higashi 1-1-3, Tukuba-City, Ibaraki-Pref., Japan, an International Depositary Authority for the deposit of microorganisms) and HDA-907 strain (deposited on November 7, 1995 as an International Deposit under the number FERM HP-5286 at the National Institute of Bioscience and Human-Technology, the Agency of Industrial Science and Technology of Japan, at Higashi 1-1-3, Tukuba-City, Ibaraki-Pref., Japan, an International Depositary Authority for the deposit of microorganisms), in which the hybridoma cells were prepared by extracting lymphocytic plasmablast cells from lymphoid organs of mammalian animals such as mice immunized with human annexin-V, an antigenic protein from human heart, and fusing lymphocytic plasmablast cells with myeloma cells.<br class="style-scope patent-text">     The anti-human-annexin-V monoclonal antibodies obtained in the present invention are ones capable of recognizing specifically human annexin-V as the antigenic protein.<br class="style-scope patent-text">    In addition to the anti-human-annexin-V monoclonal antibodies there can be also obtained, according to the present invention, anti-annexin-V monoclonal antibodies which will cross-react with annexin-V as antigenic protein derived from various animals (e. g. beagles and rats).<br class="style-scope patent-text">    These cross-reacting anti-annexin-V monoclonal antibodies are considered to have an ability to recognize antigenic determinant sites occurring commonly on the annexin-V protein molecules. Such sites having antigenic determinants common to the annexin-V protein molecules are important ones for maintaining the molecular structure of annexin-V reserved among different animal species.<br class="style-scope patent-text">     The use of the anti-human-annexin-V monoclonal antibodies of the present invention makes it possible to diagnose patients with ischemic diseases such as myocardial infarction and angina pectoris by means of ELISA, for example, through the measurement of human annexin-V concentration in the blood. Thus, although conventionally thought impossible, myocardial infarction and angina pectoris can be diagnosed quickly and reliably even at the early stages of the diseases, and the reliable diagnosis can be conducted free of influence by rheumatoid factor. <br class="style-scope patent-text"> <br class="style-scope patent-text"> Another exemplarly advantage of the present invention is that it can be applied in autopsy or post mortem to stain the cardiac muscle tissue using the anti-human-annexin-V monoclonal antibodies so as to detect the distribution of human annexin-V<br class="style-scope patent-text">through the cardiac muscle tissue.<br class="style-scope patent-text">    In a further aspect of the present invention, there can be obtained anti-human-annexin-V monoclonal antibodies which are different in reactivity and are capable of recognizing different antigenic determinants on a human annexin-V molecule. By l0 selecting, from a group of such anti-human-annexin-V monoclonal antibodies, two different types of anti-human-annexin-V<br class="style-scope patent-text">monoclonal antibodies different from each other in antigenic determinant for recognition and combining them, it is possible to determine human annexin-V with a high sensitivity and 15~ reproducibility by means of ELISA.<br class="style-scope patent-text">     Thus, by the combination of the anti-human-annexin-V<br class="style-scope patent-text">monoclonal antibodies having different specificities to different antigenic determinants, preparation is now possible of highly reliable reagents for the assay of myocardial infarction and 20 angina pectoris.<br class="style-scope patent-text">    The anti-human-annexin-V monoclonal antibodies of the present invention are also suitable for use in tissue-staining, in addition to their use in the ELISA system for the assay of human annexin-V. Through the tissue-staining analysis, it is 25 possible to identify the areas in the myocardial tissue of human heart where human anexin localizes or distributes, and of the areas where human annexin-V passes from the myocardial tissue due to ischemia, thereby greatly contributing to molecular physiological and other studies. It is also possible to recover annexin-V molecules of a high purity from the tissue extracts through the purification by means of affinity chromatography using the anti-human-annexin-V monoclonal antibodies or the anti-s annexin-V monoclonal antibodies. Further, identification of annexin-V molecules can be made by means of Western blotting.<br class="style-scope patent-text">   As can be seen from the above, the anti-human-annexin-V<br class="style-scope patent-text">monoclonal antibodies and the anti-annexin-V monoclonal antibodies obtained from various animals according to the present invention can be used in molecular and physiological studies on annexin-V occurring in humans and various animals, thereby making a great contribution in the wide range of areas including both basic medicine and clinical medicine. </div>
    </disclosure>
  </div>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(19)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result" hidden="">translated from </div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><div mxw-id="PCLM325275039" lang="EN" load-source="patent-office" class="claims style-scope patent-text">
    <claim-statement class="style-scope patent-text"> The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows: </claim-statement>
    <div class="claim style-scope patent-text"> <div num="1" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">1. An anti-annexin-V monoclonal antibody produced by a hybridoma cell line which is selected from the group consisting of the hybridoma cell lines deposited as FERM BP-5284 and FERM BP-5286 at the International Depository Authority for the deposit of microorganisms, said anti-annexin-V monoclonal antibody being cross-reactive with annexin-V from the heart cells of one or more mammalian species. </div>
    </div>
    </div> <div class="claim style-scope patent-text"> <div num="2" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">2. A hydridoma cell line selected from the group consisting of the hybridoma cell lines deposited as FERM BP-5284 and FERM BP-5286 at the International depository Authority for the deposit of microorganisms, said hybridoma cell line having the ability to produce an anti-annexin-V monoclonal antibody which has a binding specificity to an antigenic determinant on annexin-V antigenic protein and which is capable of cross-reacting with annexin-V from the heart of one or more mammalian species. </div>
    </div>
    </div> <div class="claim style-scope patent-text"> <div num="3" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">3. A diagnostic agent for myocardial infarction and angina pectoris which comprises:<br class="style-scope patent-text">a first reagent containing a first anti-annexin-V monoclonal antibody being produced by a hybridoma cell line selected from the group consisting of the hybridoma cell lines deposited as FERM BP-5284 and FERM BP-5286 at the International Depository Authority for the deposit of microorganisms;<br class="style-scope patent-text">a second reagent containing a second anti-annexin-V monoclonal antibody being produced by the other hybridoma cell line selected from said group, or polyclonal antibody, wherein the antibody of the second reagent is labeled;<br class="style-scope patent-text">wherein the antibodies of both reagents are cross-reactive with annexin-V from human heart cells and the annexin-V antigen is annexin-V from heart cells of one or more mammalian species. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="4" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">4. The diagnostic agent for myocardial infarction and angina pectoris of claim 3 in which the first anti-annexin-V monoclonal antibody is anti-annexin-V <br class="style-scope patent-text">monoclonal antibody produced by the hybridoma cell line FERM BP-5284 and the labeled second anti-annexin-V monoclonal antibody is produced by labeling the anti-annexin-V<br class="style-scope patent-text">monoclonal antibody produced by the hybridoma cell line FERM BP-5286. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="5" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">5. The diagnostic agent for myocardial infarction and angina pectoris of claim 3 in which the first anti-annexin-V monoclonal antibody is anti-annexin-V <br class="style-scope patent-text">monoclonal antibody produced by the hybridoma cell line FERM B-5286 and the labeled second anti-annexin-V monoclonal antibody is produced by labeling the anti-annexin-V <br class="style-scope patent-text">monoclonal antibody produced by the hybridoma cell line FERM BP-5284. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="6" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">6. The diagnostic agent for myocardial infarction and angina pectoris of claim 3 in which the first anti-annexin-V monoclonal antibody is anti-annexin-V <br class="style-scope patent-text">monoclonal antibody produced by the hybridoma cell line FERM BP-5284 and the labeled second anti-annexin-V polyclonal antibody is anti-dog-annexin-V antibody which cross-reacts with human annexin-V. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="7" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">7. The diagnostic agent for myocardial infarction and angina pectoris of claim 3 in which the first anti-annexin-V monoclonal antibody is anti-annexin-V <br class="style-scope patent-text">monoclonal antibody produced by the hybridoma cell line FERM BP-5286 and the labeled second anti-annexin-V polyclonal antibody is anti-dog-annexin-V antibody which cross-reacts with human annexin-V. </div>
    </div>
    </div> <div class="claim style-scope patent-text"> <div num="8" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">8. A method for diagnosing myocardial infarction and angina pectoris comprising the steps o~<br class="style-scope patent-text">causing an antigen-antibody reaction of annexin-V in a sample with a first anti-annexin-V<br class="style-scope patent-text">monoclonal antibody to form an annexin-V antigen/anti-annexin-V monoclonal antibody complex;<br class="style-scope patent-text">allowing the antigenic site of annexin-V of the formed annexin-V antigen/anti-annexin-V<br class="style-scope patent-text">monoclonal antibody complex to be bound with a labeled second anti-annexin-V<br class="style-scope patent-text">monoclonal antibody or labeled anti-annexin-V polyclonal antibody so as to form a labeled form of said annexin-V antigen/anti-annexin-V monoclonal antibody complex bound with the polyclonal or monoclonal antibody; and quantitatively analyzing the labeled form of said complex to perform said diagnosis. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="9" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">9. The method of diagnosing myocardial infarction or angina pectoris of claim 8 in which the first anti-annexin-V monoclonal antibody is produced by a hybridoma cell line selected from the group consisting of the hybridoma cell lines deposited as FERM BP-5284 and FERM BP-5286 at the International Depository Authority for the deposit of microorganisms, and the labeled second anti-annexin-V monoclonal antibody is produced by labeling the second anti-annexin-V monoclonal antibody produced being different from the first anti-annexin-V monoclonal antibody produced by a hybridoma cell line which is selected from the same said group, wherein said first and second anti-annexin monoclonal antibodies have a binding specificity for an antigenic determinant on annexin-V protein from human heart cells. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="10" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">10. The method for diagnosing myocardial infarction and angina pectoris of claim 8 in which the first anti-annexin-V monoclonal antibody is anti-annexin-V <br class="style-scope patent-text">monoclonal antibody produced by the hydridoma cell line FERM BP-5284. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="11" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">11. The method for diagnosing myocardial infarction and angina pectoris of claim 8 in which the first anti-annexin-V monoclonal antibody is anti-annexin-V <br class="style-scope patent-text">monoclonal antibody produced by the hybridoma cell line FERM BP-5286. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="12" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">12. The method for diagnosing myocardial infarction and angina pectoris of claim 8 in which the labeled second anti-annexin-V monoclonal antibody is anti-annexin-V<br class="style-scope patent-text">monoclonal antibody produced by the hybridoma cell line FERM BP-5284. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="13" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">13. The method for diagnosing myocardial infarction angina pectoris of claim 8 in which the labeled second anti-annexin-V monoclonal antibody is anti-annexin-V<br class="style-scope patent-text">monoclonal antibody produced by the hybridoma cell line FERM BP-5286. </div>
    </div>
    </div> <div class="claim style-scope patent-text"> <div num="14" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">14. A method for analyzing annexin-V in human cardiac muscle or in a sample which comprises causing an antigen-antibody reaction of human annexin-V in the human cardiac muscle or the sample with an anti-annexin-V monoclonal antibody produced by a hybridoma cell line selected from the group consisting of the hybridoma cell lines deposited as FERM BP-5284 and FERM BP-5286 at the International Depository Authority for the deposit of microorganisms, to form an annexin-V antigen-anti-annexin-V monoclonal antibody complex and quantitatively analyzing the formed annexin V<br class="style-scope patent-text">antigen-anti-annexin-V monoclonal antibody complex. </div>
    </div>
    </div> <div class="claim style-scope patent-text"> <div num="15" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">15. A method for analyzing annexin-V in a sample which comprises the steps of:<br class="style-scope patent-text">causing an antigen-antibody reaction of human annexin-V in the sample with a first anti-annexin-V monoclonal antibody produced by a hybridoma cell line selected from the group consisting of the hybridoma cell lines deposited as FERM BP-5284 and FERM BP-5286 at the International Depository Authority for the deposit of microorganisms to form an annexin-V antigen-anti-annexin-V monoclonal antibody complex, allowing the antigenic site of human annexin-V of the formed annexin-V <br class="style-scope patent-text">antigenic-anti-annexin-V monoclonal antibody complex to be bound with a labeled second anti-annexin-V monoclonal antibody or anti-annexin-V polyclonal antibody, so as to form a labeled from of said annexin-V antigen-anti-annexin-V monoclonal polyclonal antibody complex bound with labeled anti-annexin-V polyclonal antibody or labeled the second anti-annexin-V monoclonal antibody;<br class="style-scope patent-text">quantitatively analyzing the labeled form of the complex and; <br class="style-scope patent-text"> <br class="style-scope patent-text"> said labeled second anti-annexin monoclonal antibody is produced by labeling second anti-annexin-V monoclonal antibody being different from the first anti-annexin-V<br class="style-scope patent-text">monoclonal antibody and produced by a hybridoma cell line which is selected from the group consisting of the hybridoma cell line deposited as FERM BP-5284 and FERM <br class="style-scope patent-text">BP-5286 at the International Depository Authority for the deposit of microorganisms. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="16" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">16. The method of claim 15 in which the first anti-annexin-V monoclonal antibody is one produced by the hybridoma cell line FERM BP-5284 and has a binding specificity for an antigenic determinant on human annexin-V antigenic protein. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="17" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">17. The method of claim 15 in which the first anti-annexin-V monoclonal antibody is one produced by the hybridoma cell line FERM BP-5286 and has a binding specificity for an antigenic determinant on human annexin-V antigenic protein. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="18" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">18. The method of claim 15 in which the labeled second anti-annexin-V <br class="style-scope patent-text">monoclonal antibody is produced by labeling the anti-annexin-V monoclonal antibody produced by hybridoma cell line FERM BP-5284 and has a binding specificity for an antigenic determinant on human annexin-V antigenic protein. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="19" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">19. The method of claim 15 in which the labeled second anti-annexin-V <br class="style-scope patent-text">monoclonal antibody is produced by labeling the anti-annexin-V monoclonal antibody produced by hybridoma cell line FERM BP-5286 at and has a binding specificity for an antigenic determinant on human annexin-V antigenic protein. </div>
    </div>
  </div> </div>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5767247A/en"><a id="link" href="#" class="style-scope state-modifier">US5767247A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-06-16</span>
                    <span class="td style-scope patent-result">Anti-annexin-V monoclonal antibodies, and preparation and use thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2008360A1/en"><a id="link" href="#" class="style-scope state-modifier">CA2008360A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-07-23</span>
                    <span class="td style-scope patent-result">Myocardial infarction immunoassay 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1994004563A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1994004563A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1994-03-03</span>
                    <span class="td style-scope patent-result">PEPTIDES CONTAINING RESPECTIVE AMINO ACID SEQUENCES SELECTED FROM AMONG THOSE OF LIPOPROTEIN(a) AND APOLIPOPROTEIN(a), ANTIBODIES RESPECTIVELY RECOGNIZING THESE AMINO ACID SEQUENCES, AND METHOD OF ASSAYING WITH THESE ANTIBODIES 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2012175602A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2012175602A2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-12-27</span>
                    <span class="td style-scope patent-result">Elisa for calprotectin 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2274776C/en"><a id="link" href="#" class="style-scope state-modifier">CA2274776C</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-11-25</span>
                    <span class="td style-scope patent-result">Method for analyzing annexin v in urine and use thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2884277B1/en"><a id="link" href="#" class="style-scope state-modifier">EP2884277B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-10-10</span>
                    <span class="td style-scope patent-result">Method and immunoassay reagent for measuring PIVKA-II 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPH04503006A/en"><a id="link" href="#" class="style-scope state-modifier">JPH04503006A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-06-04</span>
                    <span class="td style-scope patent-result">
  Blood coagulation factor XIIa beta monoclonal antibodies and immunoassays
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP3018110B2/en"><a id="link" href="#" class="style-scope state-modifier">JP3018110B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-03-13</span>
                    <span class="td style-scope patent-result">
  Monoclonal antibody
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2001091517A/en"><a id="link" href="#" class="style-scope state-modifier">JP2001091517A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-04-06</span>
                    <span class="td style-scope patent-result">Method for detecting low-specific-gravity lipoprotein (ldl) in blood or modification low specific gravity lipoprotein 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2180830C/en"><a id="link" href="#" class="style-scope state-modifier">CA2180830C</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-10-31</span>
                    <span class="td style-scope patent-result">Anti-annexin-v monoclonal antibody, process for producing the same, and use thereof 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2000239300A/en"><a id="link" href="#" class="style-scope state-modifier">JP2000239300A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-09-05</span>
                    <span class="td style-scope patent-result">Monoclonal antibody against apolipoprotein a-i 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5039611A/en"><a id="link" href="#" class="style-scope state-modifier">US5039611A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991-08-13</span>
                    <span class="td style-scope patent-result">Monoclonal antibodies to superficial papillary bladder tumor cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA1287801C/en"><a id="link" href="#" class="style-scope state-modifier">CA1287801C</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991-08-20</span>
                    <span class="td style-scope patent-result">Method for determining human collagen peptides by way  of enzyme immunoassay 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP4164804B2/en"><a id="link" href="#" class="style-scope state-modifier">JP4164804B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-10-15</span>
                    <span class="td style-scope patent-result">
  Monoclonal antibody specific for tartrate-resistant acid phosphatase 5b and use thereof
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP4663831B2/en"><a id="link" href="#" class="style-scope state-modifier">JP4663831B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-04-06</span>
                    <span class="td style-scope patent-result">
  Monoclonal antibodies, cell lines, and methods for measuring N1, N12-diacetylspermine
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2018080114A/en"><a id="link" href="#" class="style-scope state-modifier">JP2018080114A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-05-24</span>
                    <span class="td style-scope patent-result">Anti-human VAP-1 monoclonal antibody 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP4533995B2/en"><a id="link" href="#" class="style-scope state-modifier">JP4533995B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-09-01</span>
                    <span class="td style-scope patent-result">
  Anti-ADAMTS13 monoclonal antibody
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP3142786B2/en"><a id="link" href="#" class="style-scope state-modifier">JP3142786B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-03-07</span>
                    <span class="td style-scope patent-result">
  Kit for measuring arteriosclerosis and antibody used therefor
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPH0677017B2/en"><a id="link" href="#" class="style-scope state-modifier">JPH0677017B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1994-09-28</span>
                    <span class="td style-scope patent-result">
  A method for the immunoassay of human dehydrogenase type IV collagen
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP3440852B2/en"><a id="link" href="#" class="style-scope state-modifier">JP3440852B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-08-25</span>
                    <span class="td style-scope patent-result">
  Hybridoma, monoclonal antibody, assay method and immunoassay reagent
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2002515981A/en"><a id="link" href="#" class="style-scope state-modifier">JP2002515981A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-05-28</span>
                    <span class="td style-scope patent-result">
  Immunoassay using monoclonal antibodies reactive to human iNOS
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2878317B2/en"><a id="link" href="#" class="style-scope state-modifier">JP2878317B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-04-05</span>
                    <span class="td style-scope patent-result">
  Laminin measurement reagent
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2868808B2/en"><a id="link" href="#" class="style-scope state-modifier">JP2868808B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-03-10</span>
                    <span class="td style-scope patent-result">
  Activated platelet antigen measurement reagent
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2000069963A/en"><a id="link" href="#" class="style-scope state-modifier">JP2000069963A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-03-07</span>
                    <span class="td style-scope patent-result">Monoclonal antibody specific to apolipoprotein e4 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP3686977B2/en"><a id="link" href="#" class="style-scope state-modifier">JP3686977B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-08-24</span>
                    <span class="td style-scope patent-result">
  Anti-uracil monoclonal antibody and hybridoma producing the same
 
     </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (3)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        JP313958/1994<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">1994-11-11</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        JP31395894<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">1994-11-11</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1996015152A1/en"><a id="link" href="#" class="style-scope state-modifier">PCT/JP1995/002305</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">1995-11-10</span>
                    <span class="td style-scope patent-result">Antiannexin-v monoclonal antibody, process for producing the same, and use therof 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="legalEvents" class="scroll-target style-scope patent-result">
              Legal Events
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Date</span>
                    <span class="th style-scope patent-result">Code</span>
                    <span class="th style-scope patent-result">Title</span>
                    <span class="th style-scope patent-result">Description</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2002-11-12</span>
                    <span class="td nowrap style-scope patent-result">EEER</span>
                    <span class="td nowrap style-scope patent-result">Examination request</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2012-11-13</span>
                    <span class="td nowrap style-scope patent-result">MKLA</span>
                    <span class="td nowrap style-scope patent-result">Lapsed</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2012-12-25</span>
                    <span class="td nowrap style-scope patent-result">MKLA</span>
                    <span class="td nowrap style-scope patent-result">Lapsed</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20121113</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.909723471" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.909723471" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=794678359" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>